MXPA99008909A - 4,4-disubstituted-3,4-dihydro-2(1h)-quinazolinones useful as hiv reverse transcriptase inhibitors - Google Patents
4,4-disubstituted-3,4-dihydro-2(1h)-quinazolinones useful as hiv reverse transcriptase inhibitorsInfo
- Publication number
- MXPA99008909A MXPA99008909A MXPA/A/1999/008909A MX9908909A MXPA99008909A MX PA99008909 A MXPA99008909 A MX PA99008909A MX 9908909 A MX9908909 A MX 9908909A MX PA99008909 A MXPA99008909 A MX PA99008909A
- Authority
- MX
- Mexico
- Prior art keywords
- dihydro
- quinazolinone
- ch2ch2
- trifluoromethyl
- pyridyl
- Prior art date
Links
- 102000015084 HIV Reverse Transcriptase Human genes 0.000 title claims abstract description 20
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 title claims abstract description 20
- -1 4,4-disubstituted-3,4-dihydro-2(1h)-quinazolinones Chemical class 0.000 title claims description 39
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 title claims description 15
- 239000000203 mixture Substances 0.000 claims abstract description 44
- 150000003839 salts Chemical group 0.000 claims abstract description 32
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 29
- 239000003112 inhibitor Substances 0.000 claims abstract description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 1010
- 150000001875 compounds Chemical class 0.000 claims description 134
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 96
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 54
- 239000011780 sodium chloride Substances 0.000 claims description 37
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 25
- 125000000217 alkyl group Chemical group 0.000 claims description 24
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 23
- 125000000623 heterocyclic group Chemical group 0.000 claims description 21
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 17
- 229910052799 carbon Inorganic materials 0.000 claims description 15
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 15
- 208000005721 HIV Infections Diseases 0.000 claims description 14
- 229910052801 chlorine Inorganic materials 0.000 claims description 14
- 201000001820 human immunodeficiency virus infectious disease Diseases 0.000 claims description 14
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 13
- UJTMLNARSPORHR-UHFFFAOYSA-N OC2H5 Chemical compound C=C=[O+] UJTMLNARSPORHR-UHFFFAOYSA-N 0.000 claims description 13
- 229910052757 nitrogen Inorganic materials 0.000 claims description 13
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 12
- 125000005842 heteroatoms Chemical group 0.000 claims description 12
- 229910052731 fluorine Inorganic materials 0.000 claims description 11
- 229910052740 iodine Inorganic materials 0.000 claims description 11
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims description 10
- 229910052794 bromium Inorganic materials 0.000 claims description 10
- 229910052717 sulfur Inorganic materials 0.000 claims description 10
- 125000003342 alkenyl group Chemical group 0.000 claims description 9
- 125000003545 alkoxy group Chemical group 0.000 claims description 9
- 229910052760 oxygen Inorganic materials 0.000 claims description 9
- UKJZNUGEKDWQAM-UHFFFAOYSA-N 1-ethynyl-5,6-difluoro-4-propan-2-yl-4-(trifluoromethyl)-3H-quinazolin-2-one Chemical compound C1=C(F)C(F)=C2C(C(C)C)(C(F)(F)F)NC(=O)N(C#C)C2=C1 UKJZNUGEKDWQAM-UHFFFAOYSA-N 0.000 claims description 7
- 125000000304 alkynyl group Chemical group 0.000 claims description 7
- 229910052736 halogen Inorganic materials 0.000 claims description 7
- 150000002367 halogens Chemical class 0.000 claims description 7
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 7
- 102000015787 HIV Protease Human genes 0.000 claims description 6
- 108010010369 HIV Protease Proteins 0.000 claims description 6
- CBVCZFGXHXORBI-PXQQMZJSSA-N Indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 claims description 6
- NCDNCNXCDXHOMX-XGKFQTDJSA-N Ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 229960001936 indinavir Drugs 0.000 claims description 6
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 6
- 229960000311 ritonavir Drugs 0.000 claims description 6
- CTOUNZIAEBIWAW-UHFFFAOYSA-N 3,4-dihydro-1H-quinazolin-2-one Chemical compound C1=CC=C2NC(=O)NCC2=C1 CTOUNZIAEBIWAW-UHFFFAOYSA-N 0.000 claims description 5
- NQDJXKOVJZTUJA-UHFFFAOYSA-N Nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 claims description 5
- 229960001852 Saquinavir Drugs 0.000 claims description 5
- QWAXKHKRTORLEM-UGJKXSETSA-N Saquinavir Chemical group C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 5
- AVRPFRMDMNDIDH-UHFFFAOYSA-N 1H-quinazolin-2-one Chemical compound C1=CC=CC2=NC(O)=NC=C21 AVRPFRMDMNDIDH-UHFFFAOYSA-N 0.000 claims description 4
- AEELHPSJKHUGEA-UHFFFAOYSA-N 2-methylbut-1-ene Chemical group [CH2+]C(=C)C[CH2-] AEELHPSJKHUGEA-UHFFFAOYSA-N 0.000 claims description 4
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims description 4
- QAGYKUNXZHXKMR-HKWSIXNMSA-N Nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 claims description 4
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 claims description 4
- 239000004030 hiv protease inhibitor Substances 0.000 claims description 4
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 4
- 229960000884 nelfinavir Drugs 0.000 claims description 4
- 125000006592 (C2-C3) alkenyl group Chemical group 0.000 claims description 3
- 125000006593 (C2-C3) alkynyl group Chemical group 0.000 claims description 3
- GWKIPRVERALPRD-ZDUSSCGKSA-N (S)-4-ISOPROPOXYCARBONYL-6-METHOXY-3-METHYLTHIOMETHYL-3,4-DIHYDROQUINOXALIN-2(1H)-THIONE Chemical compound N1C(=S)[C@H](CSC)N(C(=O)OC(C)C)C2=CC(OC)=CC=C21 GWKIPRVERALPRD-ZDUSSCGKSA-N 0.000 claims description 3
- HOCFDYZWQYGULA-UHFFFAOYSA-N 1-(5-bromopyridin-2-yl)-3-(2-pyridin-2-ylethyl)thiourea Chemical compound N1=CC(Br)=CC=C1NC(=S)NCCC1=CC=CC=N1 HOCFDYZWQYGULA-UHFFFAOYSA-N 0.000 claims description 3
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 3
- WHFRDXVXYMGAJD-UHFFFAOYSA-N 3-[(4,7-dichloro-1,3-benzoxazol-2-yl)methylamino]-5-ethyl-6-methyl-1H-pyridin-2-one Chemical compound O=C1NC(C)=C(CC)C=C1NCC1=NC2=C(Cl)C=CC(Cl)=C2O1 WHFRDXVXYMGAJD-UHFFFAOYSA-N 0.000 claims description 3
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 3
- QCNJQJJFXFJVCX-UHFFFAOYSA-N 4-(2-cyclopropylethynyl)-5,6-difluoro-4-(trifluoromethyl)-1,3-dihydroquinazolin-2-one Chemical compound C12=C(F)C(F)=CC=C2NC(=O)NC1(C(F)(F)F)C#CC1CC1 QCNJQJJFXFJVCX-UHFFFAOYSA-N 0.000 claims description 3
- BEMYHIYXTHWXJX-UHFFFAOYSA-N 4-ethyl-1-ethynyl-5,6-difluoro-4-(trifluoromethyl)-3H-quinazolin-2-one Chemical compound C1=C(F)C(F)=C2C(CC)(C(F)(F)F)NC(=O)N(C#C)C2=C1 BEMYHIYXTHWXJX-UHFFFAOYSA-N 0.000 claims description 3
- YAWZVIWUBOKIGI-UHFFFAOYSA-N C(C)N1C(NC(C2=CC=CC=C12)C(F)(F)F)=O Chemical compound C(C)N1C(NC(C2=CC=CC=C12)C(F)(F)F)=O YAWZVIWUBOKIGI-UHFFFAOYSA-N 0.000 claims description 3
- MLILORUFDVLTSP-UHFFFAOYSA-N Emivirine Chemical compound O=C1NC(=O)N(COCC)C(CC=2C=CC=CC=2)=C1C(C)C MLILORUFDVLTSP-UHFFFAOYSA-N 0.000 claims description 3
- NJBBLOIWMSYVCQ-VZTVMPNDSA-N Kynostatin 272 Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)COC=1C2=CC=NC=C2C=CC=1)CSC)[C@H](O)C(=O)N1[C@@H](CSC1)C(=O)NC(C)(C)C)C1=CC=CC=C1 NJBBLOIWMSYVCQ-VZTVMPNDSA-N 0.000 claims description 3
- CJPLEFFCVDQQFZ-UHFFFAOYSA-N Loviride Chemical compound CC(=O)C1=CC=C(C)C=C1NC(C(N)=O)C1=C(Cl)C=CC=C1Cl CJPLEFFCVDQQFZ-UHFFFAOYSA-N 0.000 claims description 3
- 229950006243 Loviride Drugs 0.000 claims description 3
- 101710034456 MT-CO1 Proteins 0.000 claims description 3
- WHBIGIKBNXZKFE-UHFFFAOYSA-N Rescriptor Chemical compound CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 claims description 3
- 229950000977 Trovirdine Drugs 0.000 claims description 3
- HBOMLICNUCNMMY-XLPZGREQSA-N Zidovudine Chemical group O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 claims description 3
- 229960005319 delavirdine Drugs 0.000 claims description 3
- BEUUJDAEPJZWHM-COROXYKFSA-N tert-butyl N-[(2S,3S,5R)-3-hydroxy-6-[[(2S)-1-(2-methoxyethylamino)-3-methyl-1-oxobutan-2-yl]amino]-6-oxo-1-phenyl-5-[(2,3,4-trimethoxyphenyl)methyl]hexan-2-yl]carbamate Chemical compound C([C@@H]([C@@H](O)C[C@H](C(=O)N[C@H](C(=O)NCCOC)C(C)C)CC=1C(=C(OC)C(OC)=CC=1)OC)NC(=O)OC(C)(C)C)C1=CC=CC=C1 BEUUJDAEPJZWHM-COROXYKFSA-N 0.000 claims description 3
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 4
- 229960002555 Zidovudine Drugs 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- ABZKJBFNOMWVMZ-UHFFFAOYSA-N 6-chloro-4-cyclopropyl-1-ethynyl-4-(trifluoromethyl)-3H-quinazolin-2-one Chemical compound N1C(=O)N(C#C)C2=CC=C(Cl)C=C2C1(C(F)(F)F)C1CC1 ABZKJBFNOMWVMZ-UHFFFAOYSA-N 0.000 claims 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 claims 1
- RINCXYDBBGOEEQ-UHFFFAOYSA-N Succinic anhydride Chemical compound O=C1CCC(=O)O1 RINCXYDBBGOEEQ-UHFFFAOYSA-N 0.000 claims 1
- 125000005055 alkyl alkoxy group Chemical group 0.000 claims 1
- 238000004166 bioassay Methods 0.000 abstract description 19
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 6
- 208000001756 Virus Disease Diseases 0.000 abstract description 4
- 206010047461 Viral infection Diseases 0.000 abstract description 2
- 230000017613 viral reproduction Effects 0.000 abstract description 2
- 238000009007 Diagnostic Kit Methods 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 80
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 58
- 239000000243 solution Substances 0.000 description 55
- 125000004093 cyano group Chemical group *C#N 0.000 description 49
- 239000000460 chlorine Substances 0.000 description 44
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 44
- CSCPPACGZOOCGX-WFGJKAKNSA-N Deuterated acetone Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 40
- 239000000047 product Substances 0.000 description 39
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 38
- 241000700605 Viruses Species 0.000 description 33
- 238000002360 preparation method Methods 0.000 description 33
- 238000000034 method Methods 0.000 description 32
- 241000725303 Human immunodeficiency virus Species 0.000 description 31
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 31
- 235000002639 sodium chloride Nutrition 0.000 description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 29
- 239000000463 material Substances 0.000 description 29
- 210000004027 cells Anatomy 0.000 description 26
- 239000004480 active ingredient Substances 0.000 description 24
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 22
- 230000015572 biosynthetic process Effects 0.000 description 20
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 20
- WDDOQHLJFOUQMW-UHFFFAOYSA-N lithium;ethynyl(trimethyl)silane Chemical compound [Li+].C[Si](C)(C)C#[C-] WDDOQHLJFOUQMW-UHFFFAOYSA-N 0.000 description 20
- 239000000523 sample Substances 0.000 description 20
- 238000003786 synthesis reaction Methods 0.000 description 20
- 230000002194 synthesizing Effects 0.000 description 19
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- 125000005289 uranyl group Chemical group 0.000 description 16
- 239000003795 chemical substances by application Substances 0.000 description 15
- 235000019439 ethyl acetate Nutrition 0.000 description 15
- 125000002541 furyl group Chemical group 0.000 description 15
- 239000003814 drug Substances 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical class CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- 230000000840 anti-viral Effects 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 201000009910 diseases by infectious agent Diseases 0.000 description 12
- 239000008079 hexane Substances 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 239000008188 pellet Substances 0.000 description 11
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Inorganic materials [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 11
- 125000004076 pyridyl group Chemical group 0.000 description 10
- 230000002829 reduced Effects 0.000 description 10
- 239000003826 tablet Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 206010000565 Acquired immunodeficiency syndrome Diseases 0.000 description 9
- 108010092799 EC 2.7.7.49 Proteins 0.000 description 9
- 102000033147 ERVK-25 Human genes 0.000 description 9
- 239000002775 capsule Substances 0.000 description 9
- 125000006519 CCH3 Chemical group 0.000 description 8
- 108060006943 RdRp Proteins 0.000 description 8
- FPGGTKZVZWFYPV-UHFFFAOYSA-M Tetra-n-butylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 8
- 229940079593 drugs Drugs 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 7
- 125000004432 carbon atoms Chemical group C* 0.000 description 7
- WREGKURFCTUGRC-POYBYMJQSA-N ddC Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 7
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 230000003612 virological Effects 0.000 description 7
- 108010090804 Streptavidin Proteins 0.000 description 6
- 108020000999 Viral RNA Proteins 0.000 description 6
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 6
- 238000003818 flash chromatography Methods 0.000 description 6
- 238000009396 hybridization Methods 0.000 description 6
- 239000002609 media Substances 0.000 description 6
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-butyllithium Chemical group [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 6
- 239000002777 nucleoside Substances 0.000 description 6
- 150000003833 nucleoside derivatives Chemical class 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 125000001544 thienyl group Chemical group 0.000 description 6
- 102000003886 Glycoproteins Human genes 0.000 description 5
- 108090000288 Glycoproteins Proteins 0.000 description 5
- 210000000987 Immune System Anatomy 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 230000002459 sustained Effects 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 238000004293 19F NMR spectroscopy Methods 0.000 description 4
- JJWJSIAJLBEMEN-UHFFFAOYSA-N 6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-1,3-dihydroquinazolin-2-one Chemical compound N1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 JJWJSIAJLBEMEN-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- PSHKMPUSSFXUIA-UHFFFAOYSA-N N,N-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 101700043453 chch-3 Proteins 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 241001493065 dsRNA viruses Species 0.000 description 4
- KZMGYPLQYOPHEL-UHFFFAOYSA-N ethoxyethane;trifluoroborane Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 4
- NPTDXPDGUHAFKC-UHFFFAOYSA-N ethynylcyclopropane Chemical group C#CC1CC1 NPTDXPDGUHAFKC-UHFFFAOYSA-N 0.000 description 4
- 239000007903 gelatin capsule Substances 0.000 description 4
- NIZHERJWXFHGGU-UHFFFAOYSA-N isocyanato(trimethyl)silane Chemical compound C[Si](C)(C)N=C=O NIZHERJWXFHGGU-UHFFFAOYSA-N 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 229940002612 prodrugs Drugs 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
- 241000894007 species Species 0.000 description 4
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-MICDWDOJSA-N 1-deuteriopropan-2-one Chemical compound [2H]CC(C)=O CSCPPACGZOOCGX-MICDWDOJSA-N 0.000 description 3
- NHUBNHMFXQNNMV-UHFFFAOYSA-N 2-ethynylpyridine Chemical compound C#CC1=CC=CC=N1 NHUBNHMFXQNNMV-UHFFFAOYSA-N 0.000 description 3
- USCSRAJGJYMJFZ-UHFFFAOYSA-N 3-methyl-1-butyne Chemical compound CC(C)C#C USCSRAJGJYMJFZ-UHFFFAOYSA-N 0.000 description 3
- 210000004369 Blood Anatomy 0.000 description 3
- 210000001124 Body Fluids Anatomy 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 210000001035 Gastrointestinal Tract Anatomy 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N N,N-Diethylethanamine Substances CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 229920000272 Oligonucleotide Polymers 0.000 description 3
- UEXCJVNBTNXOEH-UHFFFAOYSA-N Phenylacetylene Chemical group C#CC1=CC=CC=C1 UEXCJVNBTNXOEH-UHFFFAOYSA-N 0.000 description 3
- 210000002381 Plasma Anatomy 0.000 description 3
- 229940070891 Pyridium Drugs 0.000 description 3
- 210000002966 Serum Anatomy 0.000 description 3
- 108020005202 Viral DNA Proteins 0.000 description 3
- 239000011717 all-trans-retinol Substances 0.000 description 3
- 235000019169 all-trans-retinol Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 102000004965 antibodies Human genes 0.000 description 3
- 108090001123 antibodies Proteins 0.000 description 3
- 239000003443 antiviral agent Substances 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 125000002837 carbocyclic group Chemical group 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 description 3
- 125000002883 imidazolyl group Chemical group 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 239000008297 liquid dosage form Substances 0.000 description 3
- HPQVWDOOUQVBTO-UHFFFAOYSA-N lithium aluminum hydride Chemical compound [Li+].[Al-] HPQVWDOOUQVBTO-UHFFFAOYSA-N 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 239000002808 molecular sieve Substances 0.000 description 3
- 230000003000 nontoxic Effects 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 125000004430 oxygen atoms Chemical group O* 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 125000004434 sulfur atoms Chemical group 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 210000001519 tissues Anatomy 0.000 description 3
- 239000008096 xylene Substances 0.000 description 3
- BJDCWCLMFKKGEE-KXTPALSWSA-N α-dihydroartemisinin Chemical compound O1C(OO2)(C)CC[C@H]3[C@H](C)CC[C@@H]4[C@@]32[C@@H]1O[C@H](O)[C@@H]4C BJDCWCLMFKKGEE-KXTPALSWSA-N 0.000 description 3
- KDKYADYSIPSCCQ-UHFFFAOYSA-N 1-Butyne Chemical compound CCC#C KDKYADYSIPSCCQ-UHFFFAOYSA-N 0.000 description 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 2
- HQQTZCPKNZVLFF-UHFFFAOYSA-N 4H-1,2-benzoxazin-3-one Chemical class C1=CC=C2ONC(=O)CC2=C1 HQQTZCPKNZVLFF-UHFFFAOYSA-N 0.000 description 2
- 101710027066 ALB Proteins 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 210000004366 CD4-Positive T-Lymphocytes Anatomy 0.000 description 2
- 101700036200 CRLF3 Proteins 0.000 description 2
- 229940093915 Gynecological Organic acids Drugs 0.000 description 2
- 210000000936 Intestines Anatomy 0.000 description 2
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L MgCl2 Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229960000689 Nevirapine Drugs 0.000 description 2
- NLRKCXQQSUWLCH-UHFFFAOYSA-N Nitrosobenzene Chemical class O=NC1=CC=CC=C1 NLRKCXQQSUWLCH-UHFFFAOYSA-N 0.000 description 2
- 208000001388 Opportunistic Infections Diseases 0.000 description 2
- 102000011587 Polyproteins Human genes 0.000 description 2
- 108010076039 Polyproteins Proteins 0.000 description 2
- 239000007759 RPMI Media 1640 Substances 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 125000004429 atoms Chemical group 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 239000007891 compressed tablet Substances 0.000 description 2
- 230000000875 corresponding Effects 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000005712 crystallization Effects 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000001963 growth media Substances 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000002458 infectious Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 150000004658 ketimines Chemical class 0.000 description 2
- OCZDCIYGECBNKL-UHFFFAOYSA-N lithium;alumanuide Chemical compound [Li+].[AlH4-] OCZDCIYGECBNKL-UHFFFAOYSA-N 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N o-xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 125000000160 oxazolidinyl group Chemical group 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 239000003182 parenteral nutrition solution Substances 0.000 description 2
- 230000003285 pharmacodynamic Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 230000001681 protective Effects 0.000 description 2
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 230000001603 reducing Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000001954 sterilising Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000002195 synergetic Effects 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 238000003828 vacuum filtration Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- ZGRQPKYPJYNOKX-XUXIUFHCSA-N (2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-amino-3-sulfanylpropanoyl]amino]-3-sulfanylpropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-(1H-imidazol-5-yl)propanoic acid Chemical compound C([C@H](NC(=O)[C@H](CS)NC(=O)[C@H](CS)N)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CN=CN1 ZGRQPKYPJYNOKX-XUXIUFHCSA-N 0.000 description 1
- BCHIXGBGRHLSBE-UHFFFAOYSA-N (4-methyl-2-oxochromen-7-yl) dihydrogen phosphate Chemical compound C1=C(OP(O)(O)=O)C=CC2=C1OC(=O)C=C2C BCHIXGBGRHLSBE-UHFFFAOYSA-N 0.000 description 1
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 description 1
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- ZJPHDPZUAINCNU-UHFFFAOYSA-N 1-(2-aminophenyl)-2,2,2-trifluoroethanone Chemical class NC1=CC=CC=C1C(=O)C(F)(F)F ZJPHDPZUAINCNU-UHFFFAOYSA-N 0.000 description 1
- ANUSGJXVCFPWMQ-UHFFFAOYSA-N 1-(2-phenylethyl)-3-(1,3-thiazol-2-yl)thiourea Chemical compound N=1C=CSC=1NC(=S)NCCC1=CC=CC=C1 ANUSGJXVCFPWMQ-UHFFFAOYSA-N 0.000 description 1
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 1
- XNMQEEKYCVKGBD-UHFFFAOYSA-N 2-Butyne Chemical compound CC#CC XNMQEEKYCVKGBD-UHFFFAOYSA-N 0.000 description 1
- YHPMRWZVIQTSFZ-UHFFFAOYSA-N 3,5-difluoro-2-(2-fluorophenyl)pyridine Chemical compound FC1=CC(F)=CN=C1C1=CC=CC=C1F YHPMRWZVIQTSFZ-UHFFFAOYSA-N 0.000 description 1
- 125000005986 4-piperidonyl group Chemical group 0.000 description 1
- LELMRLNNAOPAPI-UFLZEWODSA-N 5-[(3aS,4S,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoic acid;aminophosphonous acid Chemical compound NP(O)O.N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 LELMRLNNAOPAPI-UFLZEWODSA-N 0.000 description 1
- LHIJANUOQQMGNT-UHFFFAOYSA-N Aminoethylethanolamine Chemical compound NCCNCCO LHIJANUOQQMGNT-UHFFFAOYSA-N 0.000 description 1
- RWZYAGGXGHYGMB-UHFFFAOYSA-N Anthranilic acid Chemical class NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 1
- 229960000686 Benzalkonium Chloride Drugs 0.000 description 1
- OSASVXMJTNOKOY-UHFFFAOYSA-N Chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 1
- 229960004926 Chlorobutanol Drugs 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N Diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000272184 Falconiformes Species 0.000 description 1
- 210000003754 Fetus Anatomy 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229960002743 Glutamine Drugs 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006822 Human Serum Albumin Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 102000000801 Human immunodeficiency virus 1 reverse transcriptase Human genes 0.000 description 1
- 108010001522 Human immunodeficiency virus 1 reverse transcriptase Proteins 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- ARNWQMJQALNBBV-UHFFFAOYSA-N Lithium carbide Chemical class [Li+].[Li+].[C-]#[C-] ARNWQMJQALNBBV-UHFFFAOYSA-N 0.000 description 1
- 210000004698 Lymphocytes Anatomy 0.000 description 1
- 210000002540 Macrophages Anatomy 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N Methylparaben Chemical group COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- UXKHSOBQGPNQNP-UHFFFAOYSA-N NC(=N)N.[N-]=C=S Chemical compound NC(=N)N.[N-]=C=S UXKHSOBQGPNQNP-UHFFFAOYSA-N 0.000 description 1
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 1
- HTYIXCKSEQQCJO-UHFFFAOYSA-N Phenaglycodol Chemical compound CC(C)(O)C(C)(O)C1=CC=C(Cl)C=C1 HTYIXCKSEQQCJO-UHFFFAOYSA-N 0.000 description 1
- QPFYXYFORQJZEC-FOCLMDBBSA-N Phenazopyridine Chemical compound NC1=NC(N)=CC=C1\N=N\C1=CC=CC=C1 QPFYXYFORQJZEC-FOCLMDBBSA-N 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N Propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
- 210000000582 Semen Anatomy 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M Sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- HYHCSLBZRBJJCH-UHFFFAOYSA-M Sodium hydrosulfide Chemical compound [Na+].[SH-] HYHCSLBZRBJJCH-UHFFFAOYSA-M 0.000 description 1
- GRVFOGOEDUUMBP-UHFFFAOYSA-N Sodium sulfide Chemical compound [Na+].[Na+].[S-2] GRVFOGOEDUUMBP-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 210000002784 Stomach Anatomy 0.000 description 1
- 210000001744 T-Lymphocytes Anatomy 0.000 description 1
- IJOOHPMOJXWVHK-UHFFFAOYSA-N Trimethylsilyl chloride Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 1
- FPKOPBFLPLFWAD-UHFFFAOYSA-N Trinitrotoluene Chemical compound CC1=CC=C([N+]([O-])=O)C([N+]([O-])=O)=C1[N+]([O-])=O FPKOPBFLPLFWAD-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K Trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 101710022693 URA6 Proteins 0.000 description 1
- 230000036462 Unbound Effects 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 240000006722 Vanilla planifolia Species 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- 102000016350 Viral Proteins Human genes 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- DJWUNCQRNNEAKC-UHFFFAOYSA-L Zinc acetate Chemical class [Zn+2].CC([O-])=O.CC([O-])=O DJWUNCQRNNEAKC-UHFFFAOYSA-L 0.000 description 1
- IQPQWNKOIGAROB-UHFFFAOYSA-N [N-]=C=O Chemical compound [N-]=C=O IQPQWNKOIGAROB-UHFFFAOYSA-N 0.000 description 1
- ZPHLYFRGLYQDCT-UHFFFAOYSA-N [N-]=C=O.NC(=N)N Chemical compound [N-]=C=O.NC(=N)N ZPHLYFRGLYQDCT-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 230000000996 additive Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 230000000172 allergic Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 125000000751 azo group Chemical group [*]N=N[*] 0.000 description 1
- 125000003943 azolyl group Chemical group 0.000 description 1
- 108010003152 bacteriophage T7 RNA polymerase Proteins 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 101700062316 cec-3 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000295 complement Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- RGSFGYAAUTVSQA-UHFFFAOYSA-N cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000012024 dehydrating agents Substances 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 229940042399 direct acting antivirals Protease inhibitors Drugs 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000029578 entry into host Effects 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- STSCVKRWJPWALQ-UHFFFAOYSA-N ethyl 2,2,2-trifluoroacetate Chemical compound CCOC(=O)C(F)(F)F STSCVKRWJPWALQ-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 102000018694 gag-pol Fusion Proteins Human genes 0.000 description 1
- 108010027225 gag-pol Fusion Proteins Proteins 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000002068 genetic Effects 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxyl anion Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 229940027318 hydroxyurea Drugs 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 230000000043 immunodepressive Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulators Drugs 0.000 description 1
- 230000001506 immunosuppresive Effects 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052500 inorganic mineral Chemical class 0.000 description 1
- 238000003874 inverse correlation nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000011968 lewis acid catalyst Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- VSRVKRSRQFOUEF-UHFFFAOYSA-N lithide Chemical compound [Li-] VSRVKRSRQFOUEF-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M methanoate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- LTKXCIAOFZUMLR-UHFFFAOYSA-N methoxy(methyl)azanide Chemical class C[N-]OC LTKXCIAOFZUMLR-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Chemical class 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000002829 nitrogen Chemical group 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000000149 penetrating Effects 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 125000004928 piperidonyl group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- 230000002335 preservative Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 230000002633 protecting Effects 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 229910052979 sodium sulfide Inorganic materials 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 150000003413 spiro compounds Chemical class 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 125000005017 substituted alkenyl group Chemical group 0.000 description 1
- 125000004426 substituted alkynyl group Chemical group 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000011885 synergistic combination Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 239000011778 trisodium citrate Substances 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 239000005723 virus inoculator Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000003313 weakening Effects 0.000 description 1
- 150000003738 xylenes Chemical class 0.000 description 1
Abstract
The present invention relates to 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolines of formula (I), or stereoisomeric forms, stereoisomeric mixtures, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of HIV reverse transcriptase, and to pharmaceutical compositions and diagnostic kits comprising the same, and methods of using the same for treating viral infection or as an assay standard or reagent.
Description
3, 4-DIHYDRO-2- (1H) -CUINAZOLINONES 4, 4- DISSTITUTE USEFUL AS INHIBITORS OF THE
INVERSE TRANSCRIPTASA OF HIV.
Field of Invention
This invention relates generally to 3,4-dihydro-2 (1H) -quinazolinones 4, 4-dibuclides which are useful as inhibitors of HIV reverse transcriptase, pharmaceutical compositions and diagnostic devices comprising the same, methods of use of them to treat a viral infection or as a standard reagent assay, and intermediaries and processes to elaborate it.
Background of the Invention
Two different retroviruses, human immunodeficiency virus (HIV) type-1 (HIV-1) or type-2 (HIV-2), have been etiologically linked to the immunodepressive disorder, acquired immunodeficiency syndrome (AIDS). HIV-positive individuals are initially asymptomatic, but typically develop a complex
Ref: 031177 related to AIDS (ARC) followed by AIDS. Affected individuals exhibit severe immunosuppression that predisposes them to weakening and fatal terminal opportunistic infections.
The AIDS disorder is the final result of an HIV-1 or HIV-2 virus followed by its complete life cycle. The life cycle of the virus begins with the binding of the virus to itself to the T-4 lymphocyte immune cell of the human host through the binding of a glycoprotein on the surface of the protective coat of the virus with the glycoprotein CD4 in the lymphocyte cell. . Once bound, the virus gets rid of its envelope of glycoprotein, penetrating the membrane of the host cell, and discovering its RNA. The enzyme of the virus, reverse transcriptase, directs the process of transcription of the RNA in the DNA of simple braid. The RNA virus degrades and a second braid of DNA is created. Now double stranded DNA is integrated into the genes of human cells and those genes are used for the production of viruses.
At this point, the RNA polymerase completely transcribes the DNA in the RNA virus. The RNA virus is translated into the gag-poly precursor fusion polyprotein. The polyprotein is then incrusted by the HIV protease enzyme to provide the mature viral proteins. Thus, the HIV protease is responsible for the regularization of a series of incrustation events that begin with the maturation of the virus particles in a virus that is capable of infecting completely.
The typical response of the human immune system, eliminating the invasion of viruses, is put to the test because viruses infect and eliminate the T cells of the immune system. In addition, viral reverse transcriptase, the enzyme used to make a new virus particle, is not very specific, and causes transcription errors that result in a continuous change of glycoproteins on the surface of the virus's protective coat. This lack of specification weakens the effectiveness of the immune system because the antibodies specifically produced against a glycoprotein may be useless against others, thereby reducing the number of antibodies available to deal with viruses. The virus continues to reproduce as the response of the immune system continues to weaken. Eventually, HIV greatly sustains a free domain over the immune system of antibodies, allowing opportunistic infections to occur, and without the administration of anti-virus agents, immunomodulators, or both, death can follow.
These are at least three critical points in the life cycle of the virus that can be identified as possible targets for antiviral drugs: (1) the initial binding of the virus to the T-4 lymphocyte or macrophage site, (2) the transcription of the viral RNA to viral DNA
(reverse transcriptase, TI), and (3) the processing of the gag-pol protein by the HIV protease.
The inhibition of the virus is the second critical point, the process of transcription of viral RNA to viral DNA, has provided several of the general therapies used in the treatment of AIDS. This transcription can occur by the virus to reproduce because the genes of the virus are encoded in the RNA and the host cell only reads DNA. By introducing drugs that block reverse transcriptase to complete the formation of viral DNA, replication of HIV-1 can be stopped.
A number of compounds that interfere with viral replication have been developed to treat AIDS. For example, nucleoside analogs, such as 3 '-azido-3' -deoxy thymidine (AZT), 2 ', 3'-dideoxy cytidine (ddC), 2', 3'-dideoxy thymidinene (d4T), 2 ', 3 '-dideoxinosine (ddl), and 2'-3'-dideoxy-3'-thia-cytidine (3TC) have been shown to be relatively effective in HIV replication defective in the state of reverse transcriptase (TI).
An active area of research is the discovery of non-nucleoside HIV transcriptase inhibitors. As an example, it has been found that certain benzoxazinones and quinazolinones are active in the inhibition of HIV reverse transcriptase, the prevention or treatment of HIV infection and the treatment of AIDS. '
U.S. Patent 5,519,021 discloses reverse transcriptase inhibitors which are benzoxazinones of the formula:
where X is a halogen, Z can be 0
Patents EP 0.530 and WO 93/04047 disclose inhibitors of HIV reverse transcriptase which are quinazolinones of the formula A:
wherein G is a variety of groups, R and R can be H, Z can be O, R2 can be unsubstituted alkyl, unsubstituted alkenyl, unsubstituted alkynyl, unsubstituted cycloalkyl, unsubstituted heterocycle, and optionally substituted aryl, and R may be a variety of groups including sub-alkyl substituted.
WO 95/12583 also describes inhibitors of HIV reverse transcriptase of formula A. In this publication, G is a variety of groups, R3 and R4 can be H, Z can be 0, R2 is substituted alkenyl or substituted alkynyl, and R1 is cycloalkyl, alkynyl, alkenyl, or cyano. WO 95/13273 illustrates the asymmetric synthesis of one of the compounds of WO 95/12583, (S) - (-) - 6-chloro-4-cyclopropyl-3,4-dihydro-4 ((2-pyridi) ethynyl ) -2 - (1H) -quinazolinone.
The synthetic processes for making quinazolinones such as those described above are detailed in the following references: Houpis et al, Te t r. Le t t. 1994, 35 (3 7), 6811-6814; Tucker et al, J. Med. Ch em. 1994, 3 7, 2437-244; and, Huffman et al, J. Org. Ch em. 1995, 60, 1590-1594.
Patent DE 4,320,347 illustrates qui na ol nons of the formula
wherein R is a phenyl, carbocyclic ring, or a heterocyclic ring. Compounds of this type are not considered to be part of the present invention.
Despite the current success of reverse transcriptase inhibitors, it has been found that patients with HIV can begin to resist a simple inhibitor. Thus, it is desirable to develop additional inhibitors to further combat HIV infection.
Description of the invention
Accordingly, an object of the present invention is to provide novel reverse transcriptase inhibitors.
It is another object of the present invention to provide a novel method for the treatment of HIV infection, which comprises administering to a host in need of such treatment a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt thereof.
It is another object of the present invention to provide a novel method for the treatment of infection, by HIV comprising administering to the host in need thereof a therapeutically effective combination of (a) one of the compounds of the present invention and (b) one or more compounds selected from the group consisting of inhibitors of HIV reverse transcriptase and inhibitors of HIV protease.
It is another object of the present invention to provide pharmaceutical compositions with reverse transcriptase inhibitory activity comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt thereof.
It is another object of the present invention to provide a method for inhibiting HIV present in a blood fluid sample comprising treating the blood fluid sample with an effective amount of a compound of the present invention.
It is another object of the present invention to provide a device or container containing at least one of the compounds of the present invention in an amount effective to be used as a standard or reagent in a test or assay to determine the ability of a potential pharmacist. to inhibit HIV reverse transcriptase, the growth of HIV, or both.
These and other objects, which will be apparent during the following detailed description, will be executed by the inventors discovering that the compounds of formula (I):
wherein R1, R2, R3, and R8 are defined below, stereoisomeric forms, mixtures of stereoisomeric forms or pharmaceutically acceptable salt forms thereof, are effective reverse transcriptase inhibitors.
Detailed Description of the Preferred Modalities.
[1] Thus, in a first embodiment, the present invention provides a novel compound of formula I:
or a tereoisomer or pharmaceutically acceptable salt thereof, wherein:
RJ is alkyl C; substituted with 1-7 halogen;
R 'is selected from C? _5 alkyl substituted with
1-2 R, C2_5 alkenyl substituted with 1-2 R "1, and C2-alkynyl substituted with 1 R;
R3 in each appearing, is independently selected from alkyl C? _, OH, alkoxy C? _, F, Cl, Br, I, NR5R5a, N02, CN, C (0) R6, NHC (0) R7, and NHC (O) NR5R5a;
alternatively, if two R3 are presented and are attached to the adjacent carbons, then these can be combined to form -OCH20-;
R4 is selected from C3_5 cycloalkyl substituted with 0-2 of R3, phenyl substituted with 0-5 of
R, and a 5-6 membered heterocyclic system containing from 1-3 heteroatoms selected from O, N, and S, substituted with 0-2 of R3;
R5 and R5a are independently selected from H and Ci_3 alkyl;
R 'is selected from H, OH alkyl to the coxi
R7 is selected from C3_3alkyl and C3_3alkoxy;
R8 is selected from H, C3_5 cycloalkyl, and Ci_3 alkyl; Y,
n is selected from 0, 1, 2, 3, and 4.
[2] In a preferred embodiment, the present invention provides a novel compound of formula I, wherein:
R is C1-3 alkyl substituted with 1-7 halogen;
R2 is selected from C1-5 alkyl substituted with 1 of R4, C2-5 alkenyl substituted with 1 of R4, and C2-5 alkynyl substituted with 1 of R4;
R3 in each appearing is independently selected from C C - alkyl, OH, C? _4 alkoxy, F, Cl, Br, I, NR5R5a, N02, CN, C (0) R6, NHC (0) R7, and NHC ( O) NR5R5a;
alternatively, if two of R3 are presented and are bonded to the adjacent carbons, then these may be combined to form -0CH20-;
R is selected from C3-5 cycloalkyl substituted with 0-2 of R3, phenyl substituted with 0-2 of R3, and a 5-6 member heterocyclic system containing from 1-3 heteroatoms selected from O, N, and S, substituted with 0-1 of R3;
R5 and R5a are independently selected from H,
CH3 and C2H5.
R (selected from H, OH, CH3, C2H5, OCH3, OC2H5 and NR5R5a,
R7 is selected from CH3, C2H5, OCH3, and OC2H5;
R8 is selected from H, cyclopropyl, CH3 and C2H5; Y,
n is selected from 0, 1, 2, and 3.
[3] In a more preferred embodiment, the present invention provides a novel compound of formula I, wherein:
R1 is selected from CF3, and C2F5;
R is selected from C1-3 alkyl substituted with 1 R4, C2-3 alkenyl substituted with 1 R4, and C2-3 alkynyl substituted with 1 R4;
R3, in each appearing is independently selected from C1-3 alkyl, OH, C3-alkoxy, F, Cl, Br, I, NR5R5a, N02, CN, C (0) R6, NHC (0) R7, and NHC (O) NR5R5a;
alternatively, if two of R3 are presented and are bonded to adjacent carbons, then these can be combined to form -OCH20-;
R is selected from C3-5 cycloalkyl substituted with 0-2 of R3, phenyl substituted with 0-2 R3, and a 5-6 member heterocyclic system containing 1-3 heteroatoms selected from O, N, and S, substituted with 0 -1 R3;
R and RDa are independently selected from H
CH3 ,. and C2H5
R 'is selected from H, OH, CH3'. ? H • OCH3, OC2K5 and NR5R5a;
R7 is selected from CH3, C2H5, OCH3, and OC H5;
R8 is selected from H, CH and C2H5; Y
n is selected from 0, 1, and 2.
[4] In still a more preferred embodiment, the present invention provides a novel compound of formula I, wherein:
R1 is CF3;
R2 is selected from C1-3 alkyl substituted with 1 R4, C2_3 alkenyl substituted with 1 R4, and C2-3 alkynyl substituted with 1 R4;
R3 in each appearing is independently selected from C1-3alkyl, OH, C1-3.alkoxy, F, Cl, NR5R5a, N02, CN, C (0) R6, NHC (0) R ~, and NHC ( O NR5R5a,
alternatively, if two R's are presented and attached to the adjacent carbons, then these can be combined to form -CH20-;
R is selected from cyclopropyl substituted with 0-1 R3, phenyl substituted with 0-2 R3, and a 5-6 member heterocyclic system containing from 1-3 heteroatoms selected from 0, N, and S, substituted with 0-1 R3 , wherein the heterocyclic system is selected from 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-furanyl, 3-furanyl, 2-thienyl, 3-thienyl, 2-oxazolyl, 2-thiazolyl, -i-soxazolyl, and 2- imidazolyl;
R5 and R5a are independently selected from H,
CH3 and C2H5;
Rb is selected from H, OH, CH3, C2H5, OCH3, OC2H5,
And NR5R5a;
R is selected from CH3, C2H5, OCH, and OC2H5.
R is selected from H, CH3 and C2H5; Y,
n is selected from 1 and 2.
[5] In a further preferred embodiment, wherein the compound is of the formula
the.
[5] In a further preferred embodiment, wherein the compound is of the formula Ib:
Ib.
[7] In a further preferred embodiment, the compound of formula I is selected from:
(+ / -) - β-chloro-4-cyclopropylethynyl-4-trifluoromethyl-3,4-dihydro-2 (1H) -quina zol inona;
(+ / -) -6-chloro-4- (2-pyridyl) ethynyl-4-trifluoromethyl-3,4-dihydro-2 (1H) -quinazolinone;
(+ / -) -6-chloro-4-phenylethynyl-4-trifluoromethyl-3,4-dihydro-2 (1H) -quinazolinone;
(+/-) - 4-cyclopropylethynyl-6-methoxy-4-trifluoromethyl-3,4-dihydro-2 (1H) -quinazolinone;
(+/-) -6-methoxy- (2-pyridyl) ethynyl-4-trifluoromethyl-3,4-dihydro-2 (1H) -quinazolinone;
(+/-) -6-methoxy-4-phenylethynyl-4-trifluoromethyl-3,4-dihydro-2 (1H) -quinazolinone;
(+/-) -4-cyclopropylethynyl-5, β-difluoro-4-tri-fluororneti 1-3, 4-dihydro-2 (1H) -quinazolinone;
(+/-) - 5,6-difluoro-4- (2-pyridyl) ethynyl-4-trifluoromethyl-3, -dihydro-2 (1H) -quinazolinone;
(+/-) -5,6-difluoro-4-phenylethynyltrifluoromethyl-3,4-dihydro-2 (1H) -quinazolinone;
(+/-) - 4-cyclopropylethynyl-6-fluoro-4-trifluoromethyl-3, -dihydro-2 (1H) -quinazolinone;
(+ / -) -6-fluoro-4- (2-pyridyl) ethynyl-4-trifluoromethyl-3,4-dihydro-2 (1H) -quinazolinone;
(+/-) -6-fluoro-4-phenylethynyl-4-tri-fluoromethyl-3,4-dihydro-2 (1H) -quinazolinone;
(+/-) - 6-fluoro-4- (2'-2-pyridyl) ethyl-4-trifluoromethyl-3,4-dihydro-2 (1H) -quinazolinone;
(+/-) -6-fluoro-4-phenylethyl-4-trifluoromethyl-3,4-dihydro-2 (1H) -quinazolinone;
(-) - 6-chloro-4-cyclopropylethynyl-4-tri-fluororne-3-yl-dihydro-2 (1H) -quinazolinone;
(+) - 6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-3,4-dihydro-2 (1H) -quinazolinone;
(+) -4-cyclopropylethynyl-5,6-di-fluoro-4-t-rifluoromet-3-yl-dihydro-2 (1H) -quinazolinone;
(-) -4-cyclopropylethynyl-5, β-difluoro-4-trifluoromethyl-3,4-dihydro-2 (1H) -quinazolinone;
(+) -4-E-cyclopropyletenyl-5,6-difluoro-4-trifluoromethyl-3, -dihydro-2 (1H) -quinazolinone; Y,
(-) - 6-chloro-4-E-cyclopropyletenyl-4-trifluoromethyl-3, 4-dihydro-2 (1H) -quinazolinone;
or a pharmaceutically acceptable salt thereof.
[8] In a second embodiment, the present invention provides a novel compound of formula II:
II
or a tereoisomer or pharmaceutically acceptable salt thereof, wherein:
R2 is C = C-R4a;
RJ is selected from alkyl C? _, OH, C4-alkoxy, F, .'Cl, Br, I, NR5R5a, N02, CN, C (0) R6,
NHC (0) Re, NHC (0) R7, and NHC (0) NR5R5a;
Ri 4a is selected from methyl, ethyl, n-propyl, i-propyl, i-butyl, t-butyl, and i-pentyl
R5 and R5a are independently selected from H and C1-3 alkyl,
R 'is selected from H, OH, alkyl Ci. coxi
C? -4, and NR5R5a;
R is selected from C1_3alkyl and C3_3alkoxy;
OR R is selected from H, C3_5 cycloalkyl, and C1_3alkyl; Y,
n is selected from 0, 1, 2, 3, and 4.
[9] In another preferred embodiment, the present invention provides a novel compound of formula II, wherein:
R2 is C = C-R4a;
RJ is selected from C C4alkyl, OH, C ?4alkoxy, F, Cl, Br, I, NR5R5a, N02, CN, C (0) Rc ', and NHC (0) R7;
R, 4a is selected from methyl, ethyl, n-propyl, i-propyl, i-butyl, t-butyl, and i-pentyl;
R and R .5a are independently selected from H
CH3 and C2H5
R < is selected from H, OH, CH3, C2H5, 0CH3, OC2H5 and NR5R5a;
R7 is selected from CH3, C2H5, OCH3, and OC2H5;
R8 is selected from H, cyclopropyl, CH3 and C2Hs; Y
n is selected from 0, 1, and 2.
[10] In a further preferred embodiment, wherein the compound is of the formula lialia.
[11] In a further preferred embodiment, wherein the compound is of formula 11b:
lib.
[12] In another more preferred embodiment, the compound of formula II is selected from:
(+/-) - 6-chloro-4-isopropylethynyl-4-trifluoromethyl-3,4-dihydro-2 (1H) -quinazolinone;
(+ / -) -6-chloro-4-ethynylnyl-4-trifluoromethyl-3,4-dihydro-2 (1H) -quinazolinone;
(+ / -) - 4-isopropylethynyl-6-methoxy-4-tri fluorome-3, 4-dihydro-2 (1H) -quinazolinone;
(+/-) -5,6-difluoro-4-isopropylethynyl-4-trifluoromethyl-3, -dihydro-2 (1H) -quinazolinone;
(+/-) -5,6-D-fluoro-4-ethylethynyl-4-tri fluoromethyl-3, -dihydro-2 (1H) -quinazolinone;
(+/-) -5,6-difluoro-4-isopentyl-4-trifluoromethyl-3,4-dihydro-2 (1H) -quinazolinone;
(+/-) -6-fluoro-4-isopropylethynyl-4-trifluoromethyl-3,4-dihydro-2 (1H) -quinazolinone;
(+/-) -6-fluoro-4-ethylethynyl-4-tri fluorome-3, 4-dihydro-2 (1H) -quinazolinone;
(-) -5,6-difluoro-4-isopropylethynyl-4-trifluoromethyl-3,4-dihydro-2 (1H) -quinazolinone;
(+) - 5,6-difluoro-4-isopropylethynyl-4-trifluoromethyl-3,4-dihydro-2 (1H) -quinazolinone;
(-) -5,6-difluoro-4-ethylethynyl- -tri fluoromethyl-3-dihydro-2 (1H) -quinazolinone; and, (+) - 5, β-difluoro-4-ethynylnyl-4-trifluoromethyl '3,4-dihydro-2 (1H) -quinazolinone;
a pharmaceutically acceptable salt thereof
In a third embodiment, the present invention provides a novel pharmaceutically effective composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of formula I or II or a pharmaceutically acceptable salt thereof.
In a fourth embodiment, the present invention provides a novel method for treating an HIV infection comprising administering to a host in need of such treatment, a therapeutically effective amount of a compound of formula I or II or a pharmaceutically acceptable salt thereof.
In a fifth embodiment, the present invention provides a novel method for the treatment of an HIV infection comprising administering, in combination, to a host in need thereof, a therapeutically effective amount of: (a) a compound of formula I or II; and, (b) at least one compound selected from the group consisting of HIV reverse transcriptase inhibitors and HIV protease inhibitors.
In another preferred embodiment, the reverse transcriptase inhibitor is selected from AZT, 3TC, ddI, ddC, d4T, delavirdine, TIBO derivatives, BI-RG-587, nevirapine, L-697,661, LY73497, Ro 18,893, loviride, trovirdine, MKC-442, and HBY 097, and the protease inhibitor is selected from saquinavir, ritonavir, indinavir, VX-478, nelfinavir, KNI-272, CGP-61755, U-140690, and ABT-378.
Notwithstanding a preferred embodiment, the reverse transcriptase inhibitor is selected from AZT and 3TC and the protease inhibitor is selected from saquinavir, ritonavir, nelfinavir, and indinavir.
In yet a further preferred embodiment, the reverse transcriptase inhibitor is AZT.
In yet another preferred preferred embodiment, the protease inhibitor is indinavir.
In a sixth embodiment, the present invention provides a pharmaceutical device useful for the treatment of HIV infection, comprising a therapeutically effective amount of: (a) a compound of formula I or II; and, (b) at least one compound selected from the group consisting of HIV reverse transcriptase inhibitors and HIV protease inhibitors, in one or more sterile containers.
In a seventh embodiment, the present invention provides a novel method for inhibiting HIV present in a body fluid sample comprising treating the body fluid sample with an effective amount of a compound of formula I or II.
In an eighth embodiment, the present invention for providing a novel device or container comprises a compound of formula I or II in an amount effective to be used as a standard or reagent in a test or assay to determine the ability of a potential pharmacist to inhibit HIV reverse transcriptase, HIV growth, or both.
Definitions .
As used herein, the following terms and expressions have the indicated meanings. It will be appreciated that the compounds of the present invention contain an asymmetrically substituted carbon atom, and can be isolated in optically active or racemic forms. The form for preparing optically active forms, such as by resolution of racemic forms or by synthesis, from optically active starting materials is well known in the art. All chiral, diastereomeric, racemic forms and all geometrically isomeric forms of a structure are tried, except the specific stereochemical or isomeric forms are specifically indicated.
The processes of the present invention are contemplated to be practiced on at least one multigram scale, kilogram scale, multikilogram scale, or industrial scale. The multigram scale, as used herein, is preferably the scale wherein at least one starting material is present in 10 grams or more, more preferably at least 50 grams or more, however more preferably at least 100 grams or more. The multikilogram scale, as used herein, is projected to mean the scale where more than one kilogram of at least one starting material is used. The industrial scale, as used here, is projected to mean a scale that is other than the laboratory scale and that is sufficient to distribute enough product for both clinical trials or distribution for consumers.
As used herein, "alkyl" is projected to include both straight chain saturated aliphatic hydrocarbon groups having the specific number of carbon atoms. Examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, t-butyl, n-pentyl, and s-pentyl. "Haloalkyl" is projected to include both groups of straight or branched chain saturated aliphatic hydrocarbons having the specific number of carbon atoms, substituted with 1 or more halogens (for example -CVFW where v = 1 to 3 and w = 1 to ( 2v + l)). Examples of haloalkyls include, but are not limited to, trifluoromethyl, trichloromethyl, pentafluoroethyl, and pentachloroethyl. "Alkoxy" represents an alkyl group as defined above with the indicated number of carbon atoms attached together with the oxygen bridge. Examples of alkoxy include, but are not limited to, methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, s-butoxy, t-butoxy, n-pentoxy, and s-pentoxy. "Cycloalkyl" is projected to include saturated ring groups, such as cyclopropyl, cyclobutyl, or cyclopentyl. "Alkenyl" is projected to include hydrocarbon chains of either straight or branched configuration and one or more unsaturated carbon-carbon bonds that may occur at any stable point along the chain, such as ethenyl, propenyl, and the like. "Alkynyl" is projected to include hydrocarbon chains of either straight or branched configuration and one or more triple carbon-carbon bonds that can occur at any stable point along the chain, such as ethynyl, propynyl, and the like.
"Halo" or "halogen" as used herein refers to fluoride, chlorine, bromine and iodine. "Counter-ion" is used to represent negatively charged, small species, such as chlorine, bromine, hydroxide, acetate, sulfate and the like.
As used herein, "aryl" or "aromatic residues" is projected to mean an aromatic portion containing the specific number of carbon atoms, such as phenyl or naphthyl. As used herein, "carbocyclic" or "carbocyclic residue" is projected to mean any 3 to 6 membered monocyclic ring, which may be saturated or partially unsaturated. Examples of such carbocycles include, but are not limited to, cyclopropyl, cyclopentane, cyclohexyl, phenyl, biphenyl, naphthyl, indanyl, adamantyl, or tetrahydronaphthyl (tetralino).
As used herein, the term "heterogeneous" or "heterocyclic system" is projected to mean a 5- to 6-membered monocyclic heterocyclic ring that is partially saturated or unsaturated (aromatic), and that consists of carbon atoms and from 1 to 3 heteroatoms independently selected from the group consisting of N, O and S. The nitrogen and sulfur heteroatoms may optionally be oxidized. The heterocyclic ring can be attached to this pendant group at any heteroatom or carbon atom resulting in a stable structure. The heterocyclic rings described herein can be substituted on carbon or on a nitrogen atom if the resulting compound is stable. If it is specifically noted, a nitrogen in the heterocyclic may optionally be quaternized. It is preferred that when the total number of S and O atoms in the heterocycle exceeds 1, then these heteroatoms are not adjacent to each other. It is preferred that the total number of S and O atoms in the heterocyclic is not greater than 1. As used herein, the term "aromatic heterocyclic system" is projected to mean a 5-6 membered monocyclic heterocyclic aromatic ring consisting of carbon atoms and from 1 to 3 heteroatoms independently selected from the group consisting of N, O and S. It is preferred that the total number of S and O atoms in the aromatic heterocyclic is not greater than 1.
Examples of heterocycles include, but are not limited to, 2 -pirrolidonilo, 2H-pyrrolyl, 4-piperidonyl, 6H-1, 2, 5-thiadiazinyl, 2H, 6H- 1, 5, 2 -ditiazinilo, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, isoxazolyl, morpholinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1, 2, -oxadiazolyl, 1,2,5-oxadiazolyl, 1, 3, 4 -oxadiazolyl, oxazolidinyl, oxazolyl, piperazinyl, piperidinyl , pteridinyl, piperidonyl, 4 -piperidonilo, pteridinyl, purinyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridizinyl, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, pyrrolyl, tetrahydrofuranyl, 6H-1, 2, 5 - 1i to adi zini 1 or, 1,2,3- thiadiazolyl, 1,2,4-thiadiazolyl, c, _ thiadiazolyl, 1, 3, 4-thiadiazolyl, thiazolyl, thienyl, t ienotiazolilo, t ienooxa zolil or, thienoimidazolyl, thiophenyl, triazinyl , 1,2,3-triazolyl, 1,2-triazolyl, 1, 2, 5-triazolyl, and 1,3,4-triazolyl. Preferred heterocyclics include, but are not limited to, pyridinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, and oxazolidinyl. Also included are fused rings and spiro compounds containing, for example, the above heterocycles.
As used herein, "HIV reverse transcriptase inhibitor" is projected to refer to both nucleoside and non-nucleoside inhibitors of HIV reverse transcriptase
(IT) Examples of nucleoside CT inhibitors include, but are not limited to, AZT, ddC, ddl, d4T, and 3TC. Examples of non-nucleoside CT inhibitors include, but are not limited to, delavirdine (Pharmacia and Upjohn U90152S), TIBO derivatives, BI-RG-587, nevirapine (Boehringer
Ingelheim), L-697,661, LY 73497, Ro 18,893 (Roche), loviride (Janssen), trovirdine (Lilly), MKC-442"(Triangle), and HBY 097 (Hoechst).
As used herein, "HIV protease inhibitor" is projected to refer to compounds that inhibit HIV protease. Examples include, but are not limited to, saquinavir (Roche, Ro31-8959), ritonavir (Abbott, ABT-538), indinavir (Merck, MK-639), VX-478 (Vertex / Glaxo Wellcome), nefilnavir (Agouron, AG-1343), KNI-272 (Japan Energy), CGP-61755 (Ciba-Geigy), U-140690 (Pharmacia and Upjohn), and ABT-378. Additional examples include cyclic protease inhibitors described in WO 93/07128, WO 94/19329, WO 94/22840, and PCT Application US No. 96/03426.
As used herein, "pharmaceutically acceptable salts" refers to derivatives of the disclosed compounds wherein the familiar compounds are modified to make acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, salts of organic acids or minerals of basic residues such as amines; alkaline or organic salts or acid residues such as carboxylic acids; and similar. The pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the familiar compounds formed, for example, from non-toxic organic or inorganic acids. For example, such conventional non-toxic salts include those derived from inorganic acids such as hydrochloride, hydrobromide, sulfuric, sulfamic, phosphoric, nitric and the like; and salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymethyl, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2- toxibenzoic, fumaric, toluensul phonic, methanesulfonic, ethane disulfonic, oxalic, isethonic, and the like.
The pharmaceutically acceptable salts of the present invention can be synthesized from the family compound containing a basic or acid portion by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, ether such as non-aqueous medium, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. A list of appropriate salts can be found in Remin gt on 's Pha rma ceu ti cal Sci in ces, 17th edition, Mack
Publishing Company, Easton, PA, 1985, page 1418, the description of which is incorporated herein for reference.
The phrase "pharmaceutically acceptable" is used herein to refer to those compounds, materials, compositions, and / or dosage forms that are, within the scope of sound medical judgment, appropriate to be used in contact with the tissues of humans and animals without excessive toxicity, irritation, allergic response, or other problem or complication provided with a reasonable benefit / risk range.
"Pro-medicaments" are projected to include any of the co-valently linked carriers that release the family drug in accordance with formula (I) or other formulas or compounds of the present invention in vi when such pro-drugs are administered to a mammalian subject. The pro-medicines of a compound of the present invention, for example of formula (I), are prepared by modifying the functional groups present in the compounds in such a way that the modifications are cut, both in routine or in vivo manipulation, for the family compound. The pro-drugs include compounds of the present invention wherein the hydroxy or amino group is linked to any group which, when the pro-drug is administered to a mammalian subject, cuts to form a free hydroxyl or free amino, respectively. Examples of pro-drugs include, but are not limited to, acetate derivatives, formate and benzoate of functional alcohol and amine groups in the compounds of the present invention, and the like.
"Stable compound" and "stable structure" are mentioned to indicate a compound that is sufficiently robust to survive isolated for a useful degree of purity for a reaction mixture, and formulation into an effective therapeutic agent. Only stable compounds are contemplated by the present invention.
"Substituted" is projected to indicate that one or more hydrogens in the atom indicated in the expression using "substituted" is replaced with a selection of the indicated group (s), with the proviso that the said normal valence is not exceeded, and that the substitution results in a stable compound. When the substituent is a keto group (ie, = 0), then 2 hydrogens are replaced in the atom.
"Therapeutically effective amount" is projected to include an amount of a compound of the present invention or an amount of the combination of rei-indicated compounds effective to inhibit HIV infection or treat the symptoms of HIV infection in a host. The combination of the compounds is preferable in a synergistic combination. Synergy, as described for example by Chou and Talalay, Adv.
Enzyme Regul. 22: 27-55 (1984), occurs when the effect (in this case, the inhibition of HIV replication) of the compounds when administered in combination is greater than the additive effect of the compounds when administered alone as an agent simple. In general, a synergistic effect is more clearly demonstrated at sub-optimal concentrations of the compounds. The synergy can be in terms of low cytotoxicity, increased anti-viral effect, or some other beneficial effect of the combination compared with the individual components.
Synthesis
The compounds of the present invention can be prepared in a number of ways well known to one skilled in the art of organic synthesis. The compounds of the present invention can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or variations immediately after appreciated by those skilled in the art. Preferred methods include, but are not limited to those methods described below. Each of the references cited below are incorporated herein for reference.
IT'S BURNING 1
TMSCl. RlMgX base
Scheme 1 illustrates a method of preparing ce to-anilines from an appropriately substituted 2-aminobenzoic acid. The acid is converted to its N-methoxy-N-methyl amide derivative which can then be displaced to obtain the R 1 -substituted ketone. Keto-anions are useful intermediates for the presently claimed compounds.
E SQUEMA 2
Scheme 2 describes another method of preparing keto-anilines, this time from which an aniline is appropriately substituted. After iodination and protection of the amine, a group such as trifluoromethyl can be introduced using a strong base and ethyl trifluoroacetate. Deprotection provides cet o-aniline. Additional means of preparing cet o-anilines are known to one of skill in the art, for example, Houpis et al, Te tr. Le t t. 1994, 35 (3 7), 6811-6814, the content of which is incorporated herein by reference.
SCHEME 3
Another method for making 2-tri-fluoroacetylanilines is shown in Scheme 3. After forming the protected aniline, the amide is then reduced and the trifluoromethyl group is added. Oxidation with an oxidant, such as Mn02, provides the useful intermediate.
Using the general method detailed in Scheme 4, one can prepare compounds of the present invention. The keto-aniline 1_, which can be prepared by the methods described in Schemes 1 and 2, is treated with rimethylsilyl isocyanate in dry tetrahydrofuran and the presence of dimethylaminopyridine followed by tetrabutylammonium fluoride to give the hydroxy urea 2_. The 2-hydroxy urea is then dehydrated with a dehydrating agent such as a 4Á molecular sieve in refluxing toluene or xylenes to give ketimine 3_. A substituted acetylenic R2 group is added by treating the ketimide 3_ with a lithium acetylide, which is prepared in a separate vessel by reacting the corresponding acetylene substituted with n-butyllithium in dry tetrahydrofuran, to give the 4,4-disubstituted 3,4-dihydro-2 (1H) -quinazolinone 4_, a compound of formula I the acetylenic bond of the compound 4_ can be reduced, for example, by catalytic hydrogenation, to give the corresponding alkenyl group (not shown) or the saturated compound 5.
Other R groups can also be introduced by directly reacting imine 3_ with an R2Li lithiate or a Grignard R2MgX reagent in the presence or absence of a Lewis acid catalyst, such as BF3 etherate. See also Huffman et al., J. Org. Ch em. 1995, 60, 1590-1594, the contents of which are incorporated herein for reference.
In certain cases, an enantiomer of a compound of Formula I or II may display superior activity compared to the other. When required, the separation of the racemic material can be performed by CLAP using a chiral column as exemplified in Examples 27-34 (Scheme 4) or by a resolution using a resolving agent such as chlophonic chloride as in Thomas J. Tucker, et al. al, J. Med. Ch em. 1994, 3 7, 2437-2444. A chiral compound of Formula I can also be synthesized directly using a chiral catalyst or a chiral ligand, for example, in Mark A. -Huffman, et al, J. Org. Chem. 1995, 60, 1590-1594.
Other embodiments of the invention will be apparent in the course of the following descriptions of embodiments of the invention which are given for illustration of the invention and are not intended to limit the same.
E j emplos
The abbreviations used in the Examples are defined as follows: "° C" for degrees centigrade, "d" for doublet, "dd" for double of doublets, "eq" for equivalent or equivalents, "g" for gram or grams, " mg "for milligram or milligrams," mL "for milliliter or milliliters," H "for hydrogen or hydrogens," hr "for hour or hours," m "for multiplet," M "for molar," min "for minute or minutes , "MHz" for megahertz, "EM" for mass spectroscopy, "nmr" or "NMR" for magnetic resonance spectroscopy, "t" for triplet, "CCD" thin layer chromatography, "EDAC" for l-hydrochloride (3-dimethylaminopropyl) -3-ethylcarbodiimide, "DIPEA" for diisopropylethylamine, "TBAF" for tetrabutylammonium fluoride, "LAH" for lithium aluminum hydride, and "TEA" for triethylamine.
Use 1
Preparation of (+ / -) - 6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-3,4-dihydro-2 (1H) -quinazolinone (R 4 = Cyclopropyl).
Step 1. Synthesis of Il-a from I-a.
To a solution of compound I-a (4.55 g, 20.2 mmol) in anhydrous THF (40 mL) was added dimethylaminopyridine (0.25 g, 2.02 mmol) and trimethylsilyl isocyanate (6.05 g, 7.11 mL, 52.5 mmol). The mixture was stirred at room temperature for approximately 16 hours, then tetrabutylammonium fluoride (21 mL of a 1 M solution in THF) was added. The thick solution was diluted with additional THF (20 mL) and stirred at room temperature for 0.5 hour. The THF was removed under reduced pressure, the residue was taken up in EtOAc (100 L) and washed sequentially with IN HCl (70 mL), saturated aqueous NaHCO 3 (70 mL), and saturated aqueous NaCl (50 mL). The organic phase was dried over MgSO4, filtered and concentrated under reduced pressure to give a light yellow solid. The yellow color was stirred during trituration with hexanes to give the bund (5.09 g, 94%) as a white solid: 1 H NMR (300 Mhz, acetone-d) d 9.06 (br s, 1 H), 7.48 (s, 1 H), 7.40 (br s, 1 H), 7.34 (dd, J = 8.8, 2.6 Hz, 1 H), 6.97 (d, J = 8.8 Hz, 1 H); 19 F NMR (282 MHz, acetone-d) d -86.33, -86.35; IR (KBr Pellet) 1724, 1678, 1398, 1198, 1174 cm "1; MS (Cl) m / e 266 (MH +, 100).
Step 2. Synthesis of Ill-a from Il-a.
A suspension of 11 -a (5.09 g, 19.1 mmol) in toluene (150 mL) containing 4 A molecular sieve (approximately 100 mg) was heated to reflux for 16 hours. The resulting light yellow solution was cooled to room temperature, the precipitated solids were dissolved in acetone and the molecular sieve was removed by vacuum filtration. The filtrate was concentrated under reduced pressure, and triturated with hexanes to give Ill-a (4.25 g, 89%) as a yellow solid: 2 H NMR (300 MHz, acetone-d 6) d 7.86-7.82 (m, 2 H ), 7.61 (d, J = 8.8 Hz, 1 H); NMR MHz, acetone-de) d -67.88.
Step 3. Synthesis of IV-a from Illa
A solution of cyclopropylacetylene (13.0 mL of a 30% by weight solution in toluene / THF / hexanes, 59.0 mmol) in anhydrous THF (118 L) was cooled to -78 ° C, treated with n-BuLi (32.8 mL of a 1.6 M solution in hexanes, 52.4 mmoles), warming to 0 ° C in an ice bath, and aging for 0.5 hours. To a solution of Ill-a (3.12 g, 12.6 mmol) in anhydrous THF (66 mL) at -78 ° C was added lithium acetylide for about 10 minutes. To this was added boron trifluoride etherate (0.89 g, 0.80 mL, 6.28 mmol), followed by removal of the ice bath. The reaction was allowed to reach room temperature and stirred at room temperature for 4 hours before quenching with 1 M citric acid (100 mL). The mixture was concentrated under reduced pressure to half its volume, diluting with EtOAc (200 mL), the aqueous phase was stirred and the organic phase was washed sequentially with saturated aqueous NaHCO 3 (100 mL), and saturated aqueous NaCl (100 mL). ). The organic phase was dried over MgSO4, filtered and concentrated under reduced pressure. The crude material was purified by flash chromatography (3% MeOH / CH ^ Cir) to give a thick yellow oil so that the crystalline IV-a (R4 = cyclopropyl) (3.85 g, 97%) was obtained as a white solid: m.p. 86.6-88 ° C; 1 H NMR (300 MHz, acetone-d 6) d 8.95 (br s, 1 H), 7.51 (br s, 1 H), 7.43 (br s, 1 H), 7.40 (dd, J = 8.8, 2.4 Hz, 1 H ), 7.02 (d, J = 8.8 Hz, 1 H), 1.49-1.41 (m, 1 H), 0.93-0.82 (m, 1 H), 0.77-0.74 (m, 1 H); 19 F NMR (282 MHz, acetone-d 6) d-82.96; IR (KBr Pellet) 1696, 1172 cm "1; MS (Cl) m / e calculated for C14H10CI F3N20: 315.051201, found 315.051626; 315 (MH +, 51), 332 (M + NH4 +, 100); Analysis calculated for C? 4H? 0N2Cl F30 '0.25H20; C, 52.68; H, 3.32; N, 8.78; found: C, 52.61; H, 3.35; N, 8.28.
Example 2
Preparation of (+/-) -6-chloro-4-isopeopylethynyl-4-trifluoromethyl-3,4-dihydro-2 (1H) -quinazolinone (R4 = isopropyl).
A solution of IZI-a (50 mg, 0.201 mmol) was treated with the lithium acetylide derivative of 3-methyl-1-butynyl (62 mg, 93 mL, 0.905 mmol) in accordance with the procedure of Step 3 of Example 1 The resulting crude material was purified by flash chromatography (35% EtOAc / hexanes) to provide 26 mg (41%) of the desired product: X H NMR (300 MHz) d 9.08 (br s, 1 H), 7.59 (br s, 1 H), 7.53 (br s, 1 H), 7.40 (dd, J = 8.4, 2.2 Hz, 1 H), 7.02 (d, J = 8.8 Hz, 1 H9, 2.81-2.68 (m, 1 H), 1.20 (dd, J = 6.6 Hz, 6H); 19F NMR (282 MHz, acetone-d6) d -83.05; MS (Cl) m / e calculated for C? 4H? 2ClF3N20: 317.066851, found 317.069433; 317 (MH +, 43), 334 (M + NH 4 +, 100).
Example 3
Preparation of (+/-) -6-chloro-4- (2-pyridyl) ethynyl-4 -tr fluoromethyl-3,4-dihydro-2 (1H) -quinazolinone (R4 = 2-pyridyl)
A solution of Ill-a (100 mg, 0.402 mmol) was treated with the lithium acetylide derived from 2-ethynylpyridine (0.19 g, 1.81 mmol) in accordance with the procedure of Step 3 of Example 1. The resulting crude material was purified by CLAP (2.5% MeOH / CH2Cl2) to provide 85 mg (60%) of the desired product: mp 105 ° C dec .; : H NMR (300 MHz, acetone-d6) d 9.14 (br s, 1 H), 8.64-8.61 (m, 1H), 7.89-7.84 (m, 2 H), 7.70-7.66 (m, 2H), 7.48 - 7.43 (m, 2 H), 7.09 (d, J = 8.8 Hz, 1 H); qF NMR (282 MHz, acetone-de) d -82.48; IR (KBr Pellet) 1704, 1430, 1186 cm "1; MS (Cl) m / e calculated for C 16 H 10 ClF 3 N 3 ?: 352.046450, found 352.046956; 352 (MH +, 100); Analysis calculated for C? 6H9ClF3N3O-0.125 H20: C, 54.3; H, 2.56; N, 11.9; found: C, 54.71; H, 3.03; N, 11.3.
Example 4
Preparation of (+/-) -6-chloro-4-ethylenenethynyl-4-trifluoromethyl-3,4-dihydro-2- (1H) -quinazolinone (R 4 = ethyl).
A solution of Ill-a (100 mg, 0.402 mmol) was treated with the lithium acetylide derived from 1-butine (109 mg, 2.01 mmol) in accordance with the procedure of Step 3 of Example 1. The resulting crude material was purified by CLAP (2.5% MeOH / CH2Cl2) to provide 79 mg (65%) of the desired product: aH NMR (300 MH ?, acetone-dβ) d 9.05 (br s, 1 H), 7.54 (br s, 2 H) , 7.41-7.39 (m, 1 H), 7.02 (d, J = 8.4 Hz, 1 H), 2.36-2.32 (m, 2 H), 2.18-1.13 (m, 3 H); 15 F NMR (282 MHz, acetone-dg) d-82.99; MS (Cl) m / e calculated for Ci3H10ClF3N2 ?: 303.051201, found 303.051882; 303 (MH +, 55), 320 (M + NH 4 +, 100).
Example 5
Preparation of (+/-) -6-chloro-4-enylethynyl-4-trifluoromethyl-3,4-dihydro-2 (1H) -quinazolinone (R 4 = Phenyl)
A solution of Ill-a (100 mg, 0.402 mmol) was treated with the lithium acetylide derived from phenyl acetylene (185 mg, 1.81 mmol) according to the procedure of Step 3 of Example 1. The resulting crude material was purified by CLAP (2.5% MeOH / CH2Cl2) to provide 54 mg (38%) of the desired product: XH NMR (300 MHz, acetone-d6) d 9.07 (br s, 1H), 7.74 (br s, 1 H), 7.62- 7.58 (m, 2H), 7.48-7.40 (m, 4H), 7.08 (d, J = 8.4 Hz, 1 H); 19 F NMR (282 MHz, acetone-d 6) d-82.67; IR (KBr pellet) 1696, 1186 cm "1; MS (Cl) m / e calculated for C? 7H ?? ClF3N20: 351.051201, found 351.051704; 351 (MH *, '51), 368 (M + N0H4, 100); Analysis calculated for C? 7H10ClF3N2O- 0.25 H20: c, 57.48; H, 2.98; N, 7.89; found: C, 57.00; H, 3.03; N, 7.48;
Example 6
Preparation of (+/-) -4-cyclopropylethynyl-6-methoxy-4-trifluoromethyl-3, -dihydro-2 (1H) -quinazolinone (R = Cyclopropyl)
SAW-? VlII-a
Step 1. Synthesis of VI- from V- A solution of Va (0.50 g, 2.28 mmole) was treated with dimethylaminopyridine and trimethylsilyl isocyanate as described in Step 1 of Example 1 to provide 0.58 g (97%) of the desired product: XH NMR (300 MHz, acetone-de) d 8.81 (br s, 1 H), 7.17 (br s, 1 H), 7.11 (br s, 1 H), 7.00-6.92 (m, 2 H) , 6.83 (s, 1 H), 3.76 (s, 3H); 19 F NMR (282 MHz, acetone-d 6) d -85.99.
Step 2. Synthesis of Vil-a from Vi-a
A solution of Vi-a (0.58 g, 2.21 mmol) was heated in refluxing toluene as described in Step 2 of Example 1 to provide 0.50 g (93%) of the desired product: 1 H NMR (300 MHz, acetone-d6 ) d 7.52 (br s, 2 H), 7.27 (s, 1 H), 3.90 (s, 3 H); 19 F NMR (282 MHz, acetone-d 6) d -68.06.
Step 3. Synthesis of Vlll-a from Vil-a.
A solution of Vil-a (100 mg, 0.410 mmol) was treated with the lithium acetylide derived from the cyclopropylacetylene (0.41 mL of a 30% by weight solution in toluene / THF / hexanes, 1.85 mmol) in accordance with the procedure of Step 3 of Example 1. The resulting crude material was purified by CLAP (2.5% MeOH / CH 2 Cl 2) to provide 103 mg (81%) of the desired product: 1 H NMR (300 MHz, acetone-d 6) d 8.77 (br s, 1 H), 7.29 (br s, 1 H), 7.06 (br s, 1 H), 6.99-6.90 (m, 2 H), 3.77 (s, 3 H), 1.46-1.38 (m, 1 H), 0.91 -0.85 (m, 2 H), 0.79-0.72 (m, 2 H); 19 F NMR (282 MHz, acetone-d 6) d-82.61; MS (Cl) m / e calculated for C15H? 4F3N202: 311.100738, found 311.099970; 311 (MH +, 100).
Example 7
Preparation of (+/-) -4-isopropylethynyl-6-methoxy-4-trifluoromethyl-3,4-dihydro-2 (1H) -quinazolinone (R4 = Isopropyl).
A solution of Vil-a (100 mg, 0.410 mmol) was treated with the lithium acetylide derived from 3-methyl-1-butyne (126 mg, 0.19 mL, 1.85 mmol) in accordance with the procedure of Step 3 of Example 1 The resulting crude material was purified by flash chromatography (2.5% MeOH / CH2Cl2) to provide 30 mg (24%) of the desired product: mp. 228-229 ° C; 1 H NMR (300 MHz, acetone-de) d 8.72 (br s, 1H), 7.27 (br s, 1H), 7.00-6.91 (m, 2 H), 3.77 (s, 3H), 2.73-2.67 (m, 1H), 1.20 (dd, J = 7.0, 1.5 Hz, 6H); 19F NRM (282 MHz, acetone-de) d-82.71; (KBr pellet) 1696, 1428, 1190, 1176 cm'1; MS (Cl) m / e calculated for C15H16F3N2? 2: 313.116388, found 313.115871; 313 (MH +, 100), 330 (M + NH 4 *, 15); calculated analysis for C15H? 5 F3N202: C, 57.69; H, • 4.84; N, 8.97; Found: C, 57.74; H, 5.01; N, 8.57.
E j emp lo 8.
Preparation of (+/-) -6-methoxy-4- (2-pyridyl) ethynyl-4-tri-loromethyl-3,4-dihydro-2 (1H) -quinazolinone (R 4 = 2-pyridyl).
A solution of Vi-a (100 mg, 0.410) was treated with the lithium acetylide derived from 2-y-piperazine (0.19 g, 1.85 mmol) in accordance with the procedure of Step 3 of Example 1. The resulting crude material purified by flash chromatography (2.5% MeOH / CH2Cl2) to provide 56 mg (39%) of the desired product: 1 H NMR (300 MHz, acetone-d 6) d 8.81 (br s, 1 H), 8.61 (d, J = 4.8 Hz, 1H), 7.88-7.82 (m, 1H), 7.66 (d, J = 7.7 Hz, 7.61 (br s, 1H), 7.46-7.42 (m, 1 H), 7.23 (br s, 1 H) , 7.06-6.97 (m, 2H), 3.79 (s, 3 H); 19F NRM (282 MHz, acetone-d6) d -82.13; IR (KBr pellet) 1698, 1518, 1464, 1430, 1244, 1208, 1184 cm "1; MS (Cl) m / e calculated for C? 7H? 3F3N302: 348.095987, found 348.095629; 348 (MfT, 100); calculated for C1-7HY2F3 3O2"0.25 C3Hc-0: C, 58.92; H, 3.76; N, 11.61; found: C, 59.38; H, 4.04; N, 11.35.
Example 9
Preparation of (+/-) -6-methoxy-4-phenylethynyl-4-trifluoromethyl-3,4-dihydro-2 (1H) -quinazolinone (R 4 = Phenyl).
A solution of Vil-a (100 mg, 0.410 mmol) was treated with the lithium acetylide derived from phenylaceffylene (0.19 g, 1.85 mmol) in accordance with the procedure of Step 3 of Example 1. The resulting crude material was purified by chromatography Instantaneous (2.5% MeOH / CH2Cl2) to provide 34 mg (24%) of the desired product: mp 206.2-207.7 ° C; X H NMR (300 MHz, acetone-d 6) d 8.85 (br s, 1 H), 7.60-7.57 (m, 3 H), 7.49-7.39 (m, 3 H), 7.21 (br s, 1 H), 7.05 -6.96 (m, 2H), 3.79 (s, 3H); 19 F NMR (282 MHz, acetone-d 6) d-82.32; IR (KBr pellet) 1696, 1516, 1430, 1236, 1204, 1184, 1128 cm "1; MS (Cl) m / e calculated for Ci8H? 4F3N2? 2: 347.100738, found 347.101482; 347 (MH", 100), 364 (M + NHT, 48); calculated for C? 8H13F3N2? 2: C, 62.43; H, 3.78; N, 8.10; found: C, 62.35; H, 3.58; N, 7.83.
Ahem 10
Preparation of (+/-) -4-cyclopropylethynyl-5,6-difluoro-4-trifluoromethyl-3, -dihydro-2 (1H) -quinazolinone (R 4 = Cyclopropyl)
Step 1. Synthesis of X-a from IX-a.
A solution of IX-a (6.46 g, 28.7 mmol) was treated with dimethylaminopi ridine and trimethylsilyl isocyanate as described in Step 1 of Example 1 to provide 6.74 g (88%) of the desired product: 1 H NRM (300 MHz NMR acetone-d6) d 9.13 (br s, 1 H), 7.45-7.32 (m, 2 H), 718 (br s, 1 H), 6.85-6.80 (m, IH); 19 F NMR (282 MHz, acetone-de) d -86.6 (d, 17.2, 3), -137.52-137.68 (m, 1), - 148.47-148.59 (m, 1).
Step 2. Synthesis of Xl-a from X-a
A solution of Xa (6.74 g, 25.1 mmol) was heated in xylene at reflux temperature as described in Step 2 of Example 1, substituting xylene for toluene, to provide 6.3 g (100%) of the desired product: 1 H NMR (300 MHz, acetone-de) d 7.92-7.83 (m, 1H), 7.46-7.44 (m, 1H); 19 F NMR (282 MHz, acetone-d 6) d -70.7 (d, 38.7, 3), -136.72 (s, 1) -146. 7-146.57 (m, 1).
Step 3. Synthesis of Xll-a from Xl-a.
A solution of Xl-a (6.28 g, 25.1 mmol) was treated with the lithium acetylide derived from cyclopropylacetylene (24.9 mL of a 30% by weight solution in toluene / THF / hexanes, 0.113 mol) in accordance with the procedure from Step 3 of Example 1. The resulting crude yellow oil was dissolved in acetone and concentrated under reduced pressure to deliver a yellow solid. Crystallization from acetone gave 5.98 g (75%) of the desired material: m.p. 86.5-88.5 ° C; 2 H NMR (300 MHz, acetone-d 6) d 9.01 (br s, 1 H), 7.46 (br s, 1 H), 7.44-7.35 (m, 1 H), 6.86- 6.81 (m, 1 H), 1.41 -1.37 (m, 1 H), 0.90-0.83 (m, 1 H), 0.74-0.69 (m, 1H); 19 F NMR (282 MHz, acetone-de) d -83.3 (d, J = 12.9, 1), -136.04-136.23 (m, 1), -148.14-148.26 (m, 1); IR (KBr Pellet) 1706, 1516, 1442, 1246, 1214, 1196 cm "1; MS (Cl) m / e calculated for C? 4H? 0F5N2O: 317.071329, found 317.070836; 317 (MH +, 100), 334 (M + NH4 +, 62); Analysis calculated for C? 4H9F5N20: C, 53.17; H, 2.88; N, 8.87; found: C, 53.30; H, 3.16; N, 8.53.
Example 11
Preparation of (+ / -) - 5,6-difluoro-4-isopropylethynyl-4-trifluoromethyl-3,4-dihydro-2 (1H) -quinazolinone (R 4 = Isopropyl).
A solution of Xl-a (7.24 g, 28.9 mmol) was treated with the lithium acetylide derived from 3-methyl-1-butyne (8.87 g, 13.3 mL, 0.130 mol) in accordance with the procedure of Step 3 of Example 1 The resulting crude material was purified by flash chromatography (2.5% MeOH / CH2Cl2) to give a yellow oil. Crystallization from acetone gave 6.77 g (74%) of the desired product: m.p. 79-80 ° C; 2 H NMR (300 MHz, acetone-de) d 9.02 (br s, 1 H), 7.50 (br s, 1 H), 7.44-7.35 (m, 1 H), 6.87-6.82 (m, 1 H), 2.69- 2.65 (m, 1H), 1.17 (d, J = 7.0 Hz, 6H); 19 F NMR (282 MHz, acetone-d 6) d -83.4 (d, J = 12.9, 1), -135.79-135.94 (m, 1), -148.1 -1 8.26 (m, 1); MS (Cl) m / e calculated for C? 4H? 2F5N20: 319.086979, found 319.087376; 319 (MH +, 100), 336 (M + NH 4 +, 76).
Example 12
Preparation of (+/-) -5,6-difluoro-4- (2-pyridyl) ethynyl-4-trifluoromethyl-3,4-dihydro-2 (1H) -quinazolinone (R 4 = 2-pyridyl).
A solution of Xl-a (100 mg, 0.400 mmol) was treated with the lithium acetylide derived from 2-ethynylpyridine (0.19 g, 1.80 mmol) according to the procedure of Step 3 of Example 1. The resulting crude material was purified by flash chromatography (4% MeOH / CH2Cl2) to provide 83 mg (59%) of the desired product: mp 219-220 ° C; 1 H NMR (300 MHz, acetone-d 6) d 9.15 (br s, 1 H), 8.61 (d, J = 4.4 Hz, 1 H), 7.88- 7.82 (m, 2 H), 7.63 (dd, J = 7.0, 1.1 Hz, 1H), 7.47-7.42 (m, 2H), 6.94-6.88 (m, 1H); 19 F NMR (282 MHz, acetone-de) d-82.8 (d, J = 12.9, 3), 135.78-135.93 (m, 1), -147.86-1 7.98 (m, 1); IR (KBr pellet) 1712, 1470, 1450, 1430, 1416, 1264, 1238, 1226, 1198, 1186 cm "1; MS (Cl) m / e calculated for C 16 H 9 F 5 N 3 O: 354.066578, found 354.066578; 354 (MH +, 100) .
Example 13
Preparation of (+/-) -5,6-difluoro-4-ethylethynyl-4-trifluoromethyl-3,4-dihydro-2 (1H) -quinazolinone (R 4 = 2-ethyl).
A solution of Xl-a (100 mg, 0.400 mmol) was treated with the lithium acetylide derived from 1-butyne (97 mg, 1.80 mmol) in accordance with the procedure of Step 3 of Example 1. The resulting crude material purified by CLAP (2.5% MeOH / CH2Cl2) to provide 69 mg (57%) of the desired product: mp 191-194 ° C; X H NMR (300 MHz, acetone-d 6) d 9.03 (br s, 1 H), 7.50 (br s, 1 H), 7.45-7.35 (m, 1 H), 6.87-6.82 (m, 1 H), 2.34 -2.27 (m, 2H), 1.20-1.15 (m, 3 H); 19 F NMR (282 MHz, acetone-de) d -83.3 (d, J = 12.9, 3), -135.79-135.98 (m, 1), -148.16-148.29 (m, 1); IR (KBr pellet) 1704, 1686, 1518, 1444, 1244, 1210, 1192, 1172 cm "1; MS (Cl) m / e calculated for C? 3H? 0F5N2O: 305.071329, found 305.071146; 305 (MH +, 100) Analysis calculated for C 13 H 9 F 5 N 2 O: C, 51.33; H, 2.98; N, 9.22; found: C, 51.00; H, 2.79; N, 8.99.
Example 14
Preparation of (+/-) -5,6-di luoro-4-enylethynyl-4-trifluoromethyl-3,4-dihydr-2 (1H) -quinazolinone (R 4 = Phenyl).
A solution of Xl-a (100 mg, 0.400 mmol) was treated with the lithium acetylide derived from phenylacetylene (0.18 g, 0.20 mL, 1.80 mmol) according to the procedure of Step 3 of Example 1. The resulting crude material was purified by CLAP (2.5% MeOH / CH2Cl2) to provide 92 mg (65%) of the desired product: 1 H NMR (300 MHz, acetone-d6) d 9.14 (br s, 1 H), 7.80
(br s, 1 H), 7.57-7.54 (m, 2H), 7.49-7.40 (m, 4H), 6.92-6.87 (m, 1H); 1 F NMR (282 MHz, acetone-de) d -83.0 (d, J = 12.9, 3), -136.08-136.27 (m, 1), MS
(Cl) m / e calculated for C 17 H 10 F 5 N 2 O: 353.071329, found 353.071716; 353 (MH +, 42), 370 (M + NH 4 +, 100).
Example 15
Preparation of (+/-) -5,6-difluoro-4-isopentyl-4-tri l -ornethyl-3,4-dihydro-2 (1H) -quinazolinone (R 4 = Isopropyl).
Synthesis of XlII-a from Xll-a
A solution of XlII-a (R = isopropyl) (26 mg, 82 mmol) in ethanol (1 mL) and EtOAc (0.5 mL) was treated with 10% Pd on carbon (35 mg) under H2 (1 atmosphere) by 16 hours. The catalyst was removed by vacuum filtration through Celite and the filter cake was washed with EtOAc. The concentrated filtrates were concentrated under reduced pressure to provide 26 mg (100%) of the desired material. No further purification was necessary: XH NMR (300 MHz, acetone-d6) d 8.88 (br s, 1 H), 7.41-7.31 (m, 1H), 6.89-6.81 (m, 2H), 2.55-2.50 (m, 1 H), 1.64-1.45 (m, 2H), 1.06-1.02 (m, 1H), 089 (dd, J = 6.6, 2.2 Hz, 6H); 19 F NMR (282 MHz, acetone-de) d -83.22 (d, J = 12.1, 3), -138.97-139.13 (m, 1), -148.46-148.58 (m, 1); IR (KBr pellet) 1700, 1678, 1518, 1438, 1252, 11.88, 1172 cm "1; MS (Cl) m / e calculated for C? 4H16F5N20: 323.118280, found 323.116703; 323 (MH +, 100), 340 (M + NH4 +, 57).
E 16
Preparation of (+/-) - butyl-5,6-difluoro-4-trifluoromethyl-3,4-dihydro-2 (1H) -quinazolinone (R 4 = Ethyl).
A solution of XlII-a (R4 = ethyl) (20 mg, 66 mmol) in ethanol (1 mL) and EtOAc (0.5 mL) was treated with 10% Pd on carbon under H2 according to the procedure of Example 15. Purification by CLAP (2.5% MeOH / CH2Cl2) gave 12 mg (56%) of the desired product: 1 H NMR (300 MHz, acetone-d6) d 8.89 (br s, 1 H), 7.41-7.41-7.32 (m, 1 H), 6.86-6.81 (m, 2H), 2.57-2.47 (, 1 H), 1.56-1.15 (m 5H), 0.88 (t, J = 7.3 Hz, 3 H); 19F NMR (282 MHz, acetone-de) d -83.19-83.24 (m, 1), -139.14 (s, 1), -148. 9-148.62 (m, 1); MS (Cl) m / e calculated for C? 3H14F5 2 ?: 309.102629, found 309.103555; 309 (MH *, 100), 326 (M + NH 4 +, 62).
Example 17
Preparation of (+/-) -4-cyclopropylethynyl-6-f luoro-4-trifluoromethyl-3,4-dihydro-2 (1H) -quinazolinone (R4 = cyclopropyl).
Step 1. Synthesis of XV-a from XI V-a.
A solution of XlII-a (3.07 g, 14.8 mmol) was treated with dimethylaminopyridin and trimethylsilyl isocyanate as described in Step 1 of Example 1 to provide 2.81 g (76%) of the desired product.
Step 2. Synthesis of XVI-a from XV-a.
A solution of XV-a (6.74 g, 25.1 mmol) was heated in toluene at reflux temperature as described in Step 2 of Example 1 to provide 0.73 g (94%) of the desired product.
Step 3. Synthesis of XVII-a from XVI-
A solution of XVI-a (100 mg, 0.431 mmol) was treated with the lithium acetylide derived from cyclopropylacetylene (1.43 mL of a 30% by weight solution in toluene / THF / hexanes, 1.94 mmol) in accordance with the procedure from Step 3 of Example 1. The resulting crude material was purified by CLAP (2.5% MeOH / CH 2 Cl 2) to provide 4 4 mg (34%) of the desired product: 155 ° C; XH NMR (300 MHz, acetone-de) d 8.86 (br
1 H 7.36 1 H 7.30-7; m, 1 H)
7. 22-7.15 (m, 1H), 7.04-6.99 (m, 1 H), 1.47-1.42 (m, 1H), 0.90-0.87 (m, 2H), 0.76-0.75 (m, 2H); 19 F NMR (282 MHz, acetone-d 6) d-82.86, -1234.36- 123.44; MS (Cl) m / e calculated for C? 4HnF4N20: 299.080751, found 299.079976; 299 (MH +, 100).
Example 18
Preparation of (+/-) -6-fluoro-4-isopropylethynyl-4-trifluoromethyl-3,4-dihydro-2 (1H) -quinazolinone (R 4 = Isopropyl).
A solution of XVI-a (100 mg, 0.431 mmol) was treated with the lithium acetylide derived from 3-methyl-1-butyne (0.13 g, 0.20 L, 1.94 mmol) in accordance with the procedure of Step 3 of Example 1 The resulting crude material was purified by CLAP (2.5% MeOH / CH2Cl2) to provide 24 mg (18%) of the desired product: mp. 158 ° C; 1ti NMR (300 MHz, acetone-d6) d 9.07 (br s, 1 H), 7.60 (br s, 1 H), 7.32-7.30 (m, 1 H), 7.24-7.16 (m, 1 H), 7.05- 6.99 (m, 1H), 2.77-2.67 (m, 1 H), 1.20 (dd, J = 7.0, 2.6 Hz, 6H); 19 F NMR (282 MHz acetone-de) d-82.95, -123.41-123.41- 123.49; MS (301) m / e calculated for Ci 4 H 3F 4 N 20 found 301.096235; 301 (MH +, 100).
Example 19
Preparation of (+/-) -6-fluoro-4- (2-pyridyl) ethynyl-4-trifluoromethyl-3,4-dihydro-2 (1H) -quinazolinone (R 4 = 2-pyridyl).
A solution of XVI-a (100 mg, 0.431 mmol) was treated with the lithium acetylide derived from 2-ethynylpyridine (0.20 g, 1.94 mmol) in accordance with the procedure of Step 3 of Example 1. The resulting crude material was purified by CLAP
(2.5% MeOH / CH2Cl2) to provide 65 mg (45%) of the desired product: m.p. 155 ° C; 1 H NMR (300 MHz, acetone-de) d 9.02 (br s, 1 H), 8.60 (d, J = 4.0 Hz, 1 H), 7.87-7.78 (m 2 H), 7.66 (d, J = 7.7 Hz , 1 H), 7.45-7.41 (m, 2 H), 7.26-7.20 (m, 1 H), 7.09-7.05 (m, 1 H); 19 F NMR (282 MHz, acetone-de) d-82.36, -122.94-123.02; MS (Cl) m / e calculated for C? 6H? 0F4N3O: 336.076000, found 336.0741565; 336
(MH +, 25).
Example 20
Preparation of (+/-) -6-fluoro-4-ethylethynyl-4-trifluoromethyl-3,4-dihydro-2 (1H) -quinazolinone (R4 = Ethyl).
A solution of XVI-a (100 mg, 0.431 mmol) was treated with the lithium acetylide derived from 1-butyne (0.10 g, 1.94 mmol) in accordance with the procedure of Step 3 of Example 1. The resulting crude material was purified by CLAP
(2.5% MeOH / CH2Cl2) to provide 40 mg (33%) of the desired product: m.p. 190 ° C; H NMR (300 MHz, acetone-de) d 8.86 (br s, 1 H), 7.38 (br s, 1 H), 7.34-7.31 (m, 1 H), 7.22-7.16 (m, 9,001 H), 7.05 -7.00 (m, 1 H), 2.04-2.01 (m, 2H), 1.19-1.14 (m, 3 H); 1 F NMR (282 MHz, acetone-d 6) d -75,392, 123.42-123.50; EM (Cl) m / e calculated for
C? 3 HnF4N20: 287.080751 found 287.080740; 287 (MH +, 100).
Example 21 Preparation of (+/-) -6-fluoro-4-phenylethynyl-4-trifluoromethyl-3,4-dihydro- (1H) -quinazolinone (R 4 = Phenyl).
A solution of XVI-a (100 mg, 0.431 mmol) was treated with the lithium acetylide derived from phenylacetylene (0.20 g, 0.21 mL, 1.94 mmol) in accordance with the procedure of Step 3 of Example 1. The resulting crude material was purified by CLAP (2.5% MeOH / CH2Cl2) to provide 41 mg (28%) of the desired product: mp 107 ° C; X H NMR (300 MHz, acetone-de) d 9.00 (br s, H), 7.69 (br s, 1 H), 7.63-7.59 (m, 2 H), 7.50-7.40 (m, 4 H), 7.27-7.20 ( m, 1 H), 7.10-7.05 (m, 1 H); 19F NMR (282 MHz, acetone-de) d -82.56,
122. 99-123.07; MS (Cl) m / e calculated for C 17 H 11 F N 2 O: 335.080751, found 335.082057; 335 (MH +, 74), 352 (M + NH 4 +, 100).
Example 22
Preparation of (+ / -) - 6-fluoro-4-isopentyl-4-tri luorornethyl-3,4-dihydro-2 (1H) -quinazolinone (R 4 = Isopropyl).
Synthesis of XVIII-a from XVII-a
A solution of XVII-a (R4 = isopropyl) (2.6 mg, 87 mmol) in ethanol (1 mL) and EtOAc (0.5 mL) was treated with 10% Pd on carbon under H2 in accordance with the procedure of Example 15 to provide 15 mg (58%) of the desired product. No further purification was necessary: p.f. 179 ° C; a H NMR (300 MHz, acetone-d 6) d 7.02- 6.97 (m, 2 H), 6.80-6.76 (m, 1 H), 2.18-2.09 (m, 2 H), 1.92-1.82 (m, 2 H), 1.52-1.45 (, 1 H), 0.88-0.79 (m, 6H); 19 F NMR (282 MHz, acetone-d 6) d-82.60, -123.72-123.84; MS (Cl) m / e calculated for C 14 H 17 F 4 N 2 O: 305.127707, found 305.126790: 305 (MH +, 100).
Example 23
Preparation of (+/-) -6-fluoro-4- (2'-2-pyridyl) ethyl-4-trifluoromethyl-3,4-dihydro-2 (1H) -quinazolinone (R 4 = 2-pyridyl).
A solution of XVII-a (R4 = 2-pyridyl) (33 mg, 99 mmol) in ethanol (1 mL) and EtOAc (0.5 mL) was treated with 10% Pd on carbon under H2 in accordance with the procedure of Example 15 to provide 10 mg (30%) of the desired product. No additional purification is needed: p.f. 88 ° C; 1 H NMR (300 MHz, acetone-de) d 8.35 (d, J = 4. 4 Hz, 1H), 7.63 (dt, J = 7.7, 1.5 Hz, 1H), 7.20-7.13 (m, 3 H), 7.04 -6.98 (m, 1H), 6.83-6.79 (m, 1 H), 2.84-2.78 (m, 1H), 2.68-2.48 (m, 2H), 2.27-2.06 (m, 1H); 19 F NMR (282 MHz, acetone-dg) d-82.58, -123.26-123.34; MS (Cl) m / e calcd for C 16 H 14 F 4 N 3 O: 340.107300, found 340.107719; 340 (MH +, 100).
Example 24
Preparation of (+/-) -4-butyl-6-fluoro-4-trifluoromethyl-3,4-dihydro-2 (1H) -quinazolinone (R 4 = ethyl).
A solution of XVII-a (R = ethyl) (2.4 mg, 84 mmol) in ethanol (1 mL) and EtOAc (0.5 mL) was treated with 10% Pd on carbon under H2 in accordance with the procedure of Example 15 to provide 24 mg (100%) of the desired product. No further purification was necessary: p.f. 198 ° C; 1 H NMR (300 MHz, acetone-d 6) d 7.03-6.97 (m, 2 H), 6.80-6.76 (m, 1 H), 2.18-2.11 (m, 1 H), 1.90-1.81 (m, 1 H), 1.30-1.19 (m, 3 H), 0.97-0.80 (m, 4 H); 19 F NMR (282 MHz, acetone-d 6) d-82,692, -123.78- 123.86; MS (Cl) m / e calculated for Ci3H15F4N20: 291.112051, finding 291.112227; 291 (MH +, 100).
E j a lo 25.
Preparation of (+/-) -6-fluoro-4-phenylethyl-4-trifluoromethyl-3,4-dihydro-2 (1H) -quinazolinone (R4 = phenyl).
A solution of XVII-a (R4 = phenyl) (30 mg, 90 mmol) in ethanol (1 L) and EtOAc (0.5 mL) was treated with 10% Pd on carbon under H2 in accordance with Example 15 to provide 20 mg (67%) of the desired product. No further purification was necessary: p.f. 98 ° C; a H NMR (300 MHz, acetone-de) d 7.18-6.99 (m, 7H), 6.84-6.79 (, 1H), 2.68-2.60 (m 1 H), 2.48-2.12 (m, 3 H); 19F 'NMR (282 MHz, acetone-d6) d -82.67, -123.24-123.32; MS (Cl) m / e calculated for C 17 H 15 F 4 N 20: 339.112051, found 339.11081; 339 (MH +, 100).
Example 26
Preparation of (+/-) -6-fluoro-4-methylpropargyl-4-trifluoromethyl-3,4-dihydro-2 (1H) -quinazolinone (R 4 = methyl).
Synthesis of XlX-a from XVI-a.
A solution of 2-butyne (9.4 mg, 1.75 mmol) in anhydrous THF (3.5 ml) was cooled to 0 ° C, treated with n-BuLi (0.97 mL of a 1.6 M solution in hexanes, 1.55 mmol), and It was aged for 0.5 hours. To a solution of XVI-a (90 mg, 0.388 mmol) in anhydrous THF (1.9 mL) at -78 ° C was added lithium anion for 5 minutes, followed by boron trifluoride etherate (25 mL, 0.194 mmol) . The cooling bath was removed and the mixture was allowed to warm to room temperature. After 16 hours at room temperature, quenched by addition of 1 M citric acid (10 mL), diluted with EtOAc (50 mL), separated the phases and washed the organic phase sequentially with saturated aqueous NaHCO 3 (20 mL) and saturated aqueous NaCl (20 mL). The resulting material was purified by CLAP (2.5% MeOH / CH2Cl2) to provide 10 mg (9%) of the desired product: p.f. 181 ° C; XH NMR (300 MHz, acetone-de) d 8.91 (br s, 1 H), 7.27 (d, 8 / .4H), 7.18-7.08 (m, 1H), 7.02-6.97 (m.H2), 3.29 (dd, J = 16.8, 2.6 Hz, 1 H), 3.00 (dd, J = 16.8, 2.2 Hz, 1 H), 1.61-1.59 (m, 3 H); 19 F NMR (282 MH ?, acetone-d 6) d -81.86, -123.69-123.70; MS (Cl) m / e calculated for C1 H ??F4N20: 287.080751, found 287.080340; 287 (MH +, 75), 304 (M + NH 4 +, 100).
SCHEME 4: Chiral Resolution
Examples 27 and 28
Preparation of (-) - 6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-3,4-dihydro-2 (1H) -quinazolinone (Example 27) and (+) - 6-chloro-4-cyclopropylethynyl-tri-luomomethyl 3, 4-dihydro-2 (1H) -quinazolinone (Example 28).
Resolution of IV-b, c from IV-a (R4 = Cyclopropyl).
The chiral CLAP using a Quiracel OD column, 3% isopropanol, 5% CH2C12 and 92% hexanes at room temperature with a fluid range of 1.0 mL / minute and detection at 250 nm, gave the separation of IV-b to from IV-c with 99% and 99.4% enantiomeric excess, respectively. IV-b: p.f. 106-109 ° C; [OC-D25 60.34 ° (c = 0.274, MeOH). IV-c: p.f. 105-107 ° C; [a] D25 + 58.33 ° C [c = 0.288, MeOH).
Examples 29 and 30
Preparation of (+) - 4-cyclopropylethynyl-5,6-difluoro-4-trifluoromethyl-3,4-dihydro-2 (1H) -quinazolinone (Example 29) and (-) - 4-cyclopropylethynyl-5,6-di luoro-4-trifluoromethyl-3,4-dihydro-2 (1H) -quinazolinone (Example 30).
Resolution of Xll-b, c from Xll-a (R; Cyclopropyl).
The chiral CLAP using a Quiralpak AD column, 5% water and 95% methanol at room temperature with a flow rate of 0.8 mL / minute and a detection of 250 nm provided the separation of Xll-b from XII-c with enantiomeric excess and 100% and 99%, respectively. XII-b: p.f. 187 ° C; [a] D25 + 1.46 ° (c = 0.274, MeOH). XII-c: p.f. 187.5-1 C; [] ¿B - 1.45 c = 0.278, MeOH).
Examples 31 and 32
Preparation of (-) - 5,6-difluoro-4-isopropylethynyl-4-trifluoromethyl-3,4-dihydro-2 (1H) -quinazolinone (Example 31) and (+) - 5,6-difluoro-4-isopropylethynyl -4-trifluoromethyl-3,4-dihydro-2 (1H) -quinazolinone (Example 32).
Resolution of Xll-b, c from Xll-a (R 'Isopropyl).
The chiral CLAP using a Quiralpak AD column, 5% water and 95% methanol at room temperature with a flow rate of 0.5 mL / minute and a detection at 250 nm provided the separation of Xll-b from XII-c with an enantiomeric excess of 100% and 99%, respectively. Xll-b: p.f. 155 ° C; [c d5 -2.14 ° (c = 0.280, MeOH). XII-c: 98 ° C; [] c25 + 4.45 ° (c = 0.292, MeOH).
Examples 33 and 34
Preparation of (-) - 5,6-difluoro-4-ethylethynyl-4-trifluoromethyl-3,4-dihydro-2 (1H) -quinazolinone (Example 33) and (+) - 5,6-difluoro-4-ethylestynyl -4-trifluoromethyl-3,4-dihydro-2 (1H) -quinazolinone (Example 34).
Resolution of Xll-b, c from Xll-a (R4 Ethyl).
The chiral CLAP using an AS column, 20% ethanol and 80% hexanes at room temperature with a flow rate of 1.0 mL / minute and a detection at 250 nm provided the separation of Xll-b from XII-c with an enantiomeric excess of 100% and 99%, respectively. XII-b: p.f. 165-167 ° C. XII-c: p.f. 157-159 ° C.
Examples 35 and 36
Preparation of 5,6-difluoro-4- (2-hydroxyethyl) ethynyl-4-tri-loromethyl-3,4-dihydro-2 (1H) -quinazolinone (Example 35) and 5,6-difluoro-4- ( 1-hydroxyethyl) ethynyl-4-trif luoromethyl-3,4-dihydro-2 (1H) -quinazolinone (Example 36).
Compound Ex. 35 CH2CH2OH Ex .. 6 CH (OH) CK3
To a mixture of ketimine (300 mg, 1.20 mm ol) in anhydrous THF (11 mL) at -78 ° C was added sequentially a pre-cooled solution (0 ° C) of lithium acetylide protected by silyl (5.40 mmol) and BF3.0Et2 (0.60 mmol). The resulting mixture was stirred at room temperature overnight. The reaction was quenched by the addition of 1 M citric acid with EtOAc. The phases were separated, the organic phase was washed with water, saturated aqueous NaHCO3 and saturated aqueous NaCl. The organic extracts were dried over MgSO4, filtered and concentrated. The material was purified by regular phase CLAP chromatography (41.4 mm column Rainin Dynamax © using 60 A of silica @ 25 mL / minute): 2.5% MeOH / CH2Cl2 for 24 minutes, increasing to 30% MeOH / CH2Cl2 for 4 minutes, 30% MeOH / CH2Cl2 for 10 minutes, and returning to 2.5% MeOH / CH2Cl2 for 2 minutes. The yield of the protected intermediaries was 47% and 32%, respectively.
Example 35 -intermediary. P.f. 62.9-64 ° C; 1 H NMR (300 MHz, acetone-d 6) d 8.98 (br s, 1 H), 7.41-7.32 (m, 2 H), 6.83-6.78 (m, 1 H), 3.74 (t, J = 6.6 Hz, 2 H), 2.47 (t, J = 6.6 Hz, 2H), 0.81 (s, 9H), 0.00 (s, 6H); 19F NMR (282 MHz, acetone-d6) d -83.1, 135.16-135.31, -148.09-148.22; MS (Cl) calculated for C? 9H24 F5N202S i: / z 435.152723, found 435.151149; 435 (MH ", 94), 452 (M + NH ^, 100); analysis calculated for C19H23F5N2O YES: C, 52.52; H, 5.35; N, 646; found: C, 52.65; H, 5.29; N, 6.31.
Example 36-intermediary. 1 H NMR (300 MHz, acetone-de) d 8.96 (br s, 1 H), 7.50 (br s, 1 H), 7.37-7.28 (m, 1 H), 6.79- 6.74 (m, 1 H), 4.61 (q, J = 13.2, 6.6Hz, 1H), 1.30 (d J = 6.6 Hz, 3H), 0.78 (s, 9H), 0.01 (s, 6H); 19 F NMR (282 MHz, acetone-de) d -82.88-82.95, -135.20-135.42, 1 8.06-148.23; MS (Cl) calculated for C? 9H24 F5N202 Si: m / z 435.152723, found 435.152927; 435 (MH +, 51, 452 (M + NH4 +, 100); analysis calculated for C19H23F5N202Si; C, 52.52; 5.35; N, 6.46; found C, 52.54; H, 5.34; N, 6.69.
To a solution of the protected intermediate of Example 35 (0.56 mmol) in THF (1.1 mL) was added TBAF (0.62 mL of a 1.0 M solution in THF). The resulting mixture was stirred at room temperature for 1 hour, diluting with EtOAc, washing with IN HCl, saturated aqueous NaHCO 3, and saturated aqueous NaCl. The organic extract was dried over MgSO 4, filtered and concentrated. The material was purified by regular phase CLAP chromatography (41.4 mm using Rainin Dynamax® column of 60 A silica @ 25 mL / minute): 2.5% MeOH / CH2Cl2 for 24 minutes, increasing up to 30% MeOK / CH2Cl2 for 4 minutes, 30 MeOH / CH2Cl2 for 10 minutes, and returning to 2.5% MeOH / CH2Cl2 for 2 minutes. Example 35 was isolated in 82% yield.
Example 35. P.f. 190-192 ° C; 1 H NMR (300 MHz, acetone-de) d 9.05 (br s, 1 H), 7.53 (br s, 1 H), 7.45-7.36 (m, 1 H), 6.88-6.83 (m, 1 H), 4.01-3.98 (m , 1H), 3.68-3.64 (, 2H), 2.50 (t, J = 6.6
Hz 2H 19 F NMR (282 MHz, acetone-d6.3.3, - 132.68-135.88, -148.10-1 8.22; MS (Cl) calculated for C? 3H10F5N2O2: m / z - 321.066244, found
321. 066479; 321 (MH +, 100); analysis calculated for C ^ HgFsN ^: C, 48.76; H, 2.83 N, 8.76; found: C, 49.05; H, 3.23; N, 8.38.
Example 36 was synthesized in a manner analogous to that which delivers the title compound in an 88% yield. P.f. 190-191 ° C; X H NMR (300 MHz, acetone-de) d 9.06 (br s, 1H), 7.56 (br s, 1H), 6.88-6.83 (m, 1H), 4.58-4.57 (m, 2H), 1.39 (d, J = 5.5 Hz, 3H); 19 F NMR (282 MHz, acetone-d¿) d -83-15, -135.40, -135.60, -148.08-148.20; EM
(Cl) calculated for Ci3H10F5 2? 2: m / z 321.06624, found 321.066244; 321 (MHT, 58), 338 (M + NH4"100): analysis calculated for C? 3HsF5N2? 2: C, 48.76; H, 2.83; N, 8.76; found: C, 48.84; H, 2.76; N, 8.63 .
Example 37
Preparation of (+) - 4-E-cyclopropylethyl-5,6-difluoro-4-trifluoromethyl-3,4-dihydro-2 (1H) -quinazolinone.
To a solution of Xll-b (200 mg, 0.632 mmol) in anhydrous THF (1.3 mL) at room temperature was added a solution of lithium aluminum hydride (1.3 mL of a 1.0 M solution in THF). The resulting mixture was stirred at room temperature overnight. The reaction was quenched by the addition of 10% NaOH (3 mL) and water (3 mL). The mixture was diluted with EtOAc (30 mL) and the phases were separated. The organic phase was washed with saturated aqueous NaCl, dried over MgS? , filtered and concentrated. The title compound was purified by regular phase CLAP (41.4 mm column Rainin Dynamax® using 60A silica): 2.5% MeOH / CH2Cl2 for 24 minutes, increasing up to 30% MeOH / CH2Cl2 for 4 minutes, 30% MeOH / CH2Cl2 for 10 minutes, and returning to 2.5% MeOH / CH2Cl2 for 2 minutes. P.f. 80-83 ° C; ? ti NMR (300 MHz, acetone-d6) d 9.07 (br s, 1H), 7.33 (q, J = 8.8 Hz, 1H), 6.94 (br s, 1H (, 6.84-6.79 (m, 1H), 6.27 (dd, J = 15.6, 7.5 Hz, 1H), 5.67 (dd, J = 15.2, 9.4Hz, 1H), 1.65-1.56 (m, 1H), 0.80-0.71 (m, 2H), 0.50-0.42 (m , 2 H); 19 F NMR (282 MHz, acetone-d 6) d-82.68, -135.05, -148.49; MS (Cl) calculated for Ci 4 H 12 F 5 N 20: m / z 319.086979, found 319.087755; 319 (MH +
100] 20 + 72.77 ° (c = 0.382, MeOH); calculated for C? 4HnF5N20: C, 52.84; H, 3.48; N, 8.80; Found: C, 53.02; H, 3.48; N, 8.61.
Example 38
Preparation of (-) - 6-chloro-4-E-cyclopropyletenyl-4-trifluorornethyl-3,4-di-idro-2 (1H) -quinazolinone.
The title compound was prepared as described by Example 37 (starting from IV-b), except that it was purified using a Quiralcel OD column at 1.5 mL / minute in 0.5% EtOH / 20%. 'CH2Cl2 / 79.5% hexanes. P.f. 87-89 ° C; XH NMR
(300 MHz, acetone-de) d 9.08 (br s, 1H), 7.40-7.25
(m, 2H), 7.04-6.90 (m, 2H), 6.28-6.18 (, 1H), 5.64-5.52 (m, 1H), 1.68-1.55 (m, 1H), 0.83-0-71
(m,, 2H), 0.53-0.41 (m, 2H); 1SF NMR (282 MHz, acetone-d6) d -91.67; MS (Cl) calculated for C 14 H 3 ClF 3 N 20: m / z 317.066851, found
317. 065857; 317 (MH +, 100); [a] D20-6.81 ° (c = 0.382, MeOH); calculated analysis for C14H? 2Cl F3N20. 0.27 C3H60: C, 53.52; H, 4.13; N, 8.43; Found C, 53.90; H, 4.07; N, 8.80.
Unless otherwise indicated, thisguide is (+/-)
29. 6-Cl CF3 C = C-2 -furanyl K
6-Cl CF3 C = C-3 -furanyl K
31 6-Cl CF 3 C = C-2-thienyl 32 6-Cl CF 3 CsC-3-thienyl 33 6-Cl CF 3 c = -2 -oxazolyl?
34 6-Cl CF3 CsC-2-thiazolyl H
6-Cl "CF3? = C-4 isoxazolyl H
36 6-Cl CF3 CsC-2-imidazolyl K
37 6-Cl CF3 C = CCH2CH2OK K
38 6-Cl CF3 C = C-CH (0H) Me H
39 6-Cl CF3 C = C- (2-Cl) Ph H
40 6-Cl CF3 C = C- (3-Cl) Ph H
41 6-Cl CF3 OC- (4-Cl) Ph K
42 6-Cl CF3 C = C- (2-F) Ph K
43 6-Cl CF3 C = C- (3-F) Ph H
44 6-Cl CF3 C = C- (4-F) Ph H
45 6-Cl CF3 C = C- (2-OH) Ph H
46 6-Cl CF3 C = C- (3-0H) Ph H
47 6-Cl CF3 C = C- (4-OH) Ph H
48 6-Cl CF3 C = C- (2-OMe) Ph H
49 6-Cl CF3 C = C- (3-OMe) Ph H
50 6-Cl CF3 C = C- -4-OMe) Ph H
51 6-Cl CF3 C = C- (2-CN) Ph H
52 6-Cl CF3 C = C- (3-C) Ph H
53 6-Cl CF3 C = C- (4-C) Ph H
54 6-Cl CF3 C = C- (2-N02) Ph H
55 6-Cl CF3 C = C- (3-N02) Ph H
56 6-Cl CF3 C = C- (4-N? 2) Ph H
57 6-Cl CF3 C = C- (2-NH2) Ph H
58 6-Cl CF3 C = C- (3-NH2) Ph H
59 6-Cl CF3 C = C- (4-NH2) Ph H
60 6-Cl CF3 C = C-. { 2-NMe2) Ph H
61 6-Cl CF3 C = C- (3 -NMe2) Ph H
62 6-Cl CFT C = C-. { 4 -NMe2) Ph H OJ 6-Cl CF3 C = c-3-pyridyl
64 6-Cl CF3 C = C-4- Pyridyl
65 6-Cl CF3 C = c-2-furanyl H
66 6-Cl CF3 C = c-3furanyl H
67 6-Cl CF3 C = C-2-thienyl p
68 6-Cl CF3 C-C-3-ti enyl O K
69 6-Cl CF3 C = C-2-0? Azolyl H
70 6-Cl CF3 C = C-2-thiazolyl?
71 6-Cl CF3 C = C-4-isoxazolyl H
12 6-Cl CF3 C = C-2-imidazolyl K
73 6-Cl CF3 CH2CH2-cycPr H
74 6-Cl CF3 CH2CK2CH2CK2OK H
75 6-Cl CF3 CH2CK2 -CH (OH) Me H
76 6-Cl CF3 CH CH2-Ph H
77 6-Cl CF3 CH2CK2- (2-Cl) Ph H
7 788 6 6 - CCll CF3 CH2CH2- (3-Cl) Ph H 7 799 6 6 - CCll CF3 CH2CK2- (4-Cl) Ph H
80 6-Cl CF3 CH2CH2- (2-F) Ph H
81 6-Cl CF3 CH2CH2- (3-F) Ph H
8 822 6 6 - CCll CF3 CH2CH2- (4-F) Ph H
8 833 6 6 - CCll CF3 CH2CH2- (2-OH) Ph H
8 B44 6 6 - CCll CF3 CH2CH2-. { 3-OH) Ph H 5 6-Cl CH 2 CH 2 - (4-OH) Ph H 6 6-Cl CF 3 CH 2 CH 2 - (2-OMe) Ph H 7 6-Cl CF 3 CH 2 CH 2 - (3-OMe) Ph H 8 6- Cl CF 3 CH 2 CH 2 - (4-OMe) Ph H 9 6-Cl CF 3 CH 2 CH - (2-CN) Ph H 0 6-Cl CF 3 CH 2 CH 2 - (3-CN) Ph H 1 6-Cl CF 3 CH 2 CH 2 -. { 4-a-) Ph H 2 6-Cl CF 3 CH 2 CH 2 - (2 -N02) Ph H 3 6-Cl CF 3 CH 2 CK 2 - (3 -N02) Ph H 6-Cl CF 3 CH 2 CH 2 - (-N02) Ph H 6 -Cl CF3 CK2CK - (2 -NH2) Ph H 6-Cl CF3 CH2CK2- (3-KH2) Ph H 97. 6-Cl CF3 CH2 H2- (4-H2) Ph H
98 6-Cl CF3 CH2CH2- (2-NMe2) Ph K
99 6-Cl CF3 CH2CH? - (3 -NMe2) Ph K
100 6-Cl CF3 CH2CH2- (4 -NMe2)? H K
101 6-Cl CF3 CH2CH2-2- PIDID1 O "
102 6-Cl CF3 CH2CH2-3- Pyridium 1 D H
103 6-Cl CF3 CK2GÍ2- -PÍridÍlc 'K
104 6-Cl CF3 CH2CH2-2 -furanyl H
105 6-Cl CF3 CH2CH2-3 -f u r a n i 10 H
106 6-Cl CF3? __x "i2? "_í-.2 - 4. - furanyl K
107 6-Cl CF3 CH2CK2-3- thienyl H
108 6-Cl CF3 CH2CK2-2-oxazoyl H
109 6-Cl CF3 CH2CK2-2 -thiazolyl K
110 6-Cl CF3 CH2CH2-4-isoxazoill ° H
111 6-Cl CF3 CH2CK2-2-imidazolyl 0 H
112 6-Cl CF3 C = C-cycPr CH3
113 6-Cl CF3 CeC-Ph CH3
114 6-Cl CF3 C «C-2-pyridium CH3
115 6-Cl CF3 Cec-3-pyridyl CH3
116 6-Cl CF3 CEC-4-pyridyl CH3
117 6-Cl CF3 CsC-2 -furanyl CH3
118 6-Cl CF3 CsC-3- tur a ni CH3
119 6-Cl CF3 CsC-2- thienyl CH3
120 6-Cl CF3 C = C-3-thienyl CH3
121 6-Cl CF3 C = C-cycPr CH3
122 6-Cl CF3 C = C-Ph CH3
123 6-Cl CF3 C = C-2 -Piridyl CH3
124 6-Cl CF3 C = C-3-pyridi lo CH3
125 6-Cl CF3 C = C-4-pyridyl CH3
126 6-Cl CF3 C = C-2- furanyl CH3
127 6-Cl CF3 C = C-3-f uranyl CH3
128 6-Cl CF3 C = C-2-thienyl CH3
129 6-Cl CF3 C = c-3-thienyl CK3
130 6-Cl CF3 CK2CH2- rycPr CH3 131 6-Cl CF3 CK2CK2-Ph CK3
132 6-Cl CF3 CH2CK2 -2 - p i r i d i 1 or CK3
133 6-Cl CF3 CH2CK2-3-plridyl c? 3
134 6-Cl CF3 CH2CH -4- pyridyl CH3
135 6-Cl CF3 CH2CH2-2- furanyl CH3
136 6-Cl CF2 CH2CK2-3- furanyl CH3
137 6-Cl CF3 CH2CH2-2- thienyl c? 3
138 6-Cl CF3 CH2CH2-3- thienyl CH3
139 6-Cl CF3 C = C-cycPr CH2CK3
140 6-Cl CF3 Ce-C-Ph CH2CK3
141 6-Cl CF3 CsC-2-pyridyl or CH2CH3
142 6-Cl CF3 C = c73 -pyridyl CH2CH3
143 6-Cl CF3 C- -4- pir i di lo CH CH
144 6-Cl CF3 C- -2-fUranil CH2CH3
145 6-Cl CF3 CsC-3 -furanyl CH2CH3
146 6-Cl CF3 CsC-2- thienyl CH2CH3
147 6-Cl CF3 CEC-3- ti ^ nyl CH2CK3
148 6-Cl CF3 C = C-cycPr CH2CH3
149 6-Cl CF3 C = C-Ph CH2CH3
150 6-Cl CF3 C = C-2-pyridyl CH2CH3
151 6-Cl CF3 C = C-3-pyridyl CH2CH3
152 6-Cl CF3 C = C-4-pyridyl CH2CH3
153 6-Cl CF3 C = C-2-furanyl CH2CK3
154 6-Cl CF3 C = C-3-furanyl CH2CH3
155 6-Cl CF3 C = C-2-thienyl CH2CH3
156 6-Cl CF3 C = C-3-thienyl CH2CH3
157 6-Cl CF3 CH2CH2-cycPr CH CH3
158 6-Cl CF3. CK2CH2-Ph CH2CH3
159 6-Cl CF3 CH2CK2-2-p i r i d i 10 CH2CH3
160 6-Cl CF3 CH2CK2-3-pyridyl? CH2CH3
161 6-Cl CF3 CH2CH2-4 -p i r i d i 1 or CH CH3
162 6-Cl CF3 CH2CH2-2 - f u r a n f! 0 CH2CH3
163 6-Cl CF3 CH2 K2-3 -f u r a n i 1 or CH2CK3
164 6-Cl CFT CH2CH2-2 -thienyl CH2CH3 165 6-Cl CF3 CH2 c? 2 - 3 - 1 i e n i 1 or c? 2 CK 3
166 6-MeO CF3 C = CCK2CH2OH K
167 6 -MeO CF3 C = C-CH (OH) Me K
168 6 -MeO CF3 C = C- (2-Cl) Ph?
169 6 -MeO CF3 C = C- (3 -CDPh H
170 6 -MeO CF3 C = C- (4-Cl) Ph H
171 6 -MeO CF3 C = C- (2-F) Ph H
172 6 -MeO CF3 C = C- (3-F) Ph H
173 6 -MeO CF3 C = C-. { 4-F) Ph K
174 6 -MeO CF3 C = C- (2 -OH) Ph H
175 6 -MeO CF3 CsC- (3-OH) Ph H
176 6 -MeO CF3 C = C-. { 4 -OH) Ph H
177 6 -MeO CF3 C2C- (2-0Me) Ph K
178 6 -MeO CF3 CsC- (3-OMe) Ph H
179 6 -MeO CF3 CsC- (4-OMe) Ph H
180 6 -MeO CF3 CsC- (2-CN) Ph H
181 6 -MeO CF3 C «C-. { 3-CN) Ph H
182 6 -MeO CF3 OsC- (4-CN) Ph H
183 6 -MeO CF3 CßC- (2-N02) Ph H
184 6 -MeO CF3 0 = C- (3-N02) Ph H 185 6 -MeO CF3 OsC- (4-N02) Ph H 186 6 -MeO CF3 C = C- (2-NH2) Ph H 187 6 -MeO CF3 C = C- (3-NH2) Ph H 188 6 -MeO CF3 C = C- (-NH) Ph H 189 6 -MeO CF3 C = C- (2-NMe2) Ph H 190 6 -MeO CF3 C = C- (3-NMe2) Ph H 191 6 -MeO CF 3 C = C- (4-NMe 2) Ph H 192 6 -MeO CF 3 C = C-3-pyridyl H 193 6 -MeO CF 3 CsC-4-pyridyl H
194 6 -MeO CF3 c = c-2-f uranyl H 195 6 -MeO CF3 C = C-3-f uranyl H
196 6 -MeO CF3 C ^: - 2-thienyl H
197 6 -MeO CF3 CHC-3-thien.il0 H
198 6 -MeO CF3 C = C-2-o? AZolil ° H 199 6 -MeO CF3 C = C-2 -thia zolyl or K
200 6-MeO CF3 CSC-4-isoxazolyl K
201 6 -MeO CF3 C = C-2-imidazolyl?
202 6 -MeO CF3 C = CCH2CH2OH K
203 6 -MeO CF3 C = C-CH (OH) Me K
204 6 -MeO CF3 C = C- (2-Cl) Ph H
205 6 -MeO CF3 C = C- (3-Cl) Ph H
206 6 -MeO CF3 C = C- (4-Cl) Ph H
207 6 -MeO CF3 C = C- (2-F) Ph H
208 6 -MeO CF3 C = C- (3-F) Ph H
209 6 -MeO CF3 C = C- (4-F) Ph H
210 6 -MeO CF3 C = C- (2-OH) Ph H
211 6 -MeO CF3 C = C- (3-OH) Ph H
212 6 -MeO CF3 OC- (4 -OH) Ph H
213 6 -MeO CF3 C = C- (2-OMe) Ph K
214 6 -MeO CF3 C = C- (3-OMe) Ph H
215 6 -MeO CF3 C = C- (4-OMe) Ph H
216 6 -MeO CF3 C = C- (2-CN) Ph H
217 6 -MeO CF3 C = C- (3-CN) Ph H
218 6 -MeO CF3 C = C- (4-CN) Ph H
219 6 -MeO CF3 C = C- (2-N02) Ph H
220 6 -MeO CF3 C = C- (3-N02) Ph H
221 6 -MeO CF3 C = C- (4-N02) Ph H
222 6 -MeO CF3 C = C- (2- H2) Ph H
223 6 -MeO CF3 C = C- (3-NH2) Ph H
224 6 -MeO CF3 C = C- (4- H) Ph H
225 6 -MeO CF3 C = C- (2-NMe2) Ph H
226 6 -MeO CF3 C = C- (3-NMe2) Ph H
227 6 -MeO CF3 C = C- (4-NMe2) Ph H
228 6 -MeO CF3 C = C-3-pyridyl H
229 6 -MeO CF3 C = C-4-pyridyl H
230 6-MeO CF3 C = C-2-furanyl H
231 6 -MeO CF3 C = C-3-furanyl H
232 6 -MeO CF3 C = C-2-thienyl H 234 6-MeO CF3 C = C-2-OXazolyl ° H
235 6-MeO CF3 C = c-2- t i 3 zol i lo u
236 6-MeO CF3 C = c-4-isoxazole? IoH
237 6-MeO CF3 C = C-2-. imidazolyl H
238 6-MeO CF3 CH2CH2-cycPr H
239 6-MeO CF3 CH2CH2CH2CH2OH H
240 6-MeO CF3 CH2 CH2 -CH (OH) e K
241 6-MeO CF3 CH2CH2-Ph H
242 6-MeO CF3 CH2CH2- (2-Cl) Ph H
243 6-MeO CF3 CH2CH2- (3-Cl) Ph H
244 6-MeO CF3 CH2CH2- (4-Cl) Ph H
245 6-MeO CF3 CH2CH2- (2-F) Ph H
246 6-MeO CF3 CH2CH2- (3-F) Ph H
247 6-MeO CF3 CH2CH2- (4-F) Ph H
248 6-MeO CF3 CH2CH2- (2-OH) Ph H
249 6-MeO CF3 CH2CH2- (3-OH) Ph H
250 6-MeO CF3 CH2CH2- (4-OH) Ph H
251 6-MeO CF3 CH2CH2- (2-OMe) Ph H
252 6-MeO CF3 CH2CH2- (3-OMe) Ph H
253 6-MeO CF3 CH2CH2- (4-OMe) Ph H
254 6-MeO CF3 CH2CH2- (2-CN) Ph H
255 6-MeO CF3 CH2CK2- (3-CN) Ph H
256 6-MeO CF3 CH2CH2- (4-C) Ph H
257 6-MeO CF3 CH2CH2- (2-N? 2) Ph H
258 6-MeO CF3 CH CH2- (3-N02) Ph H
259 6-MeO CF3 CH2CH2- (4-N02) Ph H
260 6-MeO CF3 CH2CH2- (2-NH2) Ph H
261 • 6-MeO CF3 CH2CH2- (3-NH2) Ph H
262 6-MeO CF3 CH2CH2- (4-NH2) Ph H
263 6-MeO CF3 CH2CH2- (2 -NMe2) Ph H
264 6-MeO CF3 CH2CH2- (3-NMe2) Ph H
265 6-MeO CF3 CH2CH2- (4-NMe2) Ph H
266 6-MeO CF3 CH2CH2-2- ÍrÍdÍl? H 267 6-MeO CF 3 CH 2 CH 2 - pyridylc > K
268 6 -MeO CF3 CK2CH2- - Diridyl H
269 6 -MeO CF3 CH CK2-2- cu ~ = n i! r K
270 6 -MeO CF3 CH2CK2-3- r? ¡^? D n K
271 6 -MeO CF3 CH2CK2-4- furanyl K
272 6 -MeO CF3 CH2CH2-3-thienyl K
273 6 -MeO CF3 CH2CH2-2- oxazolyl H
274 6 -MeO CF3 CH2CH2-2- the 0l i lO H
275 6 -MeO CF3 CH2CH2- - i 0 a. a • * 0 l i lO H
276 6 -MeO CF3 c? 2CK2-2 - i p i d; azo 1 i fo H
277 6 -MeO CF3 C = C-cycPr CH3
278 6 -MeO CF3 C = C-Ph CH3
279 6 -MeO CF3 c = c-2- iridj lo CH3
280 6 -MeO CF3 C = C-3- Diridyl CH3
281 6 -MeO CF3 CsC-4-pyridyl CH3
282 6 -MeO CF3 CEC-2- furanyl CH3
283 6 -MeO CF3 C ^ - * - furanyl CH3
284 6 -MeO CF3 C = C-2-thienyl CH3
285 6 -MeO CF3 286 tiemlo CH3 6 -MeO CF3 C = C-cycPr CH3
287 6 -MeO CF3 C = C-Ph CH3 88 6 -MeO CF3 ^ - Dxpdilo CH3 89 6 -MeO CF3 C = C-3 - Diridyl CH3 90 6 -MeO CF3 C = C-4 - pyridine CH3 91 6 - MeO CF3 C = C-2-. furanyl CH3 92 6 -MeO CF3 C = C-3 -franyl CH3 93 6 -MeO CF3 C = C-2- thienyl CH3 94 6 -MeO CF3 C = C-3-thienyl CH3 95 6 -MeO CF3 CH2CH2-cycPr CH 3 96 6 -MeO CF 3 CH 2 CH 2-Ph CH 3 97 6 -MeO CF 3 CH 2 CH 2-2- Diridyl CH 3 98 6 -MeO CF 3 CH 2 CH 2 3--. . .,., 9 id piyl CK3 -MeO CF3 CH2CK2-4- pyridyl CK3 0 6 -MeO CF3 CK2CH? - - furanyl CH3 301-6-MeO CF3 CH2CK2-3 -furanyl CK3
302 6-MeO CF3 CH2CK2-2 -thienyl CH3
303 6-MeO CF3 CK2CH2-3 -thienyl C? 3
304 6-MeO CF3 C = C-cvcPr CK2CK3
305 6-MeO CF3 C = C-Ph CK2CK3
306 6-MeO CF3 CsC_2-Pyridylc CH2CK3
307 6-MeO CF3 C = C_3_pyridyl CH2CH3
308 6-MeO CF3 C = C-4-pyridyl CH2CH3
309 6-MeO CF3 csc_2_furanyl CK2CH3
310 6-MeO CF3 CsC-3-f uranyl CH2CH3
311 6-MeO CF3? ? _ == - xr_- «* > - t + .ieni - l io CH2CK3
312 6-MeO CF3 CaC-3-thienyl CH2CH3
313 6-MeO CF3 C = C-cycPr CH2CH3
314 6-MeO CF3 C = C-Ph CH2CH3
315 6-MeO CF3 C = C-2-pyridyl CH2CH3
316 6-MeO CF3 C = C-3-pyridyl CH2CH3
317 6-MeO CF3 C = C-4-pyridyl CH2CH3
318 6-MeO CF3 C = C-2-f uranyl CH2CH3
319 6-MeO CF3 c = c_3_ furanyl CH2CH3
320 6-MeO CF3 C = C-2-thienyl CH2CH3
321 6-MeO CF3 C = c-3-thienyl CH2CH3
322 6-MeO CF3 CK2CH2-cycPr CH2CH3
323 6-MeO CF3 CH2CH2-Ph CH2CH3
324 6-MeO CF3 CH2CK2-2- pyridylCH2CH3
325 6-MeO CF3 CH2CH2-3 - p i r i d i 1 oCH2CH3
326 6-MeO CF3 CH2CH2- • P i r i d i 1 c CH2CH3
327 6-MeO CF3 CH2CH2-2 -f u r a n i 1 or CH2CH3
328 6-MeO CF3 CH2CH2-3-f uranyl CH2CH3
329 6-MeO CF3 CK2CH2-2 -thienyl CH2CH3
330 6-MeO CF3 CH2CK2-3- thienyl CH283
331 5,6-diF CF3 CsC- (2-Cl) Ph H
332 5,6-diF CF3 C = C- (3-Cl) Ph H
333 5,6-diF CF3 CsC- (4-Cl) Ph H
334 5,6-diF CF3 C-? C- (2-F) Ph H 335 5,6-diF CF3 C = C- (3-F) Ph K
336 5, 6-diF CF3 C = C- (4-F) Ph K
337 5,6-diF CF3 C = C- (2-OH) Ph K
338 5,6-diF CF3 CsC- (3 -OH) Ph K
339 5, 6-diF CF3 C = C- (-OH) Ph H
340 5,6-diF CF3 C = C- (2-OMe) Ph H
341 5,6-diF CF3 C = C- (3-OMe) Ph H
342 5,6-diF CF3 C = C- (4-OMe) Ph K
343 5,6-diF CF3 C = C- (2-CN) Ph H
344 5,6-diF CF3 C = C- (3-CN) Ph H
345 5,6-diF CF3 C = C- (4-CN) Ph H
346 5,6-diF CF3 C = C- (2-N02) Ph H
347 5,6-diF CF3 C = C- (3-N02) Ph H
348 5,6-diF CF3 C = C-. { -N02) Ph H
349 5,6-diF CF3 C = C- (2-NH) Ph H
350 5,6-diF CF3 CeC- (3- H2) Ph H
351 5,6-diF CF3 CsC- (4-NH2) Ph H
352 5,6-diF CF3 CßC- (2-NMe2) Ph H
353 5,6-diF CF3 CßC- (3-NMe2) Ph H
354 5,6-diF CF3 CsC- (4- Me) Ph H
355 5,6-diF CF3 C «C-3-pyridyl H
356 5,6-diF CF3 C = C-4-pyridyl H
357 5,6-diF CF3 C = C-2- furanyl H
358 5,6-diF CF3 C = C-3-furanyl H
359 5.6-diF CF3 C = C-2- ^ •. - 360 thienyl H 5,6-diF CF3 CEC-3-thienyl H
361 5,6-diF CF3 O = c-2-oxazolyl H
362 5,6-diF CF3 CsC-2-thiazolyl H
363 5,6-diF CF3 C = C-4-isoxazolyl H
364 5, 6-diF CF3 365 C = c-2-imidazolium H 5, 6-diF CF3 C = C- (2-Cl) Ph H
366 5,6-diF CF3 C = C- (3-Cl) Ph H
367 5,6-diF CF3 OC- (4-Cl) Ph H
368 5,6-diF CF3 C = C- (2-F) Ph 369. 5, 6-diF CF3 C = C- (3-F) Ph K
370 5,6-diF CF3 OC- (4-F) Ph K
371 5,6-diF CF3 C = C- (2-OH) Ph K
372 5,6-diF CF3 C = C- (3-OH) Ph H
373 5,6-diF CF3 C = C- (4-OH) Ph H
374 5,6-diF CF3 C = C- (2-OMe) Ph H
375 5, 6-diF CF3 C = C- (3-OMe) Ph K
376 5.6-diF CF3 C = C-. { 4-OMe) Ph H
377 5,6-diF CF3 C = C- (2-CN) Ph K
378 5,6-diF CF3 C = C- (3-C) Ph H
379 5,6-diF CF3 C = C- (4 -CN) Ph H
380 5,6-diF CF3 C = C- (2-N02) Ph H
381 5,6-diF CF3 C = C- (3-N0) Ph H
382 5,6-diF CF3 C = C- (4-N02) Ph H
383 5,6-diF CF3 C = C- (2-NH2) Ph H
384 5,6-diF CF3 C = C- (3 -MH2) Ph H
385 5,6-diF CF3 C = C- (4-NH2) Ph H
386 5,6-diF CF3 C = C- (2- Me2) Ph H
387 5,6-diF CF3 C = C- (3-Me2) Ph H
388 5,6-diF CF3 C = C- (4- Me2) Ph H
389 5,6-diF CF3 C = C-3-pyridyl H
390 5,6-diF CF3 C = C-4- Pyridyl H
391 5,6-diF CF3 C = C-2-f uranyl H
392 5,6-diF CF3 C = C-3-f uranyl H
393 5,6-diF CF3 C = C-2-thienyl H 394 5,6-diF CF3 C = C-3 -thienyl H
395 5,6-diF CF3 C = C-2-oxazolyl H
396 5,6-diF CF3 C = C-2-thiazolyl H
397 5,6-diF CF3 C = C-4 -isoxazolyl H
398 5,6-diF CF3 C = C-2-imi dazolyl H
399 5,6-diF CF3 CH2CH2-cycPr H
400 5,6-diF CF3 CH2C.-I2CH2CK 0H H
401 5, 6-diF CF3 CH2CH2-CH (OH) Me H
402 5,6-diF CF3 CH2CH2-Ph H 403 5,6-diF CF3 CH2CH2- (2-CI)? H H
404 5, 6-diF CF3 CH2CK2- (3-Cl) Ph H
405 5,6-diF CF3 CH2CH2- (4-Cl) Ph K
406 5, 6-diF CF3 CH2CK2- (2-F) Ph K
407 5,6-diF CF3 CK2CH2- (3-F) Ph H
408 5,6-diF CF 3 CH 2 CH 2 -. { 4-F) Ph J £
409 5,6-diF CF3 CH2OÍ2- (2-OK) Ph U
410 5,6-diF CF3 CH2CH2- (3-OH) Ph u
411 5,6-diF CF3 CH2CK2- (4-OH) Ph H
412 5, 6-diF CF3 CH2CK2- (2-OMe) Ph H
413 5,6-diF CF3 CH2CH2- (3-OMe) Ph H
414 5, 6-diF CF3 CH2CH2- (4-OMe) Ph H
415 5,6-diF CF3 CH2CH2- (2-CN) Ph H
416 5,6-diF CF3 CH2CH2- (3-CN) Ph H
417 5,6-diF CF3 CH2CH2- (4-CN) Ph H
418 5,6-diF CF3 CH2CK2- (2-N02) Ph H
419 5,6-diF CF3 CH2CH2- (3-N02) Ph H
420 5,6-diF CF3 CH2CH2- (4-N02) Ph H
421 5,6-diF CF3 CH2CH2- (2- H2) Ph H
422 5,6-diF CF3 CH2CK2- (3-NH2) Ph H
423 5,6-diF CF3 CH CH2- (4-NH2) Ph H
424 5,6-diF CF3 CH2CK2- (2-NMe2) Ph H
425 5,6-diF CF3 CH2CH2- (3 -NMe2) Ph H
426 5,6-diF CF3 CH CH2- (4 -NMe2) Ph H
427 5,6-diF CF3 CH CK2-2- Pyridyl H
428 5,6-diF CF3 CH2CH2-3- pyridyl H
429 5,6-diF CF3 CH2CK2-4-Pyridyl H
430 5,6-diF CF3 CH2CH2 -2 -furanyl H
431 5,6-diF CF3 CH2CH2-3-f uranyl H
432 5,6-diF CF3 CH2CH2-2- thienyl H
433 5,6-diF CF3 CH2 H2-thienyl H
434 5,6-diF CF3 CH2CK2 -2 - 0 x to z 01 i 10 H
435 5,6-diF CF3 i CH2CH2-2-tiaz ° l? L? H
436 5,6-diF CF3 C? CK2-4 -isoxazolilc > K 437 5, 6-diF CF3 CH2CH2- K
438 5,6-diF CF3 C = C-cycPr c 3
439 5,6-diF CF3 C = C-2-pyridyl CH3
440 5,6-diF CF3 C = C-3-Pridyl C 3
441 5,6-diF CF3 C = C-4-pyridyl CH3
442 5, 6-diF CF3 C = C-2- furanyl CH
443 5,6-diF CF3 C ^ -3-furanyl n3
444 5,6-diF CF3 C = C-2-thienyl CH3
445 5,6-diF CF3 C = c-3- tiemlo CH3
446 5, 6-diF CF3 C = C-cycPr CH3
447 5,6-diF CF3 C = C-2-thienyl CH3
448 5,6-diF CF3 C = C-3-pyridyl CH3
449 5,6-diF CF3 C = C-4-pI idil? H3
450 5,6-diF CF3 C = C-2-f uranyl CH3
451 5,6-diF CF3 C = C-3-f uranyl CH3
452 5,6-diF CF3 C = C-2-thienyl CH3
453 5,6-diF CF3 C = C-3-thienyl ^
454 5,6-diF CF3 CH2CH -cycPr CH3
455 5,6-diF CF3 CH2CH2-Ph CH3
456 5,6-diF CF3 CH2CH2-2-pyridyl CH3
457 5,6-diF CF3 CH2CH2-3-Pridyl CH3
458 5,6-diF CF3 CH2CH2-4-pyridyl? CH3
459 5,6-diF CF3 CH2CH2-2-furanyl CH3
460 5,6-diF CF3 CH CH2-3-f uranyl CH3
461 5,6-diF CF3 CH2CH2-2- thienyl CH3
462 5,6-diF CF3 CH2CH2-3-thienyl CH3
463 5,6-diF CF3 C = C-cycPr CH2CH3
464 5,6-diF CF3 O = C-Ph CH2CH3
465 5,6-diF CF3 CsC-2-pyridyl CH CH3
466 5,6-diF CF3 c ^: _ 3_pyridyl CK2CH3
467 5,6-diF CF3 C = c-4- pir i di lo CH2CH3
468 5,6-diF CF3 OeC-2 -furanyl CH2CH3
469 5,6-diF CF3 CsC-3-furanyl CH2CH3
470 5, 6-diF CF3 CsC-2-tÍenii ° CH2CH3 471 5,6-diF CF3 C = C-3-tmemium c? 2c? 3
472 5,6-diF CF3 C = C-cycPr CH CK3
473 5,6-diF CF3 C = C-Ph CK2CH3
474 5,6-diF CF3 C = C-2-pyridylc > CH2CH3
475 5,6-diF CF3 C = C-3 -pipdyl CH2CK3
476 5,6-diF CF3 C = C-4-pyridyl CH2CH3
477 5,6-diF CF3 C = c-2-f ur añil CH2CH3
478 5,6-diF CF3 C = c-3.furanyl CK2CH3
479 5,6-diF CF3 C = C-2-thienyl CH CK3
480 5,6-diF CF3 C = C-3-thienyl CH2CK3
481 5,6-diF CF3 CH2CH2-cycPr CK2CH3
482 5,6-diF CF3 CH CK2-Ph CH2CH3
483 5,6-diF CF3 CH2CK2-2 - p i r i d i 1 or CH2CK3
484 5,6-diF CF3 CH2CH2-3 -pyridyl or CH2CH3
485 5,6-diF CF3 CH CH2-4-pyridylc, CH2CH3
486 5,6-diF CF3 CH2CK2-2-f uranyl CH2CH3
487 5,6-diF CF3 CH2CK2-3 -furanyl CH2CH3
488 5,6-diF CF3 CH2CK2-2 - i e n i 10 CH2CH3
489 5,6-diF CF3 CH2CH2-3-thienyl CH2CH3
490 5,6-diCl CF3 CsC- (2-Cl) Ph H
491 5,6-diCl CF3 C «C- (3-Cl) Ph H
492 5,6-diCl CF3 C = C- (4-Cl) Ph H
493 5,6-diCl - ^ * 3. CeC- (2-F) Ph H
494 5,6-diCl CF3 OsC- (3-F) Ph H
495 5,6-diCl CF3? EC- (4-F) Ph H
496 5,6-diCl CF3 C = C-C2-OH) Ph H
497 5,6-diCl CF3 C = C- (3-OH) Ph H
498 5,6-diCl CF3 C = C- (4-OH) Ph H
499 5,6-diCl CF3 C = C- (2-OMe) Ph H
500 5,6-diCl CF3 C = C-. { 3 -OMe) Ph H
501 5,6-diCl CF3 C = C-. { 4-OMe) Ph H
502 5,6-diCl CF3 CsC- (2-CN) Ph H
503 5,6-d Cl CF3 C = C- (3-CN) Ph H
504 5,6-diCl CF3 C = C- (4-CN) Ph K 505 5,6-diCl CF3 C = C- (2-N02) Ph H
506 5,6-diCl CF3 C = C- (3-N02) Ph K
507 5,6-diCl CF3 C = C-. { 4 -N02) Ph H
508 5,6-diCl CF3 C = C- (2-KH) Ph K
509 5,6-diCl CF3 C = C- (3 -NH2) Ph H
510 5,6-diCl CF3 C = C- (4-NH2) Ph H
511 5,6-diCl CF3 G = C- (2-NMe2) Ph H
512 5,6-diCl CF3 C = C- (3 Me) Ph H
513 5,6-diCl CF3 C = C- (4 -NMe2) Ph H
514 5,6-diCl CF3 C = C-3-pyridyl H
515 5,6-diCl CF3 C = C-4-Pyridyl H
516 5,6-diCl CF3 C = C-2 -furanyl H
517 5,6-diCl CF3 c = -3"furanyl H
518 5,6-diCl CF3 C = c-2-t ienyl H
519 5,6-diCl CF3 CeC-3 - 1 i e n i 1 or H
520 5,6-diCl CF3 CsC-2-oxazolyl H
521 5,6-diCl CF3 CsC-2-thiazolyl H
522 5,6-diCl CF3 O - - isoxazolili 0 H
523 5,6-diCl CF3 CtC-2-imidazolyl H
524 5,6-diCl CF3 C = C- (2-Cl) Ph H
525 5,6-diCl CF3 C = C- (3-Cl) Ph H
526 5,6-diCl CF3 C = C- (4-Cl) Ph H
527 5,6-diCl CF3 OC- (2-F) Ph H
528 5,6-diCl CF3 C = C- (3-F) Ph H
529 5,6-diCl CF3 C = C- (4-F) Ph H
530 5,6-diCl CF3 C = C-. { 2-0H) Ph H
531 5,6-diCl CF3 C = C- (3-OH) Ph H
532 5,6-diCl CF3 C = C- (4-OH) Ph H
533 5,6-diCl CF3 C = C- (2-OMe) Ph H
534 5,6-diCl CF3 C = C- (3-0Me) Ph H
535 5,6-diCl CF3 C = C- (4-OMe) Ph H
536 5,6-diCl CF3 C = C- (2-Gí) Ph H
537 5,6-diCl CF3 C = C- (3-C) Ph H
538 5,6-diCl CF3 c = c - (.: - CN) Ph H 539 5,6-diCl CF3 C = C- (2-N02) Ph H
540 5,6-diCl CF3 C = C- (3-N02) Ph K
541 5,6-diCl CF3 C = C- (4-N02) Ph H
542 5,6-diCl CF3 C = C- (2-NH) Ph H
543 5,6-diCl CF3 C = C- (3-NH2) Ph H
544 5,6-diCl CF3 OC- (4-H2) Ph H
545 5,6-diCl CF3 C = C- (2-NMe2) Ph H
546 5,6-diCl CF3 C = C- (3-NMe2) Ph H
547 5,6-diCl CF3 C = C- (4- Me2) Ph H
548 5,6-diCl CF3 C = C-3-pyridyl H
573 5,6-diCl CF3 CK2 .2 - (- OMe) Ph K
574 5,6-diCl CF3 CH2CK2- (2-CN) Ph H
575 5,6-diCl CF3 CH CH2- (3-CN) Ph H
576 5,6-diCl CF3 CH2CK2- (4-CN) Ph H
577 5,6-diCl CF3 CH2CH2- (2-N02) Ph K
578 5,6-diCl CF3 CH2CK2- (3-N02) Ph H
579 5,6-diCl CF3 CH2CH2- (4-N02) Ph H
580 5,6-diCl CF3 CH2CK2- (2-NH2) Ph H
581 5,6-diCl CF3 CH2 CH2 - (3 -NH2) Ph H
582 5,6-diCl CF3 CH2CH2- (4-NH2) Ph H
583 5,6-diCl CF3 CH2 CH2 - (2 -NMe2) Ph H
584 5,6-diCl CF3 CH CH2 - (3 - Me2) Ph H
585 5,6-diCl CF3 CH2CH2- (4-NMe2) Ph H
586 5,6-diCl CF3 CH CH2-2-Prididyl H
587 5,6-diCl CF3 CH2CH2-3-Pyridyl H
588 5,6-diCl CF3 CH2CH2-4-pyri di lo H
589 5,6-diCl CF3 CH2CH2-2-furanyl H
590 5,6-diCl CF3 CH2CH2-3-furanyl H
591 5,6-diCl CF3 CH2CH2-2-thienyl H
592 5,6-diCl CF3 CH2CH2-3-thienyl H
593 5,6-diCl CF3 CH2CH2-2- oxazolyl H
594 5,6-diCl CF3 CH2CH2-2-thiazole or H
595 5,6-diCl CF3 CH2CH2- -.IS oxazolyl H
596 5,6-diCl CF3 CH2CH2-2-i idazolyl H
597 5,6-diCl CF3 C = C-cycPr CH3
598 5,6-diCl CF3 CsC-2-pyridyl CH3
599 5,6-diCl CF3 C = C-3-pyridyl H3
600 5,6-diCl CF3 C = C-4-pyridyl or ^ 3
601 5,6-diCl CF3 CsC-2-f uranxlo CH3
602 5,6-diCl CF3 C = C-3-f uranyl H3
603 5,6-diCl CF3 C- -2- thienyl CH3
604 5,6-diCl CF3 C = c-3- ienyl CH3
605 5,6-diCl CF3 C = C-cycPr CH3
606 5,6-diCl CF3 C = C-2-pyridyl CK3 607 5,6-diCl CF3 C = C-3- Pir i di i o Cíi3
608 -. 608-5.6-diCl CF3 C = C- pyridyl CH,
609 5,6-diCl CF3 C = c-2-furanüo CK3
610 5,6-diCl CF3 r_r., Furanyl
611 5,6-diCl CF3 C = C-2-thienyl CK3
612 5,6-diCl CF3 c = c_3 -thienyl c? 3
613 5,6-diCl CF3 CK2 Ci-cy c Pr CH3
614 5,6-diCl CF3 CK2CH2-Ph CK3
615 5,6-diCl CF3 CH2CK2-2-pyridyl CH3
616 5,6-diCl CF3 CH2CH2-3 -pyridyl CH3
617 5,6-diCl CF3 CH2CH2-4-pyridyl CH3
618 5,6-diCl CF3 CH2CK2-2-furanyl CH3
619 5, 6-diCl CF3 CH2CK2-3-f uranyl CH3
620 5,6-diCl CF3 CH2CK2-2-thienyl CH3
621 5,6-diCl CF3 CH2CH2-3-thienyl CH3
622 5,6-diCl CF3 CeC-cycPr CH CH3
623 5,6-diCl CF3 CeC-Ph CH2CH3
624 5,6-diCl CF3 CsC-2-piri üo CH2CH3
625 5,6-diCl CF3 C -3-pyridyl CH2CH3
626 5,6-diCl CF3 C ^ -4-pyrid-yl CH2CH3
627 5,6-diCl CF3 sC-2-furanyl CH2CH3
628 5,6-diCl CF3 C = C-3-furanyl CH2CH3
629 5,6-diCl CF3 C = C-2-thienyl CH H3
630 5,6-diCl CF3 ^^ - thienyl CH2CH3
631 5,6-diCl CF3 C = C-cycPr CH2CH3
632 5,6-diCl CF3 C = C-Ph CH2CH3
633 5,6-diCl CF3 C = C-2-pyridylc CH2CH3
634 5,6-diCl CF3 C = C-3-pyridyl or CK2CH3
635 5,6-diCl CF3 C = C-4-pyridyl CH2CH3
636 5,6-diCl CF3 C = c-2-f uranyl CH CH3
637 5,6-diCl CF3 c = C-3-f uranyl CH2CH3
638 5,6-diCl CF3 C = C-2-thienyl Gi2CH3
639 5,6-diCl CF3 C = C ~ 3"thienyl CK2CH3
640 5,6-diCl CF3 CH CH2-cycPr CH, CH, 71 641 5,6-diCl CF3 CH CH2-Ph CH CK3
642 5,6-diCl CF3 CH2CH2-2 -Piridyl CK2CK3
643 5,6-diCl CF3 CH2CK2-3 pyridyl CH2CH3
644 5,6-diCl CF3 CK2CK2- -pyridyl CH2CH3
645 5,6-diCl CF3 CH2CH2-2 -furanyl CH2CK3
646 5,6-diCl CF3 CK2CK2-3 -furanyl CH2CH3
647 5, O-diCl CF3 CH2CK2-2 -thienyl CH2CK3
648 5,6-diCl CF3 CH2CK2-3 -thienyl CH2CH3
649 6-F CF3 C = CCH CH2OH H
650 6-F CF3 C = C-CH (OH) Me H
651 6-F CF3 C = C- (2-Cl) Ph H
652 6-F CF3 C = C- (3-Cl) Ph K
653 6-F CF3 C = C- (4-Cl) Ph H
654 6-F CF3 CsC- (2-F) Ph H
655 6-F CF3 OeC- (3-F) Ph H
656 6-F CF3 CHC- (4-F) Ph H
657 6-F CF3 O = C- (2-0H) Ph H
658 6-F CF3 C? C- (3-OH) Ph H
659 6-F CF3 C «C- (4-OH) Ph H
660 6-F CF3 CsC- (2-OMe) Ph H
661 6-F CF3 CsC- (3-OMe) Ph H
662 6-F CF3 C = C- (4 -OMe) Ph H
663 6-F CF3 C = C- (2-CN) Ph H
664 6-F CF3 C = C- (3-CN) Ph H
665 6-F CF3 C = C- (4-CN) Ph H
666 6-F CF3 C = C- (2-N02) Ph H
667 6-F CF3 C = C- (3-N02) Ph H
668 6-F CF3 C = C- (4-N02) Ph H
669 6-F CF3 C = C- (2-NH2) Ph H
670 6-F CF3 C = € - (3-NH2) Ph H
671 6-F CF3 C = C- (4- H2) Ph H
672 6-F CF3 C = C-. { 2-NMe2) Ph H
673 6-F CF3 C = C- (3-NMe) Ph K
674 6-F CF3? EC- (4-KMe2) Ph H 675 6-F CF3 C = C-3-Pyridyl?
676. 6-F CF3 C = C-4-Prididyl H
677 6-F CF3 (- = ^ - - "furanyl
678 6-F CF3 C = C-3-furanyl H
679 6-F CF3 C- -2-thienyl H
680 6-F CF3 C = C-3-thienyl H
686 6-F CF3 C = C-CH (OH) Me H
687 6-F CF3 C = C- (2-Cl) Ph H
688 6-F CF3 C = C- (3-Cl) Ph H
689 6-F CF3 C = C- (4-Cl) Ph H
690 6-F CF3 OC- (2-F) Ph H
691 6-F CF3 C = C- (3-F) Ph H
692 6-F CF3 C = c- (4-F) Ph H
693 6-F CF3 C = C- (2-OH) Ph H
694 6-F CF3 C = C- (3-OH) Ph H
695 6-F CF3 C = C- (4-OH) Ph H
696 6-F CF3 C = C- (2-OMe) Ph H
697 6-F CF3 C = C- (3-0Me) Ph H
698 6-F CF3 C = C- (4-OMe) Ph H
699 6-F CF3 C = C- (2-CN) Ph H
700 6-F CF3 C = C- (3-CN) Ph H
701 6-F CF3 C = C- (4-CN) Ph H
702 6-F CF3 C = C- (2-N02) Ph H
703 6-F CF3 C = C- (3-N02) Ph H
704 6-F CF3 C = C- (4-N02) Ph H
705 6-F CF3 C = C- (2-NH2) Ph H
706 6-F CF3 C = C- (3-NH2) Ph H
707 6-F CF3 C = C- (4-NH2) Ph H 708 6-F CFi C = C- (2-Me2) Ph H 709 6-F CF3 C = C- < 3-NMe) Ph H
710 6-F CF3 C = C- (4- Me) Ph K
711 6-F CF3 C = C-3-pyridyl H
712 6-F CF3 C = C-4-pyridyl H
713 6-F CF3 C = C-2-f uranyl H
714 6-F CF3 C = c-3-furanyl H
715 6-F CF3 C = C-2-thienyl H
716 6-F CF3 c = c_3_tien? Lo H
717 6-F CF3 C = C-2-oxazyl? H
718 6-F CF3 C = C-2-thiazolyl H
719 6-F CF3 C = C-4-isoxazolyl H
720 6-F CF3 C = C-2-imidazolyl H
721 6-F CF3 CH2CH2-cycPr H
722 6-F CF3 CH2CH2CH2CH2OH H
723 6-F CF3 CH2CH2-CH (OH) Me H
724 6-F CF2 CH2CH2- (2-Cl) Ph H
725 6-F CF3 CH2CK2- (3-Cl) Ph H
726 6-F CF3 CH2CH2- (4-Cl) Ph H
727 6-F CF3 CH2CH2- (2-F) Ph H
728 6-F CF3 CH2CH2- (3-F) Ph H
729 6-F CF3 CH2CH2- (4-F) Ph H
730 6-F CF3 CH2CH2- (2-OH) Ph H
731 6-F CF3 CH CK2- (3-OH) Ph H
732 6-F CF3 CH2CH2- (4-OH) Ph H
733 6-F CF3 CH2CH2- (2-OMe) Ph H
734 6-F CF3 CH2CH2- (3-OMe) Ph H
735 6-F CF3 CH2CH2- (4-OMe) Ph H
736 6-F CF3 CH2CH2- (2-CN) Ph H
737 6-F CF3 CH2CH2- (3-CN) Ph H
738 6-F CF3 CH2CH2- (4-CN) Ph H
739 6-F CF3 CH2C? 2- (2-N02) Ph H
740 6-F CF3 CH2CH2- (3 -N02) Ph H
741 6-F CF3 CH2CH2- (4-N02) Ph H
742 6-F CF3 CH2CK2- (2-NH2) Ph H 743 .. 6-F CF3 CK2CH2 - (3 -KK2) Ph K
744 6-F CF3 CH2 CK2 - (4-NH) Ph H
745 6-F CF3 CH2 CH2 - (2 - Me2) Ph H
746 6-F CF3 CH2CK2- (3-NMe2) Ph K
747 6-F CF3 CH2CH2- (4 -NMe2) Ph H
748 6-F CF3 CH2CH2-3-pÍrÍdílo K
749 6-F CF3 CH2CH2-4-pyridyl H
750 6-F CF3 CH2CH2-2 -furanyl H
751 6-F CF3 CH2CH2r3-furanyl H
752 6-F CF3 CH2CH2-2-thienyl H
753 6-F CF3 CH2CH2-3-thienyl K
754 6-F CF3 CH2CH2-2- oxazolyl H
755 6-F CF3 CH2CH2-2-thiazolyl H
756 6-F CF3 CH2CH2-4-isoxazolylH
757 6-F CF3 CH2CH2-2-imidazolyl? H
758 6-F C v_Fr33 OsC-cycPr CH3
759 6-F C CFF33 CsC-iPr CH3
760 G-F C CFF33 CßC-Pr CH3
761 6-F C CFF33 C «C-Bu CH3
762 6-F C CFF32 OC-iBu CH3
763 6-F C CFF33 C = C-tBu CH3
764 6-F C CFF33 C = C-Et CH
765 6-F C CFF33 C = C-Me CH3
766 6-F C CFF33 c = c-Ph CH3
767 6-F C C CFFF333 CsC-2- Pyridyl CH3
768 6-F C CFF33 CEC-3-Pridine .10 CH3
769 6-F C CFF33 C = C-4-pyridi lo CH3
770 6-F C CFF3. C = C-2- f xu 771 uraani i? ic CH3
6 6 - FP CF3 C = C-3-furanilc CK3
772 6-F CF3 C = C-2-t? Enl? 0 ^ 3
773 6_F CF CF3 C = C-3-thienyl CH3 6_F CF3 C = C-cycPr CH3
775 6-F CF3 C = C-iPr CH3
776 6-F CF3 C = C-Pr CH3 777 6-F CF3 C = C-Bu CH3
778 6-F CF3 C = C-iBu CK3
779 6-F CF3 C = C-tBu CH3
780 6-F CF3 C = C-Et CH3
781 6-F CF3 C = C-Me CH3
782 6-F CF3 C = C-Ph CH3
783 6-F CF3 C = C-2-Pridyl CH3
784 6-F CF3 C = C-3-Pyridyl CH3
785 6-F CF3 C = C-4-Pridyl CH3
786 6-F CF3 C = C-2 -furanyl CIl3
787 6-F CF3 C = C-3-f uranyl CÍ 3
788 6-F CF3 C = C-2-thien? Lo CH_.
789 6-F CF3 C = C-3-tienxlc CH3
790 6-F CF3 CH CH2-cycPr CH3
791 6-F CF3 CH CH2-Ph CH3
792 6-F CF3 CH2CK2-2-Pridyl CH3
793 6-F CF3 CH2CH -3 pyridyl CH3
794 6-F CF3 CH2CH2-4pyridyl CH3
795 6-F CF3 CH2CH2-2 -furanyl CH3
796 6-F CF3 CH2CH -3-furanyl CH3
797 6-F CF3 CH2CH2-2- thienyl CH3
798 6-F CF3 CH2CK2-3-thienyl ^
799 6-F CF3 Csz-cycPr CH2CH3
800 6-F CF3 CeC-Ph CH2CH3
801 6-F CF3 C = C-2-pyridyl CH2CH3 806 6-F CF3 C = C-2-thienyl CH2CH3
807 6-F CF2 C = C-3 -thienyl CH2CK3
808 6-F CF3 C = C-cycPr CH2CH3
809 6-F CF3 C = C-Ph CH2CK3
810 6-F CF3 C = C-2-pyridyl CH2CH3 845 5-Cl CF3 C = C- (2-N02) Ph K
846 5-Cl CF3 C = C- (3-N02) Ph K
847 5-Cl CF3 C = C- (4 -N02) Ph H
848 5-Cl CF3 C = C- (2-NK2) Ph K
849 5-Cl CF3 C = C-. { 3-NK2) Ph H
850 5-Cl CF3 C = C- (4-NH2) Ph H
851 5-Cl CF3 C = C-. { 2-NMe2) Ph H
852 5-Cl CF3 C = C- (3-NMe2) Ph K
853 5-Cl CF3 C = C- (4-NMe2) Ph H 854 5-Cl CF3 C ^ -2-pyridyl or H 855 5-Cl CF3 C = C-2-pyridyl H
856 5-Cl CF3 C = C-3-p i r i d i 1 or H
857 5-Cl CF3 C = C-4-pyridyl H
858 5-Cl CF3 = -2 - u r a n i 1 or H 859 5-Cl CF3 C = C-3-furanyl H 860 5-Cl CF3 CeC-2-thienyl H
861 5-Cl CF3 C ^ C-3-thienyl H 862 5-Cl CF3 C -2-oxazolyl H
863 5-Cl CF3 CßC-2-thiazolyl H
864 5-Cl CF3 CsC-4- isoxazolyl? H
865 5-Cl CF3 C = C-2-imidazolyl H
866 5-Cl CF3 C = C-cycPr H
867 5-Cl CF3 C = CCH CH20H H
868 5-Cl CF3 C = C-CH (0H) Me H
869 5-Cl CF3 C = C-Ph H
870 5-Cl CF3 C = C- (2-Cl) Ph H
871 5-Cl CF3 C = C- (3-Cl) Ph H
872 5-Cl CF3 C = C- (4-Cl) Ph H
873 5-Cl CF3 C = C- (2-F) Ph H
874 5-Cl CF3 C = C- (3-F) Ph H
875 5-Cl CF3 C = C- (4-F) Ph H
876 5-Cl CF3 C = C- (2-OH) Ph H
877 5-Cl CF3 C = C- (3-0H) Ph H
878 5-Cl CF3 C = C- (4-OH) Ph K 913 5-Cl CF3 CH2CK2- (2-F) Ph K
914 5-Cl CF3 CH2CH2- (3-F) Ph H
915 5-Cl CF3 CH2CH2- (4-F) Ph K
916 5-Cl CF3 CH2CK2- (2-OH) Ph H
917 5-Cl CF2 CH2CH2- (3-OH) Ph H
918 5-Cl CF3 CH CH2- (4-OH) Ph H
919 5-Cl CF3 CH2CH2- (2-OMe) Ph H
920 5-Cl CF3 CH2CH - (3-OMe) Ph H
921 5-Cl CF3 CH2CK2- (4-OMe) Ph H
922 5-Cl CF3 CH2CH2- (2-CN) Ph H
923 5-Cl CF3 CH2CH2- (3-CN) Ph H
924 5-Cl CF3 CH2CH2-. { 4-CN) Ph H
925 5-Cl CF3 CH2CH2 - (2 -K0) Ph H
926 5-Cl CF3 CH CH2- (3-N02) Ph H
927 5-Cl CF3 CH2CH2- (4-N02) Ph H
928 5-Cl CF3 CH2CH2- (2-NH2) Ph H
929 5-Cl CF3 CH2CH2- (3- H2) Ph H
930 5-Cl CF3 CH2CH2- (4- H2) Ph H
931 5-Cl CF3 CH2CH2-. { 2-NMe2) Ph H
932 5-Cl CF3 CH2 CH2 - (3 -NMe2) Ph H
933 5-Cl CF3 CH2CH2- (4-NMe2) Ph H
934 5-Cl CF3 CH2CH2-2-pyridyl H
935 5-Cl CF3 CH2CH2-3-pyridyl H
936 5-Cl CF3 CH2CH2-4-pyridyl H
937 5-Cl CF3 CH2CH2-2-f uranyl or H
938 5-Cl CF3 CH2CH2-3-f ranil H
939 5-Cl CF3 CH2CH2-2-thienyl H
940 5-Cl CF3 CH2CH2-3-thienyl H
941 5-Cl CF3 CH2CH2-2-? Xazolyl H
942 5-Cl CF3 CH2CH2-2- thiazolyl H
943 5-Cl CF3 C CH2CH2-4- isoxazolylH
944 5-Cl CF3 C CH2CH2-2-imidazolyl H
945 5-Cl CF3 C = C-cycPr CH
946 5-Cl CF- > C = C-Ph CH3 981 5-Cl CF3 C = C-cycPr CH2CK3
982 5-Cl CF3 C = C-Ph CH2CK3
983 5-Cl CF3 C = C-2-pyridyl CH2CK3
984 5-Cl CF3 C = C-3-pyridyl CH2CH3
985 5-Cl CF3 C = C-4-pyridyl CH2CH3
986 5-Cl CF3 C = C-2-furanyl CHCH3
987 5-Cl CF3 C = C-3-furanyl CH2CK3
988 5-Cl CF3 C = C-2-thienyl CH2CH3
989 5-Cl CF3 OC-3 - thienyl CH2CH3
990 5-Cl CF3 CH2CH2-cycPr CK2CH3
991 5-Cl CF3 CH2CH2-Ph CH2CH3
992 5-Cl CF3 CH2CK2-2-.pyridyl CK2CH3
993 5-Cl CF3 CH2CK2-3- pyridyl CH2CH3
994 5-Cl CF3 CH2CH2-4- pyridyl CH2CH3
995 5-Cl CF3 CH2CK2-2 - furanyl CH2CH3
996 5-Cl CF3 CH2CH2-3- furanyl CH2CH3
997 5-Cl CF3 CH2CK2-2- thienyl CH2CH3
998 5-Cl CF3 CH2CH2-3-thienyl CH2CH3
999 5-F CF3 OC-cycPr H
1000 5-F CF3 CBCCH2CH2OH H
1001 5-F CF3 C = C-CH (OH) Me H
1002 5-F CF3 C = C-Ph H
1003 5-F CF3 C = C- (2-Cl) Ph H
1004 5-F CF3 C = C- (3-Cl) Ph H
1005 5-F CF3 C = C- (4-Cl) Ph H
1006 5-F CF3 C = C- (2-F) Ph H
1007 5-F CF3 C = C- (3-F) Ph H
1008 5-F CF3 C = C- (4-F) Ph H
1009 5-F CF3 C = C- (2-OH) Ph H
1010 5-F CF3 C = C- (3-OH) Ph H
1011 5-F CF3 C = C- (4-OH) Ph H
1012 5-F CF3 C = C-. { 2-OMe) Ph H
1013 5-F CF3 C = C- (3-OMe.}. Ph H
1014 5-F CF3 C = C- (4 -OMe) Ph H 1015 5-F CF3 C = C- (2-CN) Ph H
1016 5-F CF3 C = C- (3-CN) Ph K
1017 5-F CF3 C = C- (4-CN) Ph H
1018 5-F CF3 C = C- (2-N02) Phii
1019 5-F CF3 C = C- (3-N02) Ph K
1020 5-F CF3 C = C- (4-N02) Ph H
1021 5-F CF3 C = C- (2- H2) Ph H
1022 5-F CF3 C = C- (3 -NH2) Ph H
1023 5-F CF3 C = C- (4-NK2) Ph H
1024 5-F CF3 C = C- (2-NMe2) Ph H
1025 5-F CF3 C = C- (3- Me2) Ph H
1026 5-F CF3 C = C- (4-NMe) Ph H
1027 5-F CF3 C = C-2-pyridyl H
1028 5-F CF3 C = C-2-pyridyl H
1029 5-F CF3 C = C-3-pyri H
1030 5-F CF3 Cs - -pyridyl H 1031 5-F CF3 CsC-2 -furanyl H
1032 5-F CF3 C «C-3-f uranyl H 1033 5-F CF3 CEC-2-thienyl H
1034 5-F CF3 CsC-3-thienyl H
1035 5-F CF3 CsC-2-oxazolyl H
1036 5-F CF3 CeC-2-txazolyl H
1037 5-F CF3 C = c-4-isoxazolyl. D H
1038 5-F CF3 C = c-2-imidazole H
1039 5-F CF3 C = C-cycPr H
1040 5-F CF3 C = CCH2CH2OH H
1041 5-F CF3 C = C-CH (OH) Me H
1042 5-F CF3 C = C-Ph H
1043 5-F CF3 C = C- (2-Cl) Ph H
1044 5-F CF3 C = C- (3-Cl) Ph H
1045 5-F CF3 C = C- (4-Cl) Ph H
1046 5-F CF3 C = C- (2-F) Ph H
1047 5-F CF3 C = C- (3-F) Ph H
104e 5-F CF3 C = C- (4-F) Ph H 1049 5-F CF3 C = C- (2-OH) Ph K
1050 5-F CF3 C = C- (3-OH) Ph K
1051 5-F CF3 C = C- (4-OH) Ph K
1052 5-F CF3 C = C- (2-OMe) Ph H
1053 5-F CF3 C = C- (3-OMe) Ph K
1054 5-F CF3 C = C- (4-OMe) Ph K
1055 5-F CF2 C = C- (2-C) Ph H
1056 5-F CF3 C = C- (3-C) Ph H
1057 5-F CF3 C = C- (4-CN) Ph H
1058 5-F CF3 C = C- (2-N0) Ph H
1059 5-F CF3 C = C- (3-N02) Ph H
1060 5-F CF3 C = C- (4-N02) Ph H
1061 5-F CF3 C = C- (2- K) Ph H
1062 5-F CF3 C = C- (3-NH2) Ph H
1063 5-F CF3 C = C- (4-NH) Ph H
1064 5-F CF3 OC- (2-NMe2) Ph H
1065 5-F CF3 C = C- (3-NMe2) Ph H
1066 5-F CF3 C = C- (4- Me2) Ph H
1067 5-F CF3 C = C-2-pyridyl H
1068 5-F CF3 C = C-2-pyridyl H
1069 5-F CF3 C = C-3-pyridyl H
1070 5-F CF3 C = C-4-pyridyl H
1071 5-F CF3 C = C-2- furanyl H
1072 5-F CF3 C = C-3-: furanyl H
1073 5-F CF3 C = C-2-thienyl H
1074 5-F CF3 C = C-3-thienyl H
1075 5-F CF3 C = C-2-Oxazolyl H
1076 5-F CF3 C = C-2-thiazolyl H
1077 5-F CF3 C = C-4- isoxazolyl H
1078 5-F CF3 C = C-2-imidazolyl H
1079 5-F CF3 CH2CH2- ycPr H
1080 5-F CF3 CH2CH2CH2CH2OH H
1081 5-F CF3 CH2CH2-CH (OH) Me H
1082 5-F CF3 CHCH2Ph H 1083 5-F CF3 CH2CH2- (2-Ci) Ph K
1084 5-F CF3 CH2CH2- (3-Cl) Ph H
1085 5-F CF3 CK2CK2- (4-Cl) Ph H
1086 5-F CF3 CHCK2- (2-F) Ph H
1087 5-F CF3 CH2CH2- (3-F) Ph n
1088 5-F CF3 CH2CH2- (4-F) Ph K
1089 5-F CF3 CH2CK2- (2-0H) Ph K
1090 5-F CF3 CH2CH2- (3-OH) Ph K
1091 5-F CF3 CK2CH2- (4-OH) Ph H
1092 5-F CF3 CH2CH- (2-OMe) Ph H
1093 5-F CF3 CH2CK2- (3 -OMe) Ph H
1094 5-F CF3 CH2CH2- (4-OMe) Ph H
1095 5-F CF3 CH2CK2- (2-CN) Ph K
1096 5-F CF3 CH2CK2- (3-CN) Ph H
1097 5-F CF3 CH2CK2- (4-CN) Ph H
1098 5-F CF3 CH2CK2- (2-N02) Ph H
1099 5-F CF3 CH2CK2- (3-N? 2) Ph H
1100 5-F CF3 CH2CH2- (4-N02) Ph H
1101 5-F CF3 CHCH2- (2-NH2) Ph H
1102 5-F CF3 CH2CH2- (3-NH2) Ph H
1103 5-F CF3 CH2CK2- (4- H2) Ph H
1104 5-F CF2 CH2CK2- (2-NMe2) Ph H
1105 5-F CF3 CH2CH2- (3 -NMe2) Ph H
1106 5-F CF3 CH2CH2- (4- Me2) Ph H
1107 5-F CF3 CH2CH2-2-pyridyl H
1108 5-F CF3 CH2CH2-3-pyridyl H
1109 5-F CF3 CH2CH2-4-pyridyl H
1110 5-F CF3 CH2CH2-2- furanyl H
1111 5-F CF3 CH2CH2-3-furanyl H
1112 5-F CF3 CH2CH2-2-thienyl H
1113 5-F CF3 CH2CH2-3-thienyl H
1114 5-F CF3 CH2CH2-2- oxazolflo H
1115 5-F CF3 (CH2CK2-2- .thiazolyl H
1116 5-F CFT rCH2CH2- -isoxazolyl H 1117 5-F CF3 CH2CH2-2- imidazolyl K
1118 5-F CF3 C = C-cycPr H3
1119 5-F CF3 C = C-Ph CK3
1120 5-F CF3 C = C-2-pyridyl c? 3
1121 5-F CF3 C = C-3-pyridyl CH3
1122 5-F CF3 C = C-4-pyridyl CH3
1123 5-F CF3 C = C-2-: furanyl CH3
1124 5-F CF3 C = C-3-.furanyl CH3
1125 5-F CF3 C = C-2-thienyl CH3
1126 5-F CF3 C = C-3-thienyl CH3
1127 5-F CF3 C = C-cycPr CH3
1128 5-F CF3 C = C-Ph CK3
1129 5-F CF3 C = C-2- -pyridyl CK3
1130 5-F CF3 C = C-3 -. "Pyridyl CH3
1131 5-F CF3 C = C-4-pyridyl CH3
1132 5-F CF3 C = C-2- furanyl CH3
1133 5-F CF3 C = C-3-furanyl CH3
1134 5-F CF2 C = C-2-1 ienyl CH3
1135 5-F CF3 C = C-3-tthienyl CH3
1136 5-F CF3 CH2CH2-cycPr CH3
1137 5-F CF3 CH2CH2-Ph CH3
1138 5-F CF3 CH2CH2-2-pyridyl CH3
1139 5-F CF3 CH2CK2-3-pyridyl CH3
1140 5-F CF3 CH2CH2- -'pyridyl CH3
1141 5-F CF3 CH2CH2-2-furani? O CH3
1142 5-F CF3 CH2CH2-3-f ranny CH3
1143 5-F CF3 CH2CH2-2-thienyl CH3
1144 5-F CF3 CH2CH2-3- thienyl CH3
1145 5-F CF3 C = C-cycPr CH2CH3
1146 5-F CF3 OC-Ph CH2CH3
1147 5-F CF3 CEC-2-pyridyl CH2CH3
1148 5-F CF3 CsC-3-.pyridyl CH2CH3
1149 5-F CF3 C = C-4-pyridyl CH2CH3
1150 5-F CF3 C = C-2- furanyl CH2CH3 CN rH ro ro ro ro ro r ro ro ro ro ro ro ro ro ro ro ro ro ro ro ro ro ro ro ro ro ro ro ro ro ro ro
Ul Ul Ul U Ul Ui Ul Ui Ul Ul U Ul U? Ul Ui U, Ui Ui U Ul U U U U U, U U U U U U U U U U U U U U U U U U U U U? ? u U U U U U U U U U U C U U U U
Ul Ul Ul ul Ul Ul Ul Ul Ul Ul Ul Ul Ul Ui Ui Ui u. 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 Ul Ul Ul Un Uln Ul Ul ul Ul Ul l ui tn m tn l tH C r ^ ^ i ^ r ^ 8 si Or you rN ^ tn to r ^? if O rH r ^ O x- \ CN ro "» u? n?? u3 to to D io o to t? o? or ~ r ^ r ^ r ^ r ^ r ^ r ^ r-r??? CO CO CO CO CO
1-l rH rH rl H r I H H r H H H H r H r H H r H r H r H H r H H r H r H H r r r H H r H H H H H H H H H H H H H H r r r r r r H r H H H H r r r HH rH HH rl H l
1185 5-Cl, 6-F CF3 C = C-4-.pyridyl H
1186 5-Cl, 6-F CF3 C = C-2- 'furanyl H
1187 5-Cl, 6-F CF3 C = C-3: furanyl K
1188 5-Cl, 6-F CF3 C = C-2-thienyl K
1189 5-Cl, 6-F CF3 C = C-3-thienyl?
1190 5-Cl, 6-F CF3 CH2CK-cycPr K
1191 5-Cl, 6-F CF3 CH2CK2-Ph H
1192 5-Cl, 6-F CF3 CH2CH2-2- pyridyl K
1193 5-Cl, 6-F CF3 CH2CH2-3-pyridyl H
1194 5-Cl, 6-F CF3 CH2CH2-4-pyridyl H
1195 5-Cl, 6-F CF3 CH2CH2-2-furanyl H
1196 5-Cl, 6-F CF3 CH2CH2-3- furanyl H
1197 5-Cl, 6-F CF3 CH2CK2-2- thienyl H
1198 5-Cl, 6-F CF3 CH2CK2-3- 'thienyl H
1199 5-Cl, 6-F CF3 CsC-cycPr CH3
1200 5-Cl, 6-F CF3 OeC-Ph CH3
1201 5-Cl, 6-F CF3 C ^ C-2-pyridyl CH3
1202 5-Cl, 6-F CF3 CsC-3-pyridyl CH3
1203 5-Cl, 6-F CF3 Cs-C-4-pyridyl CH3
1204 5-Cl, 6-F CF3 CsC-2- furanyl CH3
1205 5-Cl, 6-F CF3 C = C-3-furanyl CH3
1206 5-Cl, 6-F CF3 C = C-2-thienyl C 3
1207 5-Cl, 6-F CF3 C «C-3-thienyl CH3
1208 5-Cl, 6-F CF3 C = C-cycPr CH3
1209 5-Cl, 6-F CF3 C = C-Ph CH3
1210 5-Cl, 6-F CF3 C = C-2- 'pyridyl CH3
1211 5-Cl, 6-F CF3 C = C-3-pyridyl CH3
1212 5-Cl, 6-F CF3 C = C-4-pyridyl CH3
1213 5-Cl, 6-F CF3 C = C-2-. furanyl CH3
1214 5-Cl, 6-F CF3 C = C-3-furanyl CH3
1215 5-Cl, 6-F CF3 C = C-2-thienyl CH3
1216 5-Cl, 6-F CF2 C = C-3-thienyl CH3
1217 5-Cl, 6-F CF3 CH2CH2-c and Pr CH3
1218 5-Cl, 6-F CF3 CH2CH-Ph CH3 1219 5-Cl, 6-F CF3 CH2CH2-2- pyridyl CK3
1220 5-Cl, 6-F CF3 CH CH2-3-.pindyl CK3
1221 5-Cl, 6-F CF3 CH2CK2-4- pyridyl CH3
1222 5-Cl, 6-F CF3 CH2 C? ' 2-:: furanyl CH3
1223 5-Cl, 6-F CF3 CHCH2-3- furanyl CH3
1224 5-Cl, 6-F CF3 CH2CH2-2- thienyl CK3
1225 5-Cl, 6-F CF3 CH2CK2-3- thienyl CH3
1226 5-F, 6-Cl CF3 C = C-cycPr H
1227 5-F, 6-Cl CF3 CsC-Ph K
1228 5-F, 6-Cl CF3 C = C-2-pyridyl H
1229 5-F, 6-Cl CF3 C = C-3-pyridyl H
1230 5-F, 6-Cl CF3 C = C-4-pyridyl K
1231 5-F, 6-Cl CF3 C = C-2-furanyl H
1232 5-F, 6-Cl CF3 C = C-3-furanyl H
1233 5-F, 6-Cl CF3 C = C-2-thienyl H
1234 5-F, 6-Cl CF3 CsC-3-thienyl H
1235 5-F, 6-Cl CF3 C = C-cycPr H
1236 5-F, 6-Cl CF3 C = C-Ph H
1237 5-F, 6-Cl CF3 C = C-2-pyridyl H
1238 5-F, 6-Cl CF3 C = C-3-pyridyl H
1239 5-F, 6-Cl CF3 C = c-4-pyridyl H
1240 5-F, 6-Cl CF3 C = C-2- furanyl H
1241 5-F, 6-Cl CF3 C = C-3-furanyl H
1242 5-F, 6-Cl CF3 C = C-2-thienyl H
1243 5-F, 6-Cl CF3 C = C-3-thienyl H
1244 5-F, 6-Cl CF3 CH2CH2-cycPr H
1245 5-F, 6-Cl CF3 CH2CH2-Ph H
1246 5-F, 6-Cl CF3 CH2CH2- - iridyl H
1247 5-F, 6-Cl CF3 CH2CK -3-: pyridyl H
1248 5-F, 6-Cl CF3 CH2CH2-4-pyridyl H
1249 5-F, 6-Cl CF3 CH2CH2-2 furanyl H
1250 5-F, 6-Cl CF3 CH2CH2-3- -furanyl H
1251 5-F, 6-Cl CF3 CH2CH-2-thienyl H
1252 5-F, 6-Cl CF 3 CH 2 CH 2 3 -thienyl H 1253 5-F, 6-Cl CF 3 C = C-cycPr c 3
1254 5-F, 6-Cl CF3 C = C-Ph c? 3
1255 5-F, 6-Cl CF3 c = C-2-pyridine CH3
1256 5-F, 6-Cl CF3 C = C-3-pyridyl c? 3
1257 5-F, 6-Cl CF3 C = C-4-pyridyl CH3
1258 5-F, 6-Cl CF3 C = C-2- furanyl c? 3
1259 5-F, 6-Cl CF 3 C = C-3-furanyl c 3
1260 5-F, 6-Cl CF3 C = C-2-thienyl CH3
1261 5-F, 6-Cl CF3 C = C-3-thienyl CH3
1262 5-F, 6-Cl CF3 C = C-cycPr CH3
1263 5-F, 6-Cl CF3 C = C-Ph CH3
1264 5-F, 6-Cl CF3 C = C-2-pyridyl CH3
1265 5-F, 6-Cl CF3 C = C-3-pyridyl CH3
1266 5-F, 6-Cl CF3 C = C-4-pyridyl CH3
1267 5-F, 6-Cl CF3 C = C-2- furanyl CH3
1268 5-F, 6-Cl CF3 C = C-3-furanyl CH3
1269 5-F, 6-Cl CF3 C = C-2-thienylb CH3
1270 5-F, 6-Cl CF3 C = C-3-thienyl CH3
1271 5-F, 6-Cl CF3 CH2CH -cycPr CH3
1272 5-F, 6-Cl CF3 CH2CH2-Ph CH3
1273 5-F, 6-Cl CF3 CH2CH2-2-pitidyl CH3
1274 5-F, 6-Cl CF3 CH2CK2-3-pyridyl CH3
1275 5-F.6-Cl CF3 CH2CK2- -pyridyl CH3
1276 5-F, 6-Cl CF3 CH2 H2-2-furanyl CH3
1277 5-F, 6-Cl CF3 CH2CH2-3-furanyl CH3
1278 5-F, 6-Cl CF3 CH2 H2-2-thienyl CH3
1279 5-F, 6-Cl CF3 CH2CH2-3-thienyl CH3
1280 6-C1.8-F CF3 C = C-cycPr H
1281 6-C1.8-F CF3 C = C-Ph H
1282 6-Cl, 8-F CF3 C = C-2- p ± ridyl H
1283 6-C1.8-F CF3 C-C-3-pyridyl H
1284 6-C1.8-F CF3 C = C-4-pyridyl H
1285 6-C1.8-F CF3 C = C-2 - furani? 0 H
1286 6-C1.8-F CF3 C = C-3-furanyl H H H H M H H H H H H H H H M H H H l- > H H H H M J LO Lo Lo OJ OJ U > The OJ OJ Ul OJ l LO J OJ 00 LO LO LO Ul Ul
(JL L? Lp L? Lp? X_. Ta. »Rf rfa» * > e * í- * - OJ LO to to tt? C to l to o to co -o cn L? ** OJ to O «5 CO in Ul ip» LO to
n ^ n'il n ^ n ^ ohi q ^ nrj ohl ol oí n n n n n nj ni T i n rij oj oi o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o r o
33 33 33 33 X 33 33 33 33 33 33 33 33 33 3: 3 33 3: 3:
1355 6-CH3 CF CH2CH2-3-pyridyl K
1356 '6-CK3 CF3 CH CH - -pyridyl?
1357 6-CK3 CF3 CH2CH2-2- furanyl K
1358 6-CH3 CF3 CH2CK2-3- furanyl H
1359 6-CH3 CF3 CH2CH2-2-thienyl K
1360 6-CK3 CF3 CH2CH2-3-thienyl K
1361 6-CH3 CF3 C = C-cycPr CH3
1362 6-CH3 CF3 C = C-Ph CH3
1363 6-CK3 CF3 c = c-2-pyridyl CH3
1364 6-CK3 CF3 c = c-3-pyridyl CH
1365 6-CK3 CF3 c = c-4-pyridyl CH3
1366 6-CK3 CF3 a = c-2- furanyl CH3
1367 6-CK3 CF3 c = c-3-furanlío CH3
1368 6-CK3 CF3 C? C-2- ienyl CH3
1369 6-CK3 CF3? Sc-3- thienyl CH3
1370 6-CK3 CF3 C = C-cycPr CH3
1371 6-CH3 CF3 C = C-Ph CH3
1372 6-CH3 CF3 c = c-2-.pyridyl CH3
1373 6-CH3 CF3 c = c-3-pyridyl CH3
1374 6-CH3 CF3 C = c-4-pyridyl CH3
1375 6-CH3 CF3 c = c-2- furanyl CH3
1376 6-CH3 CF3 c = c-3-furanyl CH3
1377 6-CH3 CF3 C = C-2- thienyl CH3
1378 6-CH3 CF3 c = c-3-thienyl CH3
1379 6-CH3 CF3 CH2CH2-cycPr CH3
1380 6-CH3 CF3 CH2CH2-Ph CH3
1381 6-CK3 CF3 CH2CH2-2- pyridyl CH3
1382 6-CK3 CF3 CH2CH2-3-pyridyl CH3
1383 6-CK3 CF3 CH2CH2-4- pyridyl CH3
1384 6-CK3 CF3 CH2CH2-2- furanyl CH3
1385 6-CH3 CF3 CH2Ch'2-3-furanyl CH3
1386 6-CH3 CF3 CH2CH2-2- ienyl CH3
1387 6-CH3 CF3 CH2CH2-3- thienyl CH3
1388 6-COCK3 CF3! -cycPr H 1389. 6-COCH;, CF3 C = C-Ph H
1390 6-COCK3 CF3 c = c-2-pyridyl K
1391 6-COCK3 CF3 c = c-3 pyridium V
1392 6-COCH3 CF3 c = e-4-pyridyl K
1393 6-COCK3 CF3 c = c-2-furanyl K
1394 6-COCK3 CF3 c = c-3-furanyl H
1395 6-COCK3 CF3 c = c-2-thienyl H
1396 6-COCH3 CF3 c = c-3-thienyl H
1397 6- H CF3 C = C-cycPr H
1398 6-NK2 CF3 C = C-Ph H
1399 6-NH2 CF3 c = c-2-pyrocarphyl H
1400 6-NH2 CF3 c = c-3-pyridyl H
1401 6-NH2 CF3 c = c-4-pyridyl H
1402 6-NH2 CF3 c = c-2-furanyl H
1403 6- H2 CF3 cs-c-3-furanyl H
1408 6-NMe2 CF3 Cßc-2-pyridyl H
1409 6- Me2 CF3? -3-pyridyl H
1410 6-MMT2 CF3 csc-4-pyridyl H
1411 6- Me2 CF3 CsC-2-furanyl H
1412 6-NMT2 CF3 c = c-3-furanyl "or H
1413 6-NMe2 CF3 c = c-2-thienyl H
1414 6-NMT2 CF3 or = c-3-thienyl H
1415 7-Cl CF3 C = € -cycPr H
1416 7-Cl CF3 CeC-Ph H
1417 7-Cl CF3 c = c-2-pyri: say H
1418 7-Cl CF3 c = c-3-pyridyl H
1419 7-Cl CF3 CHC-4-pyridyl H
1420 7-Cl CF3 C € -2-furañilo H
1421 7-Cl CF3 C? C-3-furanyl H
1422 7-Cl CF3 c = c-2-thienyl H 1423 7-Cl CF3 c = c-3-thienyl?
1424 5,6-OCK20-CF3 C = C-cycPr **
1425 5,6-OCH20-CF3 C = CCHCH2OK H
1426 5,6-OCH20-CF3 C = C-CH (OH) Me H
1427 5,6-OCH20-CF3 C = C-Ph?
1428 5,6-OCH20-CF3 C = C- (2-Cl) Ph H
1429 5.6-OCH20-CF3 C = C- (3-Cl) Ph?
1430 5,6-OCH20-CF3 C = C- (4-Cl) Ph H
1431 5.6-0CH2O- CF3 CsC- (2-F) Ph?
1432 5,6-OCH20-CF3 C = C- (3-F) Ph K
1433 5,6-OCH20-CF3 C = C- (4-F) Ph K
1434 5,6-OCH20-CF3 C = C- (2-OH) Ph H
1435 5,6-OCH20-CF3 C = C- (3-OH) Ph H
1436 5.6-0CH2O- CF3 C = C- (4-OH) Ph H
1437 5.6-OCH20-CF3 CeC-. { 2-OMe) Ph H
1438 5,6-OCH20-CF3 CsC- (3-OMe) Ph H
1439 5,6-OCH20-CF3 CßC- (4-OMe) Ph H
1440 5.6-0CH2O- CF3 C «C- (2-CN) Ph H
1441 5.6-0CH2O- CF3 Cßc- (3-CN) Ph H
1442 5,6-OCH20-CF3 CsC- (4-CN) Ph H
1443 5,6-OCH20-CF3 CsC- (2-N02) Ph H
1444 5.6-OCH20-CF3 C = C- (3-N02) Ph H
1445 5,6-OCH0- CF3 C = C- (4-N0) Ph H
1446 5,6-OCH20-CF3 C = C- (2-NH2) Ph H
1447 5.6-OCH20-CF3 C = C- (3-NH2) Ph H
1448 5,6-OCH2C-CF3 C = C- (4- H2) Ph H
1449 5,6-OCH20-CF3 OsC- (2-NMe2) Ph H
1450 5,6-OCH0-CF3 GsC- (3-NMe2) Ph H
1451 5,6-OCH20-CF2 CsC- (4-NMe2) Ph H
1452 5,6-OCH20-CF3 csz-2-pyridyl H
1453 5,6-OCH20-CF3? SC-2-pyridyl H
1454 5, 6-OCH0-CF3 c = c-3-pyridyl H
1455 5,6-OCH20-CF3 os-4-pyridyl K
1456 5,6-OCH20-CF3 csc-2- furanyl? 1457 5, 6-OCH20-CF3 c = c-3-furanyl or
1458 5.6-0CH20- CF3 c = c-2-thienyl H
1459 5, 6-0CH20-CF3 c = c-3-thienyl H
1460 5.6-0CH20-CF3 c = c-2-oxazolyl K
1461 5, 6-0CH20-CF3 c = c-2-thiazole ilo K
1462 5,6-OCH20-CF3 c = c-4-isoxazolyl K
1463 5,6-OCH20-CF3 H c = c-2-imidazolyl
1464 6-COCH3 CF3 C = C-cycPr K
1465 6-COCH3 CF3 C = C-Ph H
1466 6-COCH3 CF3 c = c-2- pyridjlo u
1467 6-COCH3 CF3 c = c-3-pyridyl H
1468 6-COCH3 CF3 c = c-4-pyridyl H
1469 6-COCH3 CF3 c = c-2- furanyl 1470 6-COCH3 CF3 c = c-3-furanyl H
1471 6-COCH3 CF3 c = c-2-thienyl H
1472 6-COCH3 CF3 c = c-3-thienyl H
1473 6-NK2 CF3 C = C-cycPr H
1474 6-NH2 CF3 C = C-Ph H
1475 6-NH2 CF3 C = C-2-: pyridjlo H
1476 6-NH2 CF3 C = c-3- ^ iridyl H
1477 6-NH2 CF3 C = c-4-pyridyl H
1478 6-NH2 CF3 c = c-2- furanyl H
1479 6-NH2 CF3 c = c-3-furanyl H
1480 6-NH2 CF3 c = c-2-thienyl H
1481 6- H2 CF3 c = C-3-thienyl H
1482 6-MMß2 CF3 C = C-cycPr H
1483 6-NMe2 CF3 C = C-Ph H
1484 6-NMe2 CF3 c = c-2-pyridyl H
1485 6-NM? 2 CF3 C = C-3-pyridyl? H
1486 6-NMT2 CF3 C = c-4-pyridyl H
1487 6-NMe2 CF3 c = C-2- furanyl H
1488 6-NMß2 CF3 c = c-3-furanyl H
1489 6-NMe2 CF3 c = c-2-thienyl H
1490 6- MT2 CF3 c = c-3-thienyl H 1491. 7-Cl CF3 C = C-cycPr H
1492 7-Cl CF3 C = C-Ph K
1493 7-Cl CF3 c = c-2-pyridyl K
1494 7-Cl CF3 c = c-3-pyridyl K
1495 7-Cl CF3 c = c-4-pyridyl K 1497 7-Cl CF3 c = c-3-furanyl K
1498 7-Cl CF3 c = c-2-thienyl H
1499 7-Cl CF3 c = c-3-thienyl H
1500 5,6-OCH20- CF3 C = C-cycPr H
1501 5, 6-OCH20-CF3 C = CCK2CH20H H
1502 5, 6-OCH0-CF3 C = C-CH (OH) Me H
1503 5,6-OCH20-CF3 C = C-Ph H
1504 5.6-0CH20- CF3 C = C- (2-Cl) Ph H
1505 5.6-0CH20- CF3 C = C-. { 3-Cl) Ph H
1506 5.6-0CH20- CF3 C = C- (4-Cl) Ph H
1507 5.6-0CH20- CF3 C = C- (2-F) Ph H
1508 5,6-0CH0- CF3 OC- (3-F) Ph H
1509 5.6-0CH20- CF3 C = C- (4-F) Ph H
1510 5.6-0CH20- CF3 C = C- (2-OH) Ph H
1511 5, 6-0CH20- CF3 C = C- (3-OH) Ph H
1512 5.6-0CH20- CF3 C = C- (4-OH) Ph H
1513 5.6-0CH20- CF3 C = C- (2-0Me) Ph H
1514 5.6-0CH20- CF3 C = C- (3-0Me) Ph H
1515 5,6-0CH0- CF3 C = C- (4-OMe) Ph H
1516 5.6-0CH20- CF3 C = C- (2-C) Ph H
1517 5, 6-0CH20- CF3 C = C- (3-C) Ph H
1518 5.6-0CH20- CF3 C = C- (4-C) Ph H
1519 -. 1519 - 5,6-0CH20- CF3 C = C- (2-N02) Ph H
1520 5,6-OCH20-CF3 C = C- (3-N02) Ph H
1521 5,6-OCH20-CF3 C = C- (4-N02) Ph H
1522 5.6-OCH20-CF3 C = C- (2-I> JH2) Ph H
1523 5.6-0CH20- CF3 C = C- (3- H2) Ph H
1524 5.6-0CK20- CF3 C = C- (4-NH2) Ph H 1525- 5,6-OCH20-CF3 C = C- (2- Me2) Ph H
1526 5,6-OCH0-CF3 C = C- (3-NMe2) Ph H
1527 5, 6-OCH20-CF3 C = C- (4-NMe2) Ph H
1528 5,6-OCH20-CF3 c = c-2-pyridyl H
1529 5, 6-OCH20-CF3 c = c-2-pyridyl H
1530 5.6-OCH20-CF3 C = c-3-pyridyl H
1531 5, 6-OCH20-CF3 c = c-4-pyridyl H
1532 5, 6-OCH20-CF3 c = c-2-: furanyl H
1533 5, 6-0CH2O-CF3 c = c-3-furanyl H
1534 5, 6-OCH2O-CF3 c = c-2-thienyl H
1535 5,6-OCH20-CF3 c = c-3-thienyl H
1536 5, 6-OCH20-CF3 c = c-2-oxazolyl H
1537 5,6-OCH20-CF3 c = c-2-thiazophil H
1538 5, 6-OCH 0-CF3 c = c-4-isoxazolyl H
1539 5, 6-OCH2O-CF3 c = c-2-imidazolyl H
1540 5.6-0CH2O- CF3 CH2CH2-cycPr H
1541 5,6-OCH20-CF3 CH2CH2CH2CH2OH H
1542 5,6-OCH20-CF3 CH2CH2-CH (OH) Me H
1543 5,6-OCH20-CF3 CH2CH2Ph H
1544 5.6-0CH2O- CF3 CH2CH2- (2-Cl) Ph H
1545 5,6-OCH20-CF3 CH2CH2- (3-Cl) Ph H
1546 S, 6-OCH20-CF3 CHCH2- (4-Cl) Ph H
1547 5,6-OCH0- CF3 CH2CH2- (2-F) Ph H
1548 5,6-OCH20-CF3 CH2CH2- (3-F) Ph H
1549 5,6-OCH20-CF3 CH2CH2- (4-F) Ph H
1550 5,6-OCH20-CF3 CH2CH2- (2-OH) Ph H
1551 5,6-OCH20-CF3 CH2CH2- (3-OH) Ph H
1552 5,6-OCH20-CF3 CH2CH2- (4-OH) Ph H
1553 5,6-OCH20-CF3 CH2CH2- (2-OMe) Ph H
1554 5,6-OCH2? - CF3 CH2CH2- (3-OMe) Ph H
1555 5,6-OCH20-CF3 CH2CH2- (4-OMe) Ph H
1556 5,6-OCH20-CF3 CH2CH2- (2-C) Ph H
1557 5,6-OCH20-CF3 CK2CH2- (3-C) Ph H
1558 5.6-0CH2O- CF3 CK2CK2- (4-CN) Ph H M H H H H H H r-1 r- 'H H H H H H H H H H H H H L? L? L? L? L? L? L? L? L? Lp L? L? L? 1/1? L? L? L? L? L? L? L? L? L? ? ? L? Lp L? L? Ul L? L? p LO co oo co 00 oo co co co 03 oo • o -o in C? ? yes or > in C? C? yes? t o LO oo • o n Lp OJ to o 00 -o C? L? l to o vo co -o L? LO NJ r-1 o. to
o hi o'tj oj ohi o ol o o o o o o o o o o o o o o o o o o o o o o o o o o o o n o o n o o n o o o o o o o o o o o r r \ 1 \ * n ^ ^ "1 H1 'liirí oh oí nrrj ohí ohl nrrJ l o'Tl h] h) hl to ui to u > u > u > to? o what? OJ
S 3 S S 0 S S S S S S S S 33 33 K 33 33 33 33 33 33 33 33 33 33 33 33 33 33 3: 3; 3:
1593 5,6-OCH20-CF3 c = c-2-furanyl CH3
1594 5,6-OCH20-CF3 c = c-3-furanyl c? 3
1595 5,6-OCH 20 -FC 3 c = c-2-thienyl c 3
1596 5.6-OCH20-CF3 c = c-3-thienyl c? 3
1597 5,6-OCH20-CF3 CH2CH2-cycPr CH3
1598 5,6-OCH20-CF3 CH2CH2-Ph CH3
1599 5,6-OCH20-CF3 CH2CH2-2- pyridyl c? 3
1600 5,6-OCH20- CF3 CH2CH2-3- pyridium lo CH3
1601 5,6-OCH20- CF3 CH2CK2-4- pjrid.ilo CH3
1602 5,6-OCH20-CF3 CH2CK2-2- furanyl CH3
1603 5,6-OCH20-CF3 CH2CH2-3-furanyl CH3
1604 5.6-OCH20-CF3 CH2CH2-2- thienylu. CH3
1605 5,6-OCH20- CF3 CH2CH2-3- thienyl CH3
1606 5,6-OCH20-CF3 OC-cycPr CHCH3
1607 5,6-OCH20-CF3 C = C-Ph CH2CH3
1608 5,6-OCH0-CF3 C? C-2-pyridyl CH2CH3
1609 5,6-OCH20-CF3 Cßc-3-pyridyl CH2CH3
1610 5,6-OCH20- CF3 Cßc-4-pyridyl CH2CH3
1611 5,6-OCH20-CF3 or @ -2-furanyl CH2CH3
1612 '5,6-OCH20-CF3 asc-3-furanyl CH2CH3
1613 5,6-OCH0-CF3 c * c-2-thienyl CH2CH3
1614 5,6-OCH 0-CF3 c = c-3-thienyl CH 2 CH 3
1615 5,6-OCH20-CF3 C = C-cycPr CH2CH3
1616 5, 6-OCH2O- CF C = C-Ph CH2CH3
1617 5,6-OCH0-CF3 c = c-2-pyridyl CH2CH3
1618 5.6-0CH20- CF3 C = C-3-pyridyl CH2CH3
1619 5,6-0CH20- CF3 CH2CH3
1620 5,6-0CH0- CF3 c = c-2- furanyl CHCH3
1621 5.6-0CH20- CF3 c = c-3-furanyl CH2CH3
1622 5.6-0CH20- CF3 c = c-2-thienyl CHCH3
1623 5,6-OCH2? - CF3 c = c-3-thienyl CH2CH3
1624 5,6-OCK20- CF3 CH2CH2- ycPr CH2CH3
1625 5,6-OCK20-CF3 CKCH2-Ph CH2CH3
1626 5,6-OCH20-CF3 CH2CH2-2- pyridyl CH2CH3 1627. 5, 6-OCH20-CF3 CK2CH2-3 -pÍ rÍd Í l o CK2CK3
1628 5,6-OCH20-CF3 CK2CH2-4-PÍrÍdÍ lo CK2CK3
1629 5.6-OCH2O-CF3 c? 2c? 2-2-furani 10 CE2CE2
1630 5 (6-OCH2O-CF3 c? 2c? 2-3-.furani lo CH2CK3
1631 5,6-OCK20-CF3 CH2CH2-2-thienyl CH2CK3
1632 5,6-OCH0-CF3 CH2CH2-3-thieni CK2CH3
Unless otherwise indicated, stereochemistry is (+/-).
Ex. # P.3 R- R2 R8
1 6-Cl CF3 C = C-Pr H
2 6-Cl CF3 C = C-Bu H
3 6-Cl CF3 O = C-iBu H
4 6-Cl CF3 CsKT-tBu H
6-Cl CF3 C = C-Me H
6 6-Cl CF3 CH2CK2CH2CH2CH3 H
7 6-Cl CF3 CH2CH2CH. { CH3) H
8 6-Cl CF3 CH2CH2CH2CH3 H
9 6-Cl CF3 CH2CH CH3 H
6-Cl CF3 CH CH2-tBu H
11 6-Cl CF3 CH CesC-CH3 H
12 6-Cl CF3 CH2C «C-CH2CH3 H
13 6-Cl CF3 C? C-iPr CH3
14 6-Cl CF3 CsC-Pr CH3
6-Cl CF3 CsC-Bu CH3
16 6-Cl CF3 CsC-iBu CH3
17 6-Cl CF3 CssC-tBu CH3
18 6-Cl CF3 Cec-Et CH3
19 6-Cl CF3 OsC-Me CH3
6-Cl CF3 CH2C = C-CH3 CH3
21 6-Cl CF3 CH2C = C-CH2CH3 CH3
22 6-Cl CF 3 CH 2 CH 2 CH (CH 3) 2 CH 3 3 6-Cl CF 3 CH 2 CH 2 CH 2 CH 3 CH 3 4 6-Cl CF 3 CH 2 CH 2 CH 3 CH 3 5-Cl CF 3 CH 2 CH 2 - Bu CH 3 6 6-Cl CF 3 CsC-iPr CH 2 CH 3 7 6-Cl CF 3 CsC- Pr CH 2 CH 3 8 6-Cl CF 3 CsC-Bu CH 2 CH 3 CCHH 22CCFH 3)) 22 CH 2 CH 3 63 6 -MeO CF 3 CK 2 CH 2 CH (CH 3) 2 c 3
64 6 -MeO CF3 CH2CH CK2CH3 CK3
65 6 -MeO CF3 CH2CH2CK3 CH3
66 6 -MeO CF3 CH2CK2-tBu CK3
67 6 -MeO CF3 C = C-iPr CH2CE3
68 6 -MeO CF3 C = C-Pr CH2CH3
69 6 -MeO CF3 C = C-Bu CH2CH3
70 6 -MeO CF3 G = C-iBu CH2CH3
71 6 -MeO CF3 C = C-tBu CH2CK3
72 6 -MeO CF3 C = C-Et CH2CK3
73 6 -MeO CF3 C = C-Me CH2CH3
74 6 -MeO CF3 CH C = C-CH3 CH2CK3
75 6 -MeO CF3 CH2C = C-CH2CH3 CH2CH3
76 6 -MeO CF3 CH2CH2CH (CH3) 2 CH2CK3
77 6 -MeO CF3 CH2CH2CH2CH3 CH2CH3
78 6 -MeO CF3 CH2CH2CH3 CH2CH3
79 6 -MeO CF3 CH2CH2-tBu CH2CH3
80 5,6-diF CF3 OC-Pr H 82 5,6-diF CF3 C «C-iBu H
83 5,6-diF CF3 OsC-tBu H
84 5,6-diF CF3 C = C-Me H
85 5.6-diF CF3 CH2C = C-CH3 H
86 5.6-diF CF3 CH2CsC-CH2CH3 H
87 5,6-diF CF3 CH2CH2CH2CH2CH3 H
88 5,6-diF CF3 CH2CK2? Í3 H
89 5,6-diF CF3 CH2CH2-tBu H
90 5,6-diF CF3 C = C-iPr CH3
91 5, 6-diF CF3 C = C-Pr CH3
92 5,6-diF CF3 Cs = C-Bu CH3
93 5,6-diF CF3 CeC-iBu CH3
94 5,6-diF CF3 C = C-tBu CH3
95 5,6-diF CF3 OeC-? T CH3
96 5,6-diF CF3 OsC-Me CH 3 H H μo H H H H H H H H | _ > μj μi H H H M to LO
Ul tO to t o t t t T o o o o o s o o o o o o o o o o o o o o o o o o o o o o o o o L? i J t O to 00 C? Lp Ul tO O LO CD cn L? C- Ul t O to co -o
L? L? W L? L? L? I L? L? L? an L? L? L? L? L? L? C? C? C? C? C? C? C? C? C? C? C? n C? C? C? s > C? P, o. P- P. p. Pi Pi I "- o. I P. - tJ H- o. I Pi Pi P. r &g - H- r-» 1 11 1J 'I »1 hl • I' ll 11" 3 • 1 11 1J hl "1
oj nhí ol oh oh ohl oí ohí oí ní oí ohl ol oi olí olíí ohl ohl ohí ohí ol oí ohi o ol oh o ol oí ohí oitl oi noh) n 1)
131 6-F CF3 C = C-Et CH3
132 6-F C? 3 CsC-Me CH3
133 6-F CF3 CH C = C-CH3 CH3
134 6-F CF3 CH2CsC-CH2CH3 c? 3
135 6-F CF3 CH2CH2CH (CK3) 2 CK3
136 6-F CF3 CH2CH2CK2CH3 CH3
137 6-F CF3 CH2CH2CH3 CH3
138 6-F CF3 CH2CK-tBu CH3
139 6-F CF3 C = C-iPr CH2CK3
140 6-F CF3 C = -Pr CH2CE3
141 6-F CF3 CsC-Bu CH2CK3
142 6-F CF3 CEC-ÍBU CH2CK3
143 6-F CF3 C = C-tBu CH2CH3
144 6-F CF3 CsC-Et CH2CK3
145 6-F CF3 CsC-Me CH2CH3
146 6-F CF3 CH2CsC-CH3 CH2CH3
147 6-F CF3 CH2CßC-CH2CH3 CH2CH3
148 6-F CF3 CH2CH2CH (CH3) 2 CHCK3
149 6-F CF3 CH2CH2CH2CH3 CH2CH3
150 6-F CF3 CH2CHCH3 CH2CH3
151 6-F CF3 CH2CH2-tBu CH2CH3
152 5-Cl CF3 C = C-iPr H
153 5-Cl CF3 CeC-Pr H
154 5-Cl CF3 C = C-Bu H
155 5-Cl CF3 C = C-iBu H
156 5-Cl CF3 C = C-tBu H
157 5-Cl CF3 C = C-Et H
158 5-Cl CF3 C = C-Me H
159 5-Cl CF3 CH2C = C-CH3 H
160 5-Cl CF3 CH2CsC-CH2CH3 H
161 5-Cl CF3 CHCH2CH2CH2CH3 H
162 5-Cl CF3 CH2CH2CH (CH3) 2 H
163 5-Cl CF3 CH2CH2CH2CH3 H
164 5-Cl CF3 CH2CK2CH3 H 165 5-Cl CF3 CH CH2-tBu K 199 - 5-F CF3 CH2C = C-CH3 H
200 5-F CF3 CH2C = C-CH CH3 H
201 5-F CF3 CK2 CH2 CH2 CH2 CH3 H
202 5-F CF3 CK2CH2CH (CH3) 2 H
203 5-F CF3 CH CH2CH2CH3 H
204 5-F CF3 CH2CH2CH3 H
205 5-F CF3 CH2CK2-tBu H
206 5-F CF3 C = C-iPr CH3
207 5-F CF3 C = C-Pr CH3
208 5-F CF3 C = C-Bu CH3
209 5-F CF3 C = C-iBu CH3
210 5-F CF3 C = C-tBu CH3
211 5-F CF3 C = C-Et CH3
212 5-F CF3 CeC-Me CH3
213 5-F CF3 CH2CEC-CH3 CH3
214 5-F CF3 CH2CeC-CH2CH3 CH3
215 5-F CF3 CH2CH2CH (CH3) 2 CH3
216 5-F CF3 CH2CH2CH2CH3 CH3
217 5-F CF3 CH2CH2CH3 CH3
218 5-F CF3 H2CH2- Bu CH3
219 5-F CF3 C * C-iPr CH2CH3
220 5-F CF3 CsC-Pr CH2CH3
221 5-F CF3 C = C-Bu CH2CH3
222 5-F CF3 CsC-iBu CH2CH3
223 5-F CF3 CEC-tBu CH2CH3
224 5-F CF3 CsC-Et CH2CH3
225 5-F CF3 C = C-Me CH2CH3
226 5-F CF3 CH2CsC-CH3 CH2CH3
227 5-F CF3 CH2C = C-CH2CH3 CH2CH3
228 5-F CF3 CH2CH2CH (CH3) 2 CH2CK3
229 5-F CF3 CH2CH2CH2CH3 CH CH3
230 5-F CF3 CH2CH2CH3 CH2CH3
231 5-F CF3 CH2CH2-tBu CH2CH3
232 5-Cl. 6-F CF3 C = C-iPr H 233 5-Cl, 6-F CF3 C = C- Pr w
234 5-Cl, 6-F CF3 C = C-Bu H
235 5-Cl, 6-F CF3 C = C-iBu K
236 5-Cl, 6-F CF3 C = C-tBu H
237 5-Cl, 6-F CF3 CsC-Et H
238 5-Cl, 6-F CF3 C = C-Me H
239 5-Cl, 6-F CF3 CH2C = C-CH3 H
240 5-Cl, 6-F CF3 CK2CsC-CK2CH3 H
241 5-Cl, 6-F CF 3 CH 2 CH 2 CH (CH 3) 2 H.
242 5-Cl, 6-F CF3 CH2CH2CH2CH3 H
243 5-Cl, 6-F CF3 CH2CH CK3 H
244 5-Cl, 6-F CF3 CH2CH2-tBu H
245 5-Cl, 6-F CF3 C = C-iPr CH3
246 5-Cl, 6-F CF3 CsC-Pr CH3 248 5-Cl, 6-F CF3 C C-ÍBU CH3
249 5-Cl, 6-F CF3 CeC-tBu CH3
260 6-C1.8-F CF3 c = c-Bu H
261 6-Cl, 8-F CF3 cse-iBu H
262 6-Cl, 8-F CF3 CsC-tBu H
263 6-C1.8-F CF3 CßC-Et H
264 6-C1.8-F CF3 CsC-Me H
265 6-C1.8-F C v_Fr3. CH2C = C-CH3 H
266 6-Cl, 8-F CF3 CH2C = C-CH CH3 H 10 Ul Ul t-J t u? LO? 00 W LO LO Ul Ul OJ OJ UJ OJ 00 LO J LO Ul J Ul UI Ul w 0J J LO Ul Ulto to (J Ul to M t M tO to t t--> MHHHHH ooooooooo it Ul) H o to O ^ J 01 L? * - J to LO ~ J C? Lp • Ul to H O LO co -J < ? Lp l. u > t M
C? C? C? C? Ol (? 01 C? C? C? C? C? C? -o -J ~ J • J 1 1 1 1 1 1 1 C? C? C? Cr?? C? 1 1 1 1 1 1 1 C? C? C? C? C? C? C? C? C?
1 1 I I I 1 i i 1 O O O O O N n 1 1 1 1 1 1 I 1 1
1 n o o o § § Y o O O O t-i CD CD CD Ü Ü CD t n 8 o O n f) o 8 8 n a n a y a a m a t t M t m CD o t t a t a a? ao to t 8
or > tl or hj or hj n itl n hl o »tl p hj o hl nl ol n hl o»?) oí ol o hj n h) o hl o h] o hl ol n > ?) or h or h] or hl nil or h) or h) or h) or h) or hl or i? or hj or h) or h | Uf UJ UJ Lo
? 8 8? 88 ?? 88? 88 ?? 88? s? | g? s? i? i? »E»
x * HI 35 m x x ¡3. K m SE m n Í? ? m TX tX x x ¡x e w m ^. O O Q O O O O O a a a a a a a a a
335 7 -Cl CF3 C = C-tBt K 336 7-Cl CF3 C = C-? T H 337 7 -Cl CF3 C = C-Me H
* Unless otherwise indicated, stereochemistry is (+/-).
Utility
The compounds of this invention possess inhibitory activity of the reverse transcriptase, in particular, inhibitory efficacy of HIV. The compounds of formula (I) possess inhibitory activity of HIV reverse transcriptase and are therefore useful as antiviral agents for the treatment of HIV infection and associated disorders. The compounds of formula
(I) have inhibitory activity of HIV reverse transcriptase and are effective as inhibitors of HIV growth. The ability of the compounds of the present invention to inhibit viral or infectious growth is demonstrated in standard viral or infectious growth assays, for example, using the assay described below.
The compounds of formula (I) of the present invention are also useful for the inhibition of HIV in an ex vivo sample containing HIV or waiting to be exposed to HIV. Thus, the compounds of the present invention can be used to inhibit HIV. present in a body fluid sample (eg, a serum or semen sample) that contains or is likely to contain or be exposed to HIV.
The compounds provided by this invention are also useful as reference or standard compounds for use in tests or assays to determine the ability of an agent to inhibit viral clonal replication and / or HIV reverse transcriptase, for example in a program of pharmaceutical resources. Thus, the compounds of the present invention can be used as a control or reference compound in such assays and as a quality control standard. The compounds of the present invention can be provided in a commercial device or container for use as such a reference or standard compound.
Since the compounds of the present invention exhibit a specific action for HIV reverse transcriptase, the compounds of the present invention may also be useful as diagnostic reagents in diagnostic assays for the detection of HIV reverse transcriptase. Thus, the inhibition of reverse transcriptase activity in an assay (such as the assays described herein) by a compound of the present invention may be indicative of the presence of HIV reverse transcriptase and HIV virus.
As used herein, "μg" means microgram, "mg" means milligram, "g" means gram, "μL" means microliter, "mL" means milliliter, "L" means liter, "nM" means nanomolar, "μM" means micromolar, "mM" means millimolar, "M" means molar and "nm" means nanometer. "Sigma" is shown for the Sigma-Aldrich Corp. of San Luis, MO.
HIV RNA assay.
Transcriptionists RNA in vi tro and plasmids DNA.
Plasmid pDAB 72 containing both the gag and pol sequences of BH10 (bp 113-1816) cloned in PTZ 19R was prepared according to Erickson-Vii tañen et al. AIDS Res ea rch and Huma n Re trovi rus is 1989, 5, 577. The plasmid was linearized with bam Hl before the generation of RNA transcripts in vi t ro using the system II Riboprobe Gemini device (Promega) with T7 RNA polymerase . The synthesized RNA was purified by treatment with DNase-free RNase
(Promega), extraction of phenol-chloroform, and ethanol precipitation. The RNA transcripts were dissolved in water, and stored at -70 ° C. The concentration of RNA was determined from
A260 • Probes
The biotinylated capture probes were purified by CLAP after synthesis in an Application Biosystems DNA synthesizer (Foster City, CA) by adding biotin from the 5 'end of the oligonucleotide, using Cocuzza's biotin-phosphoramidite ta, Te t. Le t t. 1989, 30, 6287. The biotinylated capture probe (5 -biotin-CTAGCTCCCTGCTTGCCCATACTA 3 ') complements nucleotides 889-912 of HXB2 and the biotinylated capture probe pol (5'-biot in-CCTATCATTTTTGGTTTCCAT 3') complemented nucleotides 2374-2395 of HXB2. Conjugated alkaline phosphatase oligonucleotides used as report probes were prepared by Syngene (San Diego, CA.). The pol reporter (5 'CTGTCTTACTTTGATAAAACCTC 3') was complemented to nucleotides 2403-2425 of HXB2. The gag report probe (5 'CCCAGTATTTGTCTACAGCCTTCT 3') was complemented to nucleotides 950-973 of HXB2. All nucleotide positions are those of the GenBank Computer Group Sequence Analysis Software Package (Devereau Nu cli i Aci ds Res ea rch 1984, 1 2, 387). Reporting probes were prepared as 0.5 M stored in 2 x SSC (0.3 M NaCl, 0.03 M sodium citrate), 0.05 M Tris pH 8.8, 1 mg / mL BSA. Biotinylated capture probes were prepared as 100 μM stored in water.
Streptavidin-coated plates:
Streptavidin-coated plates were obtained from Du Pont Biotechnology Systems (Boston, MA).
Storage of cells and viruses
The MT-2 and MT-4 cells were maintained in RPMI 1640 supplemented with 5% calf fetus serum (FCS) for MT-2 cells or 10% FCS for MT-4 cells, 2 nM L-glutamine and 50 μg / mL of gentamicin, all from Gibco. HIV-1 RF spread in MT-4 cells in the same medium. Batches of .virus were prepared approximately 10 days after acute infection of MT-4 cells and stored as aliquots at -70 ° C. The titers of HIV-1 (RF) infections stored were 1-3 x 10 ~ 7 PFU (plaque forming units) / mL measured as plaque assays in MT-2 cells (see below). Each aliquot of stored viruses used for infection was thawed only once.
To evaluate antiviral efficacy, the cells that were infected were subcultured one day before infection. On the day of infection, the cells were re-suspended at 5 x 10 5 cells / ml in RPMI 1640, 5% FCS for infection volumes or at 2 x 106 / ml in a Dulbecco's modified Eagles medium with 5% FCS for infection in plaques my croti t uladas. The viruses were added and the culture was continued for 3 days at 37 ° C.
HIV RNA assays
The dissolved or purified RNA cells in 3 M or 5 M GED were mixed with 5 M GED and the capture probe at a final concentration of isothiocyanate guanidine 3 M and at a final oligonucleotide concentration of 30 nM. Hybridization was carried out in a sealed U-bottom tissue 96 culture plate (Nunc or Costar) for 16-20 hours at 37 ° C. The hybridization reactions of the RNA were diluted in three steps with deionized water to a final concentration of isocyanate guanidine of 1 M and the aliquots (150 μL) were transferred to streptavidin-coated microtitre plates. The ligation of the capture probe and the hybrid capture-RNA probe to the immobilized streptavidin was allowed to proceed for 2 hours at room temperature, after the plates were washed 6 times with DuPont ELISA plate buffer (washing solution). phosphate buffered saline (PBS), 0.05% among 20). A second hybridization of test probe to the immobilized complex of the capture probe and to the hybridized RNA target was carried out in the washed streptavidin coated by adding 120 μl of a hybridization mixture containing 4 x SSC, 0.66% Triton x 100, 6.66 % of deionized formamide, 1 mg / mL of BSA and 5 nM of report probe. After annealing for one hour at 37 ° C, the plate was again washed 6 times. The activity of the immobilized alkaline phosphatase was detected by the addition of 100 μL of 0.2 nM of 4-methylumbelliferyl phosphate (MUBP, JBL Scientific) in buffer solution d (2.5 M diethanolamine pH 8.9 (JBL Scientific), 10 mM MgCl2, 5 M dehydrated zinc acetate and 5 mM N-hydroxyethyl ethylene diamine triacetic acid). The plates were incubated at 37 ° C. Fluorescence at 450 nM was measured using a microplate fluorometer (Dynateck) excising at 365 nM.
Evaluation of the compound based on the microplate in MT-2 cells infected with HIV-1:
The compounds to be evaluated were dissolved in DMSO and diluted in a de-culture medium twice for the highest concentration to be tested and a maximum DMSO concentration of 2%. Three additional dilutions of the compounds were run in a culture medium directly on the microtitre plates of U background (? Unc). After the dilution was complete, the MT-2 cells (50 μL) were added to a final concentration of 5 x 105 per mL (1 x 105 each). The cells were incubated with compounds for 30 minutes at 37 ° C in C02 incubator. To evaluate the antiviral potency, an appropriate dilution of HIV-1 (RF) virus storage (50 μL) was added to the cell-containing cultures and dilutions of the test compounds. The final volume of each of them was 200 μL. Each of the plates was laterally disinfected with 50 μL of the medium added to the virus site, while each was infected in the absence of any antiviral compound. For the evaluation of the compound's toxicity, parellels were cultured without virus infection.
After 3 days of culture at 37 ° C in a humid chamber inside a C02 incubator, all but 25 μL of the medium / well were removed from the HIV infected plates. Thirty-seven μL of 5 M GED containing the biotinylated capture probe were added to the established cells and the remaining medium in each at a final concentration of 3 M GED and a 30 nM capture probe. The hybridization of the capture probe for an HIV RNA in the cell used was carried out in the same microplate that was used to culture the virus by sealing the plate with a plate sealer (Costar), and incubating for 16-20 hours in an incubator at 37 ° C. Distilled water was then added to each to dilute the hybridization reaction three times and 150 μL of this diluted mixture was transferred to a mi-tilled plate coated with streptavidin. HIV RNA was quantified as described above. A standard curve, prepared by adding known amounts of RNA transcriptor in vi tro pDAB 72 to each containing disinfected cells used, was conducted on each of the microtitre plates in order to determine the amount of RNA virus made during the infection.
In order to standardize the inoculation of viruses used in the evaluation of the compounds for antiviral activity, the dilutions of the viruses were selected to result in an IC90 value (concentration of compound required to reduce the level of VOH RNA by 90%). dideoxicit idina (ddC) of 0.2 μg / mL. The values of
ICg0 of other antiviral compounds, both more or less potent than the ddC, were reproduced using various assortments of HIV-1 (RF) where this procedure was followed. This concentration of virus corresponds to ~ 3 x 10 5 PFU (measured by assay plate in MT-2 cells) per assay and typically yielding approximately 75% of the maximum level of maximum viral RNA made in any virus inoculation. For the HIV RNA assay, the ICgo values were determined from the percentage reduction of the signal taken (signal from the infected cell samples minus the signal from the disinfected cell samples) in the RNA assay relative to the signal taken from the untreated cells, infected in the same culture plate (average of each of them). The valid execution of the individual infection and the RNA assay tests were judged according to three criteria. This was required so that the results shown of virus infection in an RNA test signal were equal to or greater than the signal generated from the RNA 2 ng transcriptase of pDAB 72 in vi tro. The IC90 for ddC, determined in each test run, showed between 0.1 and 0.3 μg / mL. Finally, the plate level of the viral RNA produced by an effective reverse transcriptase inhibitor showed less than 10% of the level performed in an uninhibited infection. A compound is considered active if its ICgo is found to be less than 20 μM.
For the antiviral potency tests, all manipulations on my crotified plates, followed by the initial addition of a 2x concentrated compound solution to a single row of wells, was performed using a ProPette Perkin Elmer / Cetus.
Protein Link and Mutant Resistance.
In order to characterize the NNRTI analogs for each effective clinical potential, the effect of plasma proteins on antiviral potency and measurements of antiviral potency against the non-cultured type and mutant variants of HIV carrying amino acid changes at the site of known link for the NNRTIs were examined. The rationality of this test strategy is two parts:
1. Many drugs are linked exivamente to plasma proteins. Through the binding affinity for many drugs for most components of human plasma, nominally, human albumin serum
(HSA) of alpha-l-glycoprotein acid (AAG), is lower, this majority of components occurs in a high concentration in the blood. Only the free or unbound drug is available to cross the membrane of the infected cell by interaction with the target site (this is, HIV-1 reverse transcriptase, HIV-1 TI). Therefore, the effect of adding the HSA + AAG on the antiviral potency in the tissue culture more closely reflects the potency of the given compound in the clinical sample. The concentration of compound required to 90% inhibit virus replication is measured in a detection method based on the sensitive viral RNA designating IC90. The doubled increase in the apparent IC9o for the test compounds in the presence of aggregated levels of HSA and AAG reflecting the in vi vo concentrations (45 mg / ml HSA, 1 mg / ml AAG) are then calculated. The lower the doubled increase, the greater the compound available to interact with the target site.
2. The combination of the high range of virus replication in the infected individual and the poor fidelity of viral TI results in the production of quasi-species or mixtures of HIV species in the infected individual. These species may include a majority of species of non-cultivated type, but also mutant variants of HIV and the proportion of a given mutant may reflect their relative fitness and range of replication. Since several mutants include mutants that change in the amino acid sequence of the viral TI linking pre-existing species in the infected individual, the overall potential observed in the clinical sample will reflect the ability of a drug to inhibit not only HIV-1 type not cultivated, but also mutant variants. It has been constructed in this manner, in a known genetic background, mutant variants of HIV-1, which carry amino acid substitutions at the positions through which an NNRTI link is involved, and the ability of the test compounds has been measured. to inhibit the replication of these mutant viruses. The concentration of the compound required to inhibit virus replication by 90% is measured in a detection method based on sensitive viral RNA designating the ICgo. It is desirable to have a compound that has a high activity against a variety of mutants.
Two i s L r or uia ci on
The antiviral compounds of this invention can be administered as a treatment for antiviral infections by any means that produces contact of the active agent with the agents of the site of action, i.e. viral reverse transcriptase, in the body of a mammal. These can be administered by any of the conventional means available for use in conjunction with pharmaceuticals, either as individual therapeutic agents or in combination of therapeutic agents. These may be administered alone, but preferably administered with a selected pharmaceutical carrier at the bases of the chosen route of administration and standard pharmaceutical practice.
The dose administered will, of course, be variable depending on known factors, such as the pharmacodynamic characteristics of the particular agent and its mode and route of administration; the age, health and weight of the recipient; the nature and extent of the symptoms; the type of concurrent treatment; the frequency of treatment; and the desired effect. A daily dose of active ingredient may be expected to be from about 0.001 to about 1000 milligrams per kilogram of body weight, with the preferred dose being from about 0.1 to about 30 mg / kg.
The dosage forms of the compositions suitable for administration contain from about 1 mg to about 100 mg of the active ingredient per unit. In antiserum pharmaceutical compositions, the active ingredient may ordinarily be present in an amount of about 0.5-95% by weight based on the total weight of the composition. The active ingredient may be administered orally in solid dosage forms, such as capsules, tablets and powders, or in liquid dosage forms, such as elixirs, syrups and suspensions. They can also be administered parenterally, in sterile liquid dosage forms.
Gelatin capsules contain the active ingredient and carrier powders, such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. Similar diluents can be used to make compressed tablets. Such tablets and capsules can be made as sustained release products to provide a continuous release of the drug over a period of oras.- The compressed tablets can be coated with sugar or coated with a film to mask any unpleasant taste and protect the tablet from the atmosphere, or enterically coated for selective disintegration in the gastrointestinal tract. Liquid dosage forms for oral administration may contain colorants and flavors to increase patient acceptance.
In general, aqueous solutions, of suitable oil, salines, of aqueous dextrose (glucose), and related to sugar and glycols such as propylene glycol or polyethylene glycols are suitable carriers for parenteral solutions. Solutions for parenteral administration preferably contain a water soluble salt of the active ingredient, stabilizing agents are suitable, and if necessary, buffering substances. Antioxidant agents such as sodium bisulfide, sodium sulfide, or ascorbic acid, either alone or in combination, are suitable stabilizing agents. Citric acid and its salts, and sodium EDTA are also used. In addition, parenteral solutions may contain preservatives, such as benzalkonium chloride, methyl- or propyl-paraben and chlorobutanol. Suitable pharmaceutical carriers are described in Remingt on 's Pharma ceu ti cal Sciences, s upra, a standard reference text in this field.
The pharmaceutical dosage forms useful for the administration of the compounds of this invention can be illustrated as follows:
Capsules
A large number of capsule units can be prepared by hard gelatin capsules of two standard-sense pieces each with 100 mg of the active ingredient powder, 150 mg of lactose, 50 mg of cellulose, and 6 mg of stearic magnesium.
Gelatin capsules Sua e
A mixture of the active ingredient in a digestible oil such as soybean oil, cottonseed oil or olive oil can be prepared and injected by means of a positive displacement pump in gelatin to form soft gelatin capsules containing 100 mg of the active ingredient. . The capsules can then be washed and dried.
Tablets
A large number of tablets can be prepared by conventional procedure so that the unit dose is 100 mg of the active ingredient, 0.2 mg of colloidal silica dioxide, 5 milligrams of magnesium stearate, 275 mg of microcrystalline cellulose, 11 mg of starch and 98.8 mg of lactose. Appropriate coatings may be applied to increase the flavor or delay absorption.
Suspension
An aqueous suspension can be prepared for oral administration so that each 5 L contains 25 mg of the finely divided active ingredient, 200 mg of sodium carboxymethylcellulose, 5 mg of sodium benzoate, 1.0 g of sorbitol solution, USP, and 0.025 mg of vanilla.
Injectable
A parenteral composition suitable for administration by injection can be prepared by stirring 1.5% by weight of the active ingredient in 10% by volume of propylene glycol and water. The solution is sterilized by commonly used techniques.
Combination of components (a) and (b).
Each component of the therapeutic agent of this invention can independently be in any dosage form, as described above, and can also be administered in various ways, as described above. In the following description of component (b) it will be understood that one or more agents are represented as previously described. Thus, if components (a) and (b) are to treat the same or independently, each agent of component (b) may also treat the same or independently.
The components (a) and (b) of the present invention can be formulated together, in a single unit dose (that is, combined together in a capsule, tablet, powder, or liquid, etc.) as a combined product. When component (a) and (b) are not formulated together in a single unit dose, component (a) may be administered at the same time as component (b) or in any order; for example component (a) of this invention may be administered first, followed by administration of component (b), or these may be administered in reverse order. If component (b) contains more than one agent, for example, a TI inhibitor and a protease inhibitor, these agents can be administered together in any order. When they are not administered at the same time., preferably the administration of component (a) and (b) occurs in less than about one hour of separation. Preferably, the route of administration of component (a) and 8B9 is oral. The terms oral agent, oral inhibitor, oral compound, or the like, as used herein, mean compounds that can be administered orally. However it is preferred that component (a) and component (b) are both administered by the same route (which is, for example, both orally) or dosage forms, if desired, these can each be administered by different routes (which is, for example, one component of the combination product can be administered orally, and the other component can be administered intravenously) or dosage forms.
It will be appreciated, by a skilled medical practitioner in the art, that the dose of the combination therapy of the invention may vary depending on various factors such as the pharmacodynamic characteristics of the particular agent and its mode and route of administration, age, health and recipient's weight, the nature and extent of symptoms, the type of concurrent treatment, the frequency of treatment, and the desired effect, as described above.
The appropriate dose of components (a) and (b) of the present invention may be readily ascertained by a medical practitioner skilled in the art, based on the present disclosure. As a general guide, typically the daily dose may be around 100 milligrams to about 1.5 grams of each component. If component (b) represents more than one component, then typically a daily dose may be from about 100 milligrams to about 1.5 grams of each agent of component (b). As a general guide, when the compounds of component (a) and component (b) are administered in combination, the dose amount of each component may be reduced by about 70-80% relative to the usual dose of the component when it is used. administer only as a simple agent for the treatment of HIV infection, in view of the synergistic effect of the combination.
The combination of products of this invention can be formulated such that, although the active ingredients are combined in a single unit dose, physical contact between the active ingredients is minimized. In order to minimize contact, for example, where the product is orally administered, an active ingredient can be enterically coated. To cover one of the active ingredients enterically, this is possible not only to minimize contact between the combined active ingredients, but also, this is possible to control the release of one of these components in the gastrointestinal tract such that one of these components are not released in the stomach but in turn is released in the intestines. Another embodiment of this invention where oral administration is desired to provide for a combination product of the active ingredients is covered with a sustained release material that effect a sustained release totally in the gastrointestinal tract and also serves to minimize physical contact between the ingredients combined assets. In addition, the sustained release component can additionally be enteric coated in such a way that the release of this component occurs only in the intestine. Still in another approach it may involve the formulation of a combination product in which one of the components is coated with an enteric and / or sustained release polymer, and the other component is also coated with a polymer such as a low grade polymer. viscosity of hydropropyl methylcellulose or other suitable materials known in the art, in order to further separate the active components. The polymer shell serves to form an additional barrier for interaction with the other component. In each formulation where contact is prevented between components (a) and (b) by means of a coating or some other material, contact can also be prevented between the individual agents of component (b).
Dosage forms of the combination products of the present invention wherein an active ingredient is enteric coated may be in tablet form such that the enteric coated component and the other active ingredient are mixed together and then compressed into a tablet or such that the enteric coated component is compressed into a tablet layer and the other active ingredient is compressed into an additional layer. Optionally, in order to further separate the two layers, one or more layers of placebo may be presented in such a way that the placebo layer is between the layers of the active ingredients. further, the dosage forms of the present invention may be in the form of capsules wherein an active ingredient is compressed into a tablet or in the form of a plurality of microtablets, particles, granules or non-hazardous, which are then enteric coated. These microtablets, particles, granules or non-dangerous enteric coated are then placed in a capsule or compressed in one capsule along with a granulation of the other active ingredient.
This is as well as other ways of minimizing contact between the components of the combination products of the present invention, if they are administered in a single dose form or are administered in separate forms but at the same time or concurrently in the same manner, they may be quickly appreciated by those skilled in the art, based on this description.
Pharmaceutical devices useful for the treatment of an HIV infection, comprising a therapeutically effective amount of a pharmaceutical composition, comprise a compound of component (a) and one or more compounds of component (b), in one or more sterile containers, they are also within the scope of the present invention. Sterilization of the container can be carried out using a conventional sterilization methodology well known to those skilled in the art. Component (a) and component (b) can be in the same sterile container or in separate sterile containers. Sterile containers of materials may comprise separate containers, or one or more large containers, as desired. The component (a) and the component
(b), can be separated, or physically combined in a single or unit dose form as described above. Such devices may additionally, if desired, include one or more of several conventional pharmaceutical device components, such as, for example, one or more pharmaceutically acceptable carriers, additional means for mixing the components, etc., which will be readily apparent to those skilled in the art. in the technique. The instructions, either as inserts or labels, indications of quantities of the components to be administered, guides for administration, and / or guides for mixing the components, may also be included in the device.
Obviously, numerous variations and modifications of the present invention are possible in the light of the prior art. It will be understood therefore that within the scope of the appended claims, the invention may be practiced contrary to what is specifically described herein.
It is noted that in relation to this date, the best method known to the applicant to carry out the aforementioned invention, is that which is clear from the present description of the invention
Claims (18)
1. A compound of formula (I) or a tereosisomer or pharmaceutically acceptable salt thereof, characterized in that R1 is C3 alkyl substituted with 1-7 halogen; R2 is selected from C1-5 alkyl substituted with 1-2 R4, C2-5 alkenyl substituted with 1-2 R4, and C5 alkynyl substituted with 1 R4; R3 in each appearing, is independently selected from C1-4alkyl, OH, C4-4alkoxy, F, Cl, Br, I, NR5R5'a, N02, CN, C (0) R6, NHC (0) R7, and NHC (O) NR5R5a; alternatively, if two Rs are presented and are bonded to the adjacent carbons, then these can be combined to form -OCH20-; R is selected from C3_5 cycloalkyl substituted with 0-2 of R3, phenyl substituted with 0-5 of R3, and a 5-6 member heterocyclic system containing from 1-3 heteroatoms selected from O, N, and S, substituted with 0-2 of R3; R5 and R5a are independently selected from H and Ci_3 alkyl; R is selected from H, OH, C? _4 alkyl, alkoxy C1-4, and RN5R5a; R7 is selected from C3_3alkyl and C1-3alkoxy; R is selected from H, C3_5 cycloalkyl, and C1-3 alkyl; Y, n is selected from 0, 1, 2, 3, and 4.
2. The compound according to claim 1, characterized in that R1 is C1-3 alkyl substituted with 1-7 halogen; R2 is selected from C1-5 alkyl substituted with 1 R4, C2-5 alkenyl substituted with 1 R4, and C2_5 alkynyl substituted with 1 R4; R3 in each production, is independently selected from alkyl C? _, OH, C? _4 alkoxy, F, Cl, Br, I, NR5R5a, N02, CN, C (0) R? NHC (0) R ', and NHC (0 NR5R5a, alternatively, if two Rs are presented and joined to the adjacent carbons, then these may be combined to form -0CH20-; R is selected from C3-5 cycloalkyl substituted with 0-2 of R3, phenyl substituted with 0-2 of R, and a 5-6 member heterocyclic system containing from 1-3 heteroatoms selected from O, N, and S, substituted with 0-1 of R3; R5 and R5a are independently selected from H CH3 and C2H5; R s e s the e ction of H, OH, CH3, C2H5, OCH3, OC2H5, and RN5R5 a; R is selected from CH3, C2H5, OCH3 and OC; H5; R8 is selected from H, cyclopropyl, CH3 and C2H5; Y, n is selected from 0, 1, 2, and 3.
3. The compound according to claim 2, characterized in that R1 is selected from CF3, and C2F5; R is selected from C1-3 alkyl substituted with 1 R4, C2-3 alkenyl substituted with 1 R, and C2_3 alkynyl substituted with 1 R4; R in each production, is independently selected from C1-3 alkyl, OH, C1-3 alkoxy, F, Cl, Br, I, NR5R5a, N02, CN, C (0) R6, NHC (0) R7, and NHC ( O) NR5R5a; alternatively, if two of R are presented and joined to adjacent carbons, then these can be combined to form -OCH20-; R4 is selected from C3-5 cycloalkyl substituted with 0-2 of R3, phenyl substituted with 0-2 R3, and a 5-6 member heterocyclic system containing 1-3 heteroatoms selected from O, N, and S, substituted with 0 -1 R3; R and R, 5a are independently selected from H, CH 3, and C Hs; R6 is selected from H, OH, CH3, C2H5, OCH3, OC2H5, and NR5R5a, R is selected from CH3, C2H5, OCH3, and OC2H5; R8 is selected from H, CH3 and C2H5; Y n is selected from 0, 1, and 2.
4. The compound according to claim 3, characterized in that R1 is CF3; R ~ is selected from C1-3 alkyl substituted with 1 R4, C2-3 alkenyl substituted with 1 R "*, and C2-3 alkynyl substituted with 1 R4; R3 in each production is independently selected from C1-3 alkyl, OH, C1-3 alkoxy, F, Cl, NR5R5a, N02, CN, C (0) R6, NHC (0) R7, and NHC (0) NR5R5a; alternatively, if two R's are presented and attached to the adjacent carbons, then these can be combined to form -CH20-; R is selected from cyclopropyl substituted with 0-1 R3, phenyl substituted with 0-2 R3, and a 5-6 member heterocyclic system containing from 1-3 heteroatoms selected from 0, N, and S, substituted with 0-1 R3 , wherein the heterocyclic system is selected from 2-pyridyl, 3-pyridyl, 4-pyridyl, 2- furanyl, 3-furanyl, 2-thienyl, 3-thienyl, 2-oxazolyl, 2-thiazolyl, 4 -i-soxazolyl , and 2-imidazolyl; R5 and Rsa are independently selected from H, CH3 and C2H5; R6 is selected from H, OH, CH3, C2H5, OCH3, OC2H5, and NR5R5a; R7 is selected from CH3, C2H5, OCH3, and OC2H5; R8 is selected from H, CH3 and C2H5; Y, n is selected from 1 and 2.
5. The compound according to claim 4, characterized in that the compound is of the formula la:
6. The compound according to claim 4, characterized in that the compound is of the formula: Ib.
7. The compound according to claim 1, characterized in that the compound is selected from: (+/-) -6-chloro-cyclopropylethynyl-4-trifluoromethyl-3,4-dihydro-2 (1H) -quinazolinone; (+/-) -6-chloro -.- (2-pyridyl) ethynyl-4-tri fluorome-3, 4-dihydro-2 (1H) -quinazolinone; (+ / -) - 6-chloro-4-phenylethynyl-4-tri fluorome-3, 4-dihydro-2 (1H) -quinazolinone; (+ / -) -4-cyclopropylethynyl-6-methoxy-4-trifluoromethyl-3, -dihydro-2 (1H) -quinazolinone; (+/-) -6-methoxy-4- (2-pyridyl) ethynyl-4-trifluoromethyl-3,4-dihydro-2 (1H) -quinazolinone; (+/-) -6-methoxy-4-phenylethynyl-4-trifluoromethyl-3,4-dihydro-2 (1H) -quinazolinone; (+/-) - -cyclopropyl-ethynyl-5,6-di-fluoro-4-trifluoromethyl-3-dihydro-2 (1H) -quinazolinone; (+/-) - 5,6-difluoro-4- (2-pyridyl) ethynyl-4-trifluoromethyl-3, -dihydro-2 (1H) -quinazolinone; (+/-) -5,6-difluoro-4-phenylethynyl-4-tri fluorometyl-3,4-dihydro-2 (1H) -quinazolinone; (+/-) -4-cyclopropylethynyl-6-fluoro-trifluoromethyl-3,4-dihydro-2 (1H) -quinazolinone; (+ / -) -6-fluoro-4- (2-pyridyl) ethynyl-4-trifluoromethyl-3,4-dihydro-2 (1H) -quinazolinone; (+/-) -6-fluoro-4-phenylethynyl-4-trif luoromethyl-3,4-dihydr-2 (1H) -quinazolinone; (+/-) - 6-fluoro-4- (2'-2-pyridyl) ethyl-4-trifluoromethyl-3,4-dihydro-2 (1H) -quinazolinone; (+ / -) -6-fluoro-4-phenylethyl-trifluoromethyl-3,4-dihydro-2 (1H) -quinazolinone; (-) - 6-chloro-4-cyclopropyl ethynyl-4-trifluoromethyl-3,4-dihydro-2 (1H) -quinazolinone; (+) - 6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-3, -dihydro-2 (lH) -quinazolinone; (+) - 4-cyclopropylethynyl-5,6-difluoro-4-trifluoromethyl-3,4-dihydro-2 (1H) -quinazolinone; (-) -4-cyclopropylethynyl-5,6-di-fluoro-4-rifluoromethyl-3, -dihydro-2 (1H) -quinazolinone; (+) -4-E-cyclopropyletenyl-5,6-difluoro-4-trifluoromethyl-3,4-dihydro-2 (1H) -quinazolinone; Y, (-) - 6-chloro-4-E-cyclopropyletenyl-4-trifluoromethyl-3, 4-dihydro-2 (1H) -quinazolinone; or a pharmaceutically acceptable salt thereof
The compound according to formula II II or a tereoisomer or pharmaceutically acceptable salt thereof, characterized in that: R is selected from C C _4 OH alkyl, C? _4 alkoxy, F, Cl, Br, I, NR5R5a, N02, CN, C (0) R6, NHC (0) R6, NHC (0) R7, and NHC (O) NR5R5a; R, 4a is selected from methyl, ethyl, n-propyl, i-propyl, i-butyl, t-butyl, and i-pentyl R5 and R5a are independently selected from H and C3_3 alkyl; R is selected from H, OH, C? _4 alkyl, C? -4 alkoxy, and NR5R5a; R is selected from C3-3 alkyl and C1-3 alkoxy; R is selected from H, C3_5 cycloalkyl, and C ?_3 alkyl; Y, n is selected from 0, 1, 2, 3, and 4.
9. The compound according to claim 8, characterized in that R is C = C-R 4a R is selected from C C _ OH alkyl to C 1-4 r coxi F, Cl, Br, I, NR5R5a, N02, CN, C (0) R6, and NHC (O) R7; R, 4a is selected from methyl, ethyl, n-propyl, i-propyl, i-butyl, t-butyl, and i-pentyl; R5 and R5a are independently selected from H, CH3 and C2H5; R & is selected from H, OH, CH3, C2H5, OCH3, OC2H5, and NR5R5a; R is selected from CH3, C2H5, OCH3, and OC2H5; Rfc is selected from H, cyclopropyl, CH 3 and C 2 H; Y n is selected from 0, 1 and
10. The compound according to claim 9, characterized in that the compound is of the formula lia: lia
11. The compound according to claim 9, characterized in that the compound is of formula Ilb: Ilb.
12. The compound according to claim 8, characterized in that the compound is selected from: (+/-) -6-chloro-4-isopropylethynyl-4-trifluoromethyl-3,4-dihydro-2 (1H) -quinazolinone; (+/-) -6-chloro-4-ethynylnyl-4-trifluoromethyl-3,4-dihydro-2 (1H) -quinazolinone; (+/-) - 4-isopropylethynyl-6-methoxy-4-trifluoromethyl-3,4-dihydro-2 (1H) -quinazolinone; (+/-) -5,6-difluoro-4-isopropylethynyl-4-trifluoromethyl-3,4-dihydro-2 (1H) -quinazolinone; (+/-) -5,6-difluoro-4-ethynylnyl-4-trifluoromethyl-3,4-dihydro-2 (1H) -quinazolinone; (+/-) -5,6-difluoro-4-isopentyl-4 -tri fluorometyl-3-dihydro-2 (1H) -quinazolinone; (+/-) -6-fluoro-4-isopropylethynyl-4-trifluoromethyl '3,4-dihydro-2 (1H) -quinazolinone; (+/-) -6-fluoro-4-ethylethynyl-4-trifluoromethyl-3, dihydro-2 (1H) -quinazolinone; (-) -5,6-difluoro-4-isopropylethynyl-4-trifluoromethyl-3,4-dihydro-2 (1H) -quinazolinone; (+) - 5, β-difluoro-4-isopropylethynyl-4-tri-fluoromethyl-3,4-dihydro-2 (1H) -quinazolinone; (-) -5,6-difluoro-4-ethynylnyl-4-trifluoromethyl-3,4-dihydro-2 (1H) -quinazolinone; Y, (+) - 5,6-difluoro-4-ethylethynyl-4-trifluoromethyl-3,4-dihydro-2 (1H) -quinazolinone; a pharmaceutically acceptable salt thereof
13. A pharmaceutical composition, characterized in that it comprises: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of one of the rei indications 1-12 or a pharmaceutically acceptable salt thereof.
14. A method for the treatment of an HIV infection, characterized in that it comprises: administering to the host in need of treatment a therapeutically effective amount of a compound of one of claims 1-12, or a pharmaceutically acceptable salt thereof.
15. A method for the treatment of an HIV infection comprising administering, in combination, to a host in need thereof, a therapeutically effective amount of: (a) a compound of one of claims 1-12 or stereoisomeric forms, mixtures of shapes * is tereoisomeric, or pharmaceutically acceptable salts thereof; and (b) at least one compound selected from the group consisting of inhibitors of trans crypts to HIV reverse and inhibitors of HIV protease.
16. The method according to claim 15, characterized in that the reverse transcriptase inhibitor is selected from AZT, 3TC, ddl, ddC, d4T, delavirdine, TIBO derivatives, BI-RG-587, nevirapina, L-697,661, LY 73497, Ro 18,893, loviride, trovirdine, MKC-442, and HBY 097, and the protease inhibitor is selected from saquinavir, ritonavir, indinavir, VX-478, nelfinavir, KNI-272, CGP-61755, U-140690, and ABT -378.
17. The method according to claim 16, characterized in that the reverse transcriptase inhibitor is selected from AZT and 3TC and the protease inhibitor is selected from saquinavir, nelfinavir, ritonavir, and indinavir.
18. A pharmaceutical device useful for the treatment of HIV infection, characterized in that it comprises a therapeutically effective amount of: (a) a compound of one of claims 1-12 or stereoisomeric forms, mixtures of stereoisomeric forms, or pharmaceutically acceptable salts thereof; and (b) at least one compound selected from the group consisting of HIV reverse transcriptase inhibitors and HIV protease inhibitors, in one or more sterile containers.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US838540 | 1997-04-09 | ||
US071322 | 1998-01-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA99008909A true MXPA99008909A (en) | 2000-01-01 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU734928B2 (en) | 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinones useful as HIV reverse transcriptase inhibitors | |
AU773309B2 (en) | Tricyclic compounds useful as HIV reverse transcriptase inhibitors | |
JP2001505873A (en) | 4,4-Disubstituted-1,4-dihydro-2H-3,1-benzoxazin-2-ones useful as HIV reverse transcriptase inhibitors, and intermediates and methods for producing them | |
US6124302A (en) | 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinones useful as HIV reverse transcriptase inhibitors | |
MXPA04006948A (en) | Tricyclic 2-pyrimidone compounds useful as hiv reverse transcriptase inhibitors. | |
US20020177603A1 (en) | Tricyclic compounds useful as HIV reverse transcriptase inhibitors | |
US6127375A (en) | 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinthiones useful as HIV reverse transcriptase inhibitors | |
MXPA99008909A (en) | 4,4-disubstituted-3,4-dihydro-2(1h)-quinazolinones useful as hiv reverse transcriptase inhibitors | |
US6946469B2 (en) | Cyanamide, alkoxyamino, and urea derivatives of 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinones as HIV reverse transcriptase inhibitors | |
US6090821A (en) | Substituted quinolin-2 (1H)-ones useful as HIV reverse transcriptase inhibitors | |
CZ352499A3 (en) | 4,4-disubstituted-3,4-dihydro-2 (1H)-quinazolinones suitable as inhibitors of HIV reverse transcriptase | |
JP2001514256A (en) | 5,5-Disubstituted-1,5-dihydro-4,1-benzoxazepin-2 (3H) -ones useful as HIV reverse transcriptase inhibitors | |
US20040063734A1 (en) | 4,4-Disubstituted-3,4-dihydro-2 (1H)-quinazoliniones useful as HIV reverse transcriptase inhibitors | |
AU7371301A (en) | 4,4-disubstituted-3,4-dihydro-2-)1H)- quinazolinones useful as HIV reverse transcriptase inhibitors | |
US6265406B1 (en) | Substituted quinolin-2 (1H) -ones useful as HIV reverse transcriptase inhibitors | |
EA001154B1 (en) | (4r,5s,6s,7r)-hexahydro-1[5-(3-aminoinazole)methyl]-3-butyl-5,6-dihydroxy-4,7-bis[phenylmethyl]-2h-1,3-diazepin-2-one and its useas hiv protease inhibitor | |
MXPA00002158A (en) | 5,5-disubstituted-1,5-dihydro-4,1-benzoxazepin-2(3h)-ones useful as hiv reverse transcriptase inhibitors | |
AU2002254652A1 (en) | Tricyclic compounds useful as HIV reverse transcriptase inhibitors | |
MXPA99004294A (en) | (4r,5s,6s,7r)-hexahydro-1- [5-(3-aminoinazole)methyl]-3-butyl-5,6-dihydroxy-4,7-bis [phaenylmethyl]-2h-1,3-diazepin-2-one, its preparation and its use as hiv protease inhibitor | |
CA2330110A1 (en) | 1,3-benzodiazepin-2-ones and 1,3-benzoxazepin-2-ones useful as hiv reverse transcriptase inhibitors | |
MXPA99004286A (en) | 1-(3-aminoindazol-5-yl)-3-phenylmethyl-cyclic ureas useful as hiv protease inhibitors |